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Summary
Apolipoprotein E {APOE: gene, apoE: protein) is a lipid transport protein which has 
a well-characterised role in response to peripheral nerve injury. It has been 
demonstrated that the APOE s4 allele of the gene is a major risk factor for 
Alzheimer’s disease and is associated with a poor outcome after brain injury. The 
mechanisms underlying this are unclear but may involve a role for apoE in neuronal 
repair processes. This thesis investigated the role of apoE in repair processes after 
brain injury and determined whether this effect was APOE genotype dependent. In 
order to address this, models of synaptic plasticity {in vitro and in vivo) were 
validated. Using these models the role of apoE could be defined. The influence of 
APOE genotype was determined using two different lines (human promoter and 
GFAP promoter) of genetically modified mice {APOE knockout, human e3 and e4 
alleles). The main studies and results are as follows:
(1) Investigation of ApoE in Relation to Degeneration/ Regeneration Using a 
Mouse Model of Entorhinal Cortex Lesion
An in vivo model of hippocampal plasticity was characterised in C57BL/6J mice (the 
background strain of genetically modified mice used in this thesis). A lesion of the 
entorhinal cortex (ECL) was induced by stereotactic injection of ibotenic acid. 
Specific markers (synaptophysin, GAP-43 and MAP-2) were used to define the 
temporal profile of degeneration and regeneration post-ECL. In the molecular layers 
of the dentate gyrus, synaptic decline and fibre degeneration occurred up to 28 days 
post-ECL, but at 90 days post-ECL, synaptogenesis and fibre sprouting were 
observed. Alterations in apoE paralleled degeneration and regeneration post-ECL. 
ApoE was upregulated within the neuropil and reactive astrocytes at day 7 post-ECL, 
with a further increase in the neuropil of the outer molecular layer at day 90 post- 
ECL. This pattern of upregulation was similar to alterations observed for apoJ. There 
were minimal alterations in LRP (apoE receptor) with an increase in LRP 
immunoreactivity on reactive astrocytes at day 7 post-ECL. Degeneration products 
identified by silver staining were maximal 3 days post-ECL and absent by day 90 
post-ECL. This study demonstrated the utility of the entorhinal cortex lesion as a 
reproducible model of hippocampal plasticity. The results also supported a role for 
apoE in neuronal repair processes after brain injury.
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(2) Analysis of APOE Genotype Influence on CNS Plasticity in Transgenic Mice 
Expressing Human APOE s3 and s4 Alleles (under a human promoter 
sequence) Following Entorhinal Cortex Lesion
The entorhinal cortex was lesioned in APOE transgenic mice, which express human 
APOE alleles (s3, e4) in astrocytes and neurons. This study assessed APOE genotype 
influence on the long-term response to brain injury. Specific markers (synaptophysin, 
GAP-43 and MAP-2) were used to define the temporal profile of degeneration and 
regeneration post-ECL. Initially APOEs3 mice exhibited more extensive 
degeneration than s4 mice. However, with longer recovery the APOEsA mice 
demonstrated an impaired reparative capacity. There were no significant differences 
in the extent of apoE, apoJ and LRP immunoreactivity between APOEs3 and e4 
mice. There was also no significant difference in the deposition and clearance of 
degeneration products between APOEs3 and s4 mice. APOEsA mice displayed a 
deficit in MAP-2 immunoreactivity compared to APOEs3 mice that paralleled the 
deficit in reparative capacity. The dendrites in the molecular layer of APOEsA mice 
were disorganised and disarrayed. This study indicated that the s4 allele was 
associated with impaired neuronal repair. The underlying mechanism may involve 
apoE isoform differences in interactions with cytoskeletal proteins.
(3) Analysis of APOE Genotype Influence on CNS Plasticity in APOE Knockouts 
and Transgenic Mice Expressing Human APOEe3 and s4 Alleles (GFAP 
Promoter) Following Entorhinal Cortex Lesion
The entorhinal cortex was lesioned in APOE knockout, e3 and e4 transgenic mice 
(expressing human APOE in astrocytes) and the influence of APOE genotype on the 
long-term response to brain injury was assessed. In this study it was shown that mice 
expressing the APOEsA allele displayed impaired neuronal sprouting capabilities 
compared to APOE knockout and e3 mice, however there was no difference in 
synaptic density between APOE knockout, s3 and s4 mice at any time-point. 
Alterations in apoE and apoJ paralleled regeneration but there was no significant 
difference between APOEs3 and sA mice. Similarly, there were no significant 
differences in alterations in LRP, MAPs or extent of degeneration product clearance. 
This study indicated that neuronal repair mechanisms were impaired in APOEsA
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mice compared to APOE knockout and s3 mice. There were no significant 
differences in dendritic structure unlike that shown in the previous transgenic line 
and this suggests that the underlying mechanisms may not be directly related to 
cytoskeletal interactions in this particular line of transgenic (astrocytic expression).
(4) APOE Genotype Influence in the CNS of Aged APOE Knockout, e3 and e4 
Transgenic Mice (GFAP Promoter)
The ageing process is now thought of as a form of chronic brain injury and APOE 
genotype may influence age-related neurodegeneration. APOE genotype effect on 
ageing was analysed using specific markers (synaptophysin, GAP-43 and MAP-2) to 
define the temporal profile of synapse and fibre density in APOE knockout, s3 and 
e4, young (3 months) and aged (1 year) transgenic mice. There was no statistically 
significant difference in synaptic density between APOE knockout, s3 and s4 mice at 
any age. Fibre density was found to be significantly less in APOEs4 mice compared 
to APOE knockout and e3 transgenic mice at 3 months, but was not significantly 
different at 1 year of age. This was paralleled by a reduction in IML width in APOE 
e4 mice by 1 year, compared to APOE knockout and s3 transgenic mice. ApoE 
immunoreactivity was similar between the genotypes at 3 months of age. At 1 year, 
apoE neuropil immunoreactivity was increased, but to a greater extent in APOE s4 
mice. There were no significant differences in MAP-2 and apoJ immunoreactivity 
between the genotypes at any time. This study has shown that APOE genotype has no 
demonstrable influence on ageing in the brain of these transgenic mice.
(5) An In Vitro Organotypic Hippocampal Slice Model to Study APOE Genotype 
Influence on Neuronal Plasticity and Analysis of Herpes Simplex Virus as a 
Vector for APOE Delivery
(a) Characterisation of plasticity responses in hippocampal slices derived from 
C57BL/6J mice
An in vitro organotypic hippocampal slice culture method was characterised in 
C57BL/6J slices. The slices were cultured for a period of 7 or 18 days and the 
synaptic and sprouting response was assessed using specific markers (synaptophysin 
and GAP-43). At day 18 in vitro, synaptophysin and GAP-43 immunoreactivity 
increased within the molecular layers of the dentate gyrus compared with
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immunoreactivity in 7 day slices. ApoE immunoreactivity was increased within the 
neuropil of the hippocampal molecular layers at day 7 in vitro, but was reduced by 
day 18 in vitro. This study validated the use of in vitro hippocampal mouse slices to 
study apoE and APOE genotype in neuronal plasticity.
(b) Influence of APOE genotype on neuronal plasticity in vitro
Hippocampal slices were cultured from male APOE knockout, s3 and e4 transgenic 
mice and maintained in culture for a period of 7 or 18 days. The synaptic and 
sprouting response was assessed using specific markers (synaptophysin and GAP- 
43). Synaptophysin and GAP-43 immunoreactivity was similar in all slices cultured 
for 7 days. At day 18 in vitro, sprouting and reactive synaptogenesis had occurred in 
all slices, marked by an increase in GAP-43 and synaptophysin immunoreactivity. 
However, the sprouting response was significantly poorer in APOEs4 slices 
compared to APOE knockout and s3 slices. No apoE immunoreactivity was present 
in APOE knockout slices. ApoE immunoreactivity was elevated in APOEs3 and e4 
slices within the neuropil and reactive astrocytes at day 7. However, there was 
significantly greater apoE immunoreactivity in APOEs 3 slices. ApoE 
immunoreactivity was reduced at day 18 in vitro but there was no difference between 
genotypes. This study supported the previous in vivo study and indicated the s4 allele 
is associated with impaired neuronal repair mechanisms.
(c) Herpes simplex virus as a vector for gene delivery
The previous studies in this thesis indicate that APOE genotype influences repair 
processes, the e4 allele being associated with a poor capacity for repair. The next aim 
was to determine whether, the poor response associated with the e4 allele could be 
ameliorated by increasing the levels of apoE or changing the genotype present. This 
study examined the uptake and expression of a modified Herpes Simplex viral vector 
in the organotypic hippocampal slice preparation. The Herpes Simplex virus mutant 
employed in this study is non-virulent due to lack of the ICP34.5 protein. The virus 
was applied directly to the slice as a single dose on day 1 in vitro at a concentration 
of 105 or 106 virus particles with a Green Fluorescent Protein (GFP) reporter gene. 
The virus, was found to be expressed within the molecular layer of the dentate gyrus 
and was cellular in nature. Expression was sustained until day 18 in vitro. Data from
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this study suggest that this Herpes Simplex virus may be useful as a vector for APOE 
gene delivery in this in vitro model. This is an area for future development.
(6) APOE Genotype Influence on Apolipoprotein E Interaction with 
Microtubules
Although previous studies indicated that there were apoE isoform differences in 
neuronal repair i.e. differences in MAP-2 immunoreactivity, the mechanisms 
underlying this were unclear. In this study, the influence of apoE E3 and E4 on 
microtubules was assessed. Tubulin immunohistochemistry was performed on 
sections from 0 day control and 90 day survival mice, in the two different lines of 
APOE transgenic mice (human and GFAP promoter). There was a deficit in tubulin 
immunoreactivity in the molecular layers of APOEs4 mice in both lines of mice, 
indicative of an effect on microtubule proteins. The next aim was to determine the 
effect of binding of apoE E3 and E4 to microtubules and their effect on microtubule 
structure. ApoE E3 and E4 protein was isolated from the HDL fraction of human 
plasma, donated by s3 and s4 homozygotes and used to assess isoform binding to 
microtubules. At apoE concentrations of 5pg/ml and 20pg/ml it was found that the 
apoE E4 isoform was more greatly associated with microtubules compared with 
apoE E3 protein. Additionally, microtubules incubated with apoE E4 protein were 
irregularly shaped compared to those incubated with apoE E3 protein. These data 
suggests that although apoE E4 was more greatly associated with microtubules, it did 
have a detrimental effect on microtubule structure.
These studies illustrate the utility of animal models to study apoE and APOE 
genotype influence in long-term outcome after brain injury. Together, the results of 
these studies indicate that the APOE s4 allele is associated with impaired neuronal 
repair processes and that differences in cytoskeletal interactions may underlie this.
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Chapter I 
Introduction
1
1.1 Brain Repair
The capacity of the human brain to repair itself is truly remarkable. The degree of 
plasticity within the human brain following brain injury has been shown to be 
extensive where neuronal cells are capable of sprouting in an attempt at repair. 
Exploitation of this endogenous capability of the brain to repair itself could have 
significant implications for recovery from neurodegenerative disease and brain injury. 
In recent years much speculation has been made on the usefulness of growth factors 
and other such compounds in the treatment of neurodegenerative disorders such as 
Alzheimer’s disease (AD). However the ability of each individual brain to repair may 
be genetically linked and may depend on several factors. One such factor, 
apolipoprotein E, is discussed in this thesis and its function in brain plasticity 
elucidated.
1.2 Apolipoproteins
Apolipoproteins were first identified in the 1970’s as constituents of lipid complexes 
in plasma including apoAI, apoAII, apoAIV, apoCI, apoCII, apoCIII, apoB, apoD, 
apoE and apoJ (Boyles et al, 1985). These proteins are produced by the liver and 
secreted into the bloodstream. In more recent years novel members of this family have 
been identified but are present at very low concentrations within plasma (Beffert et al,
1998). All members of this protein family have been found to be associated with most 
classes of lipid, including very low density lipoprotein (VLDL), low density 
lipoprotein (LDL), high density lipoprotein (HDL) and cholesterol. This led to the 
discovery that the primary function of these proteins within plasma was to direct lipid 
metabolism (Mahley et al, 1988). In the central nervous system (CNS), the presence 
of apolipoproteins has now been identified within many cell types in the brain and also 
within cerebrospinal fluid (CSF).
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1.2.1 Apolipoprotein E
A subset o f apolipoproteins are expressed in the CNS and apolipoprotein E (apoE) is 
the most abundantly expressed apolipoprotein. ApoE was first identified in 1973 as a 
plasma constituent and it was here that its function in lipid metabolism and cholesterol 
homeostasis was first determined (Mahley et al, 1988). ApoE also performs lipid 
metabolism duties within the CNS and in recent years analysis o f the function o f apoE 
(apoE denotes protein, APOE denotes gene) within the nervous system, has revealed 
that this protein may be involved in more complex functions within the CNS. ApoE is 
present in human plasma and CSF as an integral component o f lipoproteins (VLDL 
and HDL)(Danik and Poirier et al, 1998). Lipoprotein particles consist o f  a neutral 
lipid core mainly composed o f triglycerides and cholesterol surrounded by polar 
molecules that stabilise the complex. The polar outer coat is composed o f 
phospholipids and apolipoproteins. The apolipoproteins protrude from the surface
(Figure 1.1) and direct transport and binding. CNS apoE is structurally different to
peripheral apoE in that it is differentially sialylated. ApoE is capable o f interacting 
with a host o f other brain proteins including amyloid protein and several microtubule 
associated proteins (Strittmatter et al, 1994) and it also interacts with a number of 
receptors, mainly o f the endocytic class (Beflfert et al, 1998). In human brain, it is 
widely accepted that apoE is synthesised within most subtypes o f glial cell including 
astrocytes, microglia and oligodendrocytes (Boyles et al, 1985; Mahley et al, 1987, 
Stone et al, 1995). Endogenous synthesis o f apoE within neurons has been shown 
using in situ hybridisation (Xu et al, 1999). In the peripheral nervous system apoE is 
localised mainly to Schwann cells.
C P ApoE
Cholesterol
Q  Phospholipid
components o f a lipoprotein particleFigure 1.1 Diagram illustrating the basic
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1.2.2 ApoE structure and genetic polymorphisms
Human apoE exists as a single glycosylated 34 kDa polypeptide containing 299 amino 
acids and is encoded by a four exon gene on the long arm o f  chromosome 19 (Poirier 
et al, 1995). Biochemical studies have revealed apoE contains two folded structural 
domains, an amino terminal and a carboxyl terminal. The protein contains five a  
helices where four o f  these are arranged into a four helix bundle (Weisgraber and 
Dong, 1996) (Figure 1.2). The amino terminal contains the regions that mediate 
receptor binding and the carboxyl terminal is involved in ligand binding.
Figure 1.2 Diagram 
illustrating the structure 
o f  apoE. ApoE is 
composed o f  5 helices, 
four o f  which are 
arranged into a bundle 
(Weisgraber et al, 1997)
Three major alleles o f  APOE exist within the human population at varying 
frequencies, e2(8%) e3(77%) and s4(15% ), as a result o f multiple alleles at a single 
genetic locus and differ by a single amino acid substitution at positions 112 and 158 
within the protein. The E2 isoform o f  the protein contains two cysteine residues at 
positions 112 and 158 o f  the amino acid sequence. The E3 isoform contains cysteine 
at position 112 and arginine at position 158, whereas the E4 isoform contains arginine 
residues at both positions (Weisgraber et al, 1981). The E2 and E3 iso forms o f  the 
protein exist as dimers under normal physiological conditions, whereas E4 exists in a 
monomeric state. This genetic polymorphism gives rise to three common homozygous 
phenotypes (e2/2, s3/3 and s4/4) and three heterozygous phenotypes (s2/3, s3/4 and 
c2/4), (Roses et al, 1997) which arise at varying frequencies within the general 
population. (Table 1)
D o m ain
I n te ra c t io n
NH2-te rm irta l D o m a in  C 0 2H -term in a l D o m a in
4
Genotype % within the General 
Population
&3/s3 60
s3/s4 21
&3/e2 11
e2/s4 5
82/b2 <0.5
84/s4 2
Table 1. Table illustrating the % o f the general population expressing each o f the six 
APOE genotypes (Western hemisphere).
Molecular analysis o f the gene highlighted that the s2 and e3 genotypes arose from 
the ancestral e4 allele and that the e3 allele increased in frequency (Fullerton et al, 
2000). This divergence o f genotypes occurred within the last 200,000 years. 
Statistically significant differences in allele frequency across populations o f the world 
have been identified (Davignon et al, 1988). A vast array o f population based studies 
have been carried out and the prevalence o f each APOE genotype established for each 
population. In general, the s3 allele is the most common studied to date in all 
populations ranging in frequency from 0.536 to 0.911 (Kamboh et al, 1995). The s2 
allele is the least common. The s4 allele frequency ranges from 0.052 in Sardinians to 
0.407 in Pygmies (Zekraoui et al, 1997) within the world’s populations and is 
negatively correlated with e3 allele frequencies in African and European populations 
(Corbo and Scacchi, 1999). The APOEE3 allele is now increasing in frequency within 
Europe with a relative decline in s4 allele frequency. Allelic heterogeneity is absent in 
all other animal species studied to date with the exception o f  primates.
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1.2.3 Apolipoprotein J
Another member of the apolipoprotein family, apoJ, is present within the CNS. This 
apolipoprotein is thought to perform similar plasticity promoting effects in the CNS to 
apoE and its expression after injury is also considered in this thesis. Apolipoprotein J 
(apoJ) is a 499 amino acid, 70kDa protein associated with high density lipoporteins 
(HDL) (Pasinetti et al 1994; Shanmugaratnam et al, 1997; Calero et al, 1999). 
Structurally apoJ is comprised of two disulfide-linked subunits, apoJa and p, and is 
also known by a range of other names including clusterin and sulphated glycoprotein- 
2 (De Silva et al, 1990; Stuart et al, 1992). The gene for apoJ is located on 
chromosome 8 in the human genome and the sequence has been highly conserved 
throughout evolution (Jordan-Starck et al, 1992). ApoJ has a common two allele 
polymorphism designated APOJ*l and APOJ*2 with frequencies of 0.76 and 0.24 
respectively, however these polymorphisms are only present in Black African and 
Black American populations and is monomorphic in all other populations (Kamboh et 
al, 1991). The gene for this protein was first identified in reproductive organs as a 
gene involved with apoptosis (Michel et al, 1992). More recently the role of apoJ 
within the CNS has been investigated. ApoJ synthesis is similar to apoE in the CNS, 
in that it is expressed in most classes of glial cell and neuronal cells (Danik et al, 1993; 
Pasinetti et al, 1994). Under normal conditions apoJ is widely distributed throughout 
the human brain and plays a role in lipid transport and neurotransmitter secretion. 
ApoJ also protects membrane integrity by closely associating with the membrane 
surface and is believed to perform extracellularly what heat-shock protein performs 
intracellularly in protecting membrane proteins from protease attack while folding 
occurs (Jordan-Starck et al 1992). ApoJ has been found to bind amyloid avidly in 
vivo and in vitro (Strittmatter et al, 1993; Zlokovic et al, 1994) and is believed to aid 
in cross blood-brain barrier transport of soluble amyloid.
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1.3 Apolipoprotein Receptors in the CNS
1.3.1 Receptor classification
ApoE has a wide and diverse set of functions within the CNS, however, equally 
important are the receptors which mediate its effects including the entry of lipid bound 
apolipoproteins into cells requiring the material they are chaperoning. There is a 
whole family of receptors for apolipoproteins in the peripheral system yet only a 
subset are expressed within the brain. In addition to the low density receptor related 
protein (LRP), the main receptor for apoE in the brain, several other receptors 
including the low density lipoprotein receptor (LDL), the very low density lipoprotein 
receptor (VLDL), gp330/megalin receptor (main apoJ receptor) and the 
apolipoprotein E receptor 2 are also expressed (Beffert et al, 1998). These receptors 
all share structural homology and their functional behaviour is similar in that they are 
all receptors of an endocytic class (Brown et al, 1986; Stockinger et al, 1998). 
Receptors of the LDL receptor family can be divided according to their extracellular 
domains. The LDL and VLDL are low molecular weight receptors. In contrast, the 
high molecular weight receptors such as LRP and gp330 are composed of a cluster of 
ligand binding repeats, followed by homology domains. The extracellular parts of 
these receptors appear as multiple copies of the LDL receptor. The high molecular 
weight receptors are thought to be older in evolutionary terms (Willnow et al, 1999).
1.3.2 Low density lipoprotein receptor-related protein (LRP)
In the brain LRP is expressed in neurons (dendro somatic localisation) and reactive 
astrocytes, with the most dense staining noted on neurons of the hippocampus 
(Rebeck et al, 1993, Bu et al, 1994). The VLDL receptor is localised to microglia and 
neurons as identified in AD brain and control autopsy tissue (Christie et al, 1997) and 
the LDLr has a diffuse neuropil stain (mainly present on astrocyte bodies and 
processes)(Lopes et al, 1994; Page et al, 1998; Beffert et al, 1998) with a particularly 
dense labelling of white matter (Pitas et al, 1987; Rebeck et al, 1993). There is a vast 
array of data on each receptor type and its functions, however in recent years the 
association between apoE and the LRP receptor suggest the receptor itself may be 
implicated in Alzheimer’s disease (AD). The LRP receptor is the largest endocytic
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endocytic receptor identified to date at approximately 600 kDa, with a 515kDa 
extracellular domain and an 85kDa membrane anchor (Willnow et al, 1999).
1.3.2.1 Ligand binding o f  the lipoprotein receptor related protein (LRP)
On binding with the apoE-lipid complex, the LRP receptor is internalised in coated 
pits and transported to lysosomes, where the ligand is dissociated from the receptor 
(Herz et al, 1990; Rebeck et al, 1993; Stockinger et al, 1998; Cooper and Howell,
1999). In this way the receptor and indeed apoE may be recycled to the cell surface 
for reutilisation, whilst successfully delivering lipid and cholesterol to the cell. The 
destiny of apoE once internalised, is the subject of some debate and will be discussed 
later in connection with endocytosis. This receptor is particularly remarkable because 
of its ability to bind multiple ligands including amyloid, amyloid precursor protein 
(APP) and several viruses (25 ligands in total to date) (Strickland et al, 1995; 
Kuonnas et al, 1995). Therefore, it has been found to be involved in a plethora of 
processes, which include direction of lipid metabolism within the CNS, developmental 
processes and recycling of lipid and cholesterol for the construction of cellular 
elements in neurite outgrowth.
1.3.2.2 Heparin sulphate proteoglycan
The LRP receptor is generally closely associated with a protein called heparin 
sulphate proteoglycan (HSPG). Combined the LRP and HSPG mediate the effects of 
apoE in the CNS due to their astrocytic and neuronal localisation. The HSPG 
functions in the intial capture of lipid particles from the environment, however it is 
also heavily involved in the uptake process (Mahley and Ji, 1999). The HSPG is 
capable of functioning as a receptor by itself and can bind a similar range of ligands to 
the LRP itself (Ji et al, 1998). Also associated with this receptor is the aptly named, 
Receptor Associated Protein (RAP) which interacts closely with the binding domain 
of the receptor to regulate binding ligands (Willnow et al, 1996; Umans et al, 1999). 
In several cases, this protein has been shown to competitively inhibit the binding of 
many ligands (Williams et al, 1997). RAP controls the folding of the LRP protein 
soon after it is manufactured by the endoplasmic reticulum. It associates with the 
newly synthesized protein to prevent premature ligand association (Willnow, 1998).
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1.3.3 Receptors for apoJ in the brain
ApoJ uptake is mediated primarily by a 600 kDa protein (megalin). This was first 
identified in Heymann nephritis which is a rat model of glomerulonephritis (Zheng et 
al, 1994; Kuonnas et al, 1996). This receptor was found to be concentrated within 
coated pits and therefore it also functions via endocytosis. The gp330 receptor has 
multiple ligands including lipoproteins, blood clotting factors and plasminogen, among 
others, and like the LRP receptor, gp330 associates with RAP protein intracellularly 
(Zheng et al, 1994; Panckhurst et al, 1998; Niemeier et al, 1999). Very few studies 
have focused on this receptor past basic localisation studies (Kuonnas et al, 1994) and 
little is known at present of its endogenous function. However, its function in early 
development is evidently crucial as gp330 knockout mice die perinatally and exhibit 
defective forebrain development (Willnow et al, 1996). Gp330 is expressed in 
abundance in renal tissues, retina, thyroid, inner ear and also within the ependymal 
cells and choroid plexus of the brain (Beffert et al, 1998). No study has clearly 
oulined which cell types in the brain actually express the gp330 receptor and a study 
by Page et al (1998) failed to detect mRNA for this receptor anywhere within the 
rodent brain.
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1.4 Alzheimer’s Disease
1.4.1 History and statistics
Alzheimer’s disease (AD) was first discovered in 1906 by Bavarian neurologist Alois 
Alzheimer who described the symptoms in a female patient known as Auguste D. He 
observed that the patient exhibited many of the standard features of senile dementia 
but that there were some unusual developments. He witnessed that the disease usually 
manifested itself in the seventh or eighth decade of life, however it also very often 
appeared earlier in life. Patients suffered from cognitive decline, altered behaviour and 
memory impairments in the early stages but later they also displayed motor deficits 
that were similar to those observed in Parkinson’s disease. No further progress was 
made in the field until the 1960s when Michael Kidd and Robert Terry described the 
structural neuronal changes associated with senile plaque formation and 
neurofibrillary tangles. In the 1970s it was discovered that a certain population of 
neurons within the brain were selectively vulnerable to degeneration in this disease 
and were the cholinergic neurons of forebrain nuclei. Now it is realised that 
cholinergic neurons are not solely affected and that there is widespread cell death 
throughout the brain regardless of neurotransmitter expression in AD. Only in the last 
20 years, Glenners group was able to clone and sequence the protein present within 
senile plaques and this protein is now known as p-amyloid. Extensive work has since 
been carried out on this protein and its various isoforms and its function in the normal 
and diseased state established. Production and deposition of p-amyloid is believed to 
be central to the pathogenesis of AD. P-amyloid protein (and associated processing 
proteins i.e. presenilins) is now a target for drug development in therapies for AD. 
Senile plaques in the brains of AD sufferers are composed of p-amyloid, a protein 
cleaved from the amyloid precursor protein.
AD is the most common neurodegenerative disorder, affecting approximately 10% of 
individuals under the age of 65 and a total of up to 40% of individuals under the age 
of 80 years (Gelman et a/,1989). As a whole it affects 2.5% of the worlds population. 
Approximately 20% of patients in psychiatric institutions are suffering from AD and
10
this combined with the care of elderly individuals diagnosed with the disease, is an 
important economic concern for governments around the world.
AD is classified into two clinical categories, familial and sporadic late-onset disease. 
Familial AD is inherited through the parent lineage (Selkoe, 2001) and sporadic arises 
randomly within the human population, although it has now become clear that this 
form may too have a genetic component (Saunders et al, 1993). Early AD dementia 
manifests itself clinically as small, momentary lapses in memory. This progresses to 
large voids in memory where sentences become difficult to complete because the 
original reason for the sentence being constructed is lost. In the final stages of the 
disease the individual is unable to perform simple everyday tasks and autonomic 
regulation fails (Soininen and Reikkinen, 1996). Cognitive abilties in AD patients are 
now tracked clinically worldwide using mental score testing of various forms. 
Definitive diagnosis of this disease can only be made microscopically on postmortem 
analysis.
1.4.2 Neuropathology of Alzheimer’s disease
The neuropathological features of AD are well characterised and consist of essentially 
three major components: brain atrophy (neurodegeneration), amyloid plaque 
formation and neurofibrillary tangles.
1,4,2.1 Brain atrophy
Alzheimer’s disease pathology displays a characteristic extensive synaptic decline and 
neuronal cell death in defined regions of the cortex (entorhinal cortex) and limbic 
system (hippocampus) which can strikingly lead to a loss of up to 50% of the brains 
total mass (Hyman et al, 1986; Braak and Braak, 1991; Masliah et al, 1993). Cellular 
loss ultimately leads to atrophy within defined regions of the brain, notably the cortex 
and limbic structures. Associated with this is an increase in ventricular volume with a 
parallel increase in cerebrospinal fluid (CSF) volume (Graham and Hume, 1990). Sulci 
become more exaggerated due to loss of tissue mass of the cortical gyri. Recent 
studies have shown that AD neurodegeneration changes originate in layer II of the 
entorhinal cortex spreading to the hippocampus via the perforant pathway (Braak and 
Braak, 1991; Masliah et al, 1994; Gomez-Isla et al, 1996). This then leads to
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complete disconnection of the perforant pathway and continued degeneration of intra 
and extra-hippocampal pathways eventually leads to the isolation of the hippocampus 
from the rest of the brain. This explains the associated loss of cognitive functions 
(Hyman et al, 1986). In the present day, non-invasive imaging technology such as 
MRI (magnetic resonance imaging) and CT scanning (computerised tomography) are 
used to measure brain atrophy and ventricular enlargement, and magnetic resonance 
imaging now has the resolution to detect single senile plaques in any region of the 
brain. Neurodegeneration combined with the accumulation of intra and extracellular 
amyloid plaque deposits, formation of neurofibrillary tangles (Terry and Wisniewski, 
1970; Arriagada et al, 1992; Yamaguchi et al, 1988) and a decrease in specific 
transmitters (Perry et al, 1977) creates a profound effect on the brain manifesting 
itself classically, as chronic memory loss and progressive cognitive decline (Hyman et 
a l  1986).
1.4.2.2 Amyloid plaques
Amyloid plaques are located extracellulary within most regions of the AD brain but 
are greater in density within the limbic system and association cortex (Weisgraber et 
a l  1994; Selkoe, 2001). Little was known about senile plaques beyond the original 
identification histologically, almost one hundred years ago, until the 1980’s. Glenner 
(1984) dissected out plaques from vascular tissue, cloned and sequenced the protein. 
This then led to the cloning of amyloid precursor protein (APP). Senile plaques are 
composed of amyloid protein. Amyloid p protein (Ap) exists in varying amino acid 
lengths (Ap 1-40/ Ap 1-42/43) (Borchelt et al, 1996). Amyloid p protein is a 
cleavage product of the larger amyloid precursor protein (APP). This protein is an 
axonally transported, transmembrane cell surface glycoprotein that performs a 
putative role in maintaining axon terminals and is synthesised by most cell types 
(Mattson et al, 1993; Mucke et al, 1994). Under normal physiological conditions APP 
is cleaved to produce soluble forms of p amyloid protein intracellularly which are then 
released extracellularly. Insoluble isoforms of the amyloid protein aggregate into 
plaques that cannot be degraded or released extracellularly. The processing of APP 
into Ap protein occurs in the brain under normal physiological conditions. At present 
it is unclear how senile plaques are formed in AD although common hypotheses at
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present are that plaques are due to overproduction of Ap or reduced metabolism and 
clearance from neurons.
1,4,2,3 Neurofibrillary tangles
Neuronal structure is supported by the cytoskeleton comprised of a network of 
microtubules, neurofilaments and intermediate filaments. Under normal physiological 
conditions these elements maintain cellular structure and aid in vital cellular 
mechanisms such as axonal transport. Neurofibrillary tangles are a common pathology 
found in AD and are present within the neuronal cytoplasm within brain regions 
typically affected by AD i.e. limbic system and entorhinal cortex. How tangles are 
formed is the subject of much debate, however the present prevailing hypothesis is 
that they are formed by the hyperphosphorylation of the microtubule associated 
protein tau by protein kinases. Tau is a protein involved in microtubule assembly and 
stabilization. Hyperphosphorylation of this protein results in tau protein adopting a 
paired helical filament (PHF) formation intracellularly (Terry and Wisnieski, 1970; 
Masliah et al, 1989; Arriagada et al, 1992).
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1.4.3 Genes and Alzheimer’s Disease
It became apparent that AD could be passed on genetically through the parent lineage 
and several groups became heavily involved in scanning the human genome in search 
of genes involved in the development of AD. A host of gene sites were found to be 
associated with AD including genes on chromosome 14, 1 and 21 (Selkoe, 2001). 
With the advancement of sequencing and cloning technology, these sites were found 
to encode presenilin 1, presenilin 2 and amyloid precursor protein. Mutations on 
chromosome 21 encoding APP can result in abnormal cleavage sites in the APP 
structure (Clarke and Goate, 1993). This ultimately leads to the formation of a form 
of amyloid (Ap 1-42/43) which forms aggregates more readily than the form produced 
in normal brain. Amyloid protein 1 -42/43 is toxic to neurons and is likely to aid in the 
generation of free radicals and aggregation finally leads to upsets in ionic homeostasis 
(Shoji et al, 1992; Games et al, 1995). Many APP mutations can lower the age of 
onset to approximately 30 years of age (Roses et al, 1997). Subsequently, mutations 
in genes encoding presenilin 1 and 2 were identified. These mutations, similar to the 
mutations in APP are causative for AD. There is now evidence to indicate that 
mutations in presenilins are associated with increased production of Ap 1-42/43. 
Although it had been identified that mutations in genes encoding APP, presenilin land 
2 were causative for familial AD, this still did not account for a considerable number 
of familial AD cases and indicated that other genes may be involved. This led to the 
linkage to chromosome 19, and a gene encoding APOE.
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1.4.4 APOE Genotype and Alzheimer’s Disease
1.4.4.1 APOE genotype and risk o f  AD
A study of autopsy tissue from patients suffering from sporadic late-onset AD 
highlighted an over-representation of the APOEsA allele in these subjects (Saunders et 
al, 1993), where subjects possessing an s4 allele were not only more likely to develop 
AD but had an earlier age of onset. An increasing body of evidence has highlighted 
the APOEsA allele as a major risk factor for sporadic and familial late-onset AD, 
associated with a marked over-representation of the APOEsA allele in the AD 
population (0.52) compared with a control population (0.14) (Roses et al, 1995). 
Approximately 64% of sporadic and 80% of familial late-onset AD possess the s4 
genotype compared with 30% of controls (Corder et al, 1993; Roses et al, 1996). 
This allele not only increases the susceptibility but also lowers the age of onset by 6-8 
years per inherited allele, in an allele dose dependent manner. Multiple population- 
based studies have confirmed these findings.
1.4.4.2 APOE genotype and amyloid
Amyloid plaques and neurofibrillary tangles are the classic neuropathological 
hallmarks of AD. The interaction of apoE with amyloid and microtubule associated 
proteins may be central to the development of these phenomenon and may occur in an 
isoform specific manner. In normal individuals, the binding of apoE to amyloid is 
thought to aid its proteolytic degradation and improve its solubility, however in AD a 
breakdown in this process is thought to occur (Russo et al, 1998). Ap 1-42/43 levels 
are increased in the brain in AD in an isoform specific manner such that levels are 
greatest in individuals within an APOEsA genotype (Masliah et al, 1998). Increased 
plaque density has been shown to occur in the cortex and hippocampus of subjects 
with AD carrying one or two copies of the c4 allele compared to s3 (Schmechel et al, 
1993; Rebeck et al, 1993; Hyman et al, 1995; Beffert et al, 1996). Amyloid plaques 
are strongly apoE immunoreactive (Kida et al, 1995; Sheng et al, 1996). In vitro data 
has shown that apoE E4 (delipidated) binds amyloid protein more readily, whereas 
apoE E3/E2 interacts less avidly and forms a less stable complex (Strittmatter et al, 
1993). Other groups dispute this finding (Aleshkov et al, 1997). In the presence of 
apoE E4 protein, amyloid formed complex networks that had the classical appearance
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of amyloid plaques. In the presence of apoE E3, the networks are less complex (Ma et 
al, 1994; Sanan et al, 1996). It has been suggested that these dense networks formed 
with apoE E4 are not easily broken down and removed in the clearance process and 
thus could explain the greater plaque load in APOEzA carriers. Under conditions of 
lipidation however the biochemical properties of apoE alter to the extent that apoE 
E4 binds less avidly to amyloid compared to apoE E3 (LaDu et al, 1994; Hardy et al, 
1998). ApoE can be attached along the length of amyloid fibrils or incorporated into 
the structure (Ma et al, 1994). It has also been shown that binding of amyloid to apoE 
can alter the interactions of apoE with its main receptors (Guillaume et al, 1996). 
ApoE is complexed to HDL under normal physiological conditions and HDL is also 
capable of forming an association with, and inhibits, the formation of amyloid fibrils 
(Oleson and Dago, 2000).
1.4.4.3 APOE genotype and neurofibrillary tangles
In AD, apoE immunoreactive neurons also contain neurofibrillary tangles. These 
tangles most often occur within the neuronal cytoplasm and are composed of 
hyperphosphorylated tau (Weisgraber et al, 1994). In vitro studies have shown that 
apoE E3 binds avidly to the microtubule associated protein tau whereas apoE E4 does 
not (Strittmatter et al, 1994). It is suggested that the binding of apoE to tau protects 
this protein from hyperphosphorylation and therefore defends its structure and 
prevents the formation of neurofibrillary tangles and dystrophic neurites (Weisgraber 
et al, 1994). AD patients with the e4 genotype have been shown to have a greater 
number of neurofibrillary tangles compared to e3 patients (Schmechel et al, 1993). 
Other groups dispute an APOE genotype influence on tangle density (Olichney et al, 
1996; Gomez-Isla et al, 1996).
1.4.4.4 APOE genotype and neurodegeneration in AD
Several MRI studies have highlighted a significantly greater reduction in the volume 
of specific brain regions including the hippocampus and entorhinal cortex of 
heterozygous e4 AD patients compared with controls (30% loss compared with 25% 
in controls)(Lehtovirta et al, 1995). Atrophy of these regions is more significant in s4
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homozygous AD patients (40%). In a similar study of non-demented c4 individuals 
hippocampal atrophy was also significantly greater when compared with control 
groups (Crook et al, 1986; Bigler et al, 2000). A few studies have focused on white 
matter changes in relation to APOE genotype and reported more severe deep white 
matter lesions in e4 carriers (Bronge et al, 1998), whilst other groups dispute this 
(Schmidt et al, 1996; Czech et al, 1994). A multitude of studies have shown that e4 
AD patients perform poorly in cognitive tests compared to controls. More 
interestingly, middle-aged, non-demented APOEsA individuals also display a deficit in 
cognitive capabiltites compared to non c4 control subjects (Flory et al, 2000). 
Positron emission tomography (PET) images show a state of hypometabolism in the 
brains of clinically diagnosed AD patients (Mielke et al, 1998). Progeny of AD 
patients also display altered glucose metabolism (Small et al, 1996). Non-demented 
e3/e4 heterozygotes of approximately 50 years of age display glucose 
hypometabolism when compared to s3/e3 siblings (Reiman et al, 1996). The PET 
images from e3/e4 and s4/s4 non-aged individuals resembled that observed in AD 
sufferers (Roses, 1997). The authors suggested that this measure could act as a 
predictor of AD since it was approximately 20 years before onset that these metabolic 
abnormalities manifested.
1.4.4.5 APOE genotype and brain levels o f  apoE
Cholinergic dysfunction in AD patients is shown to be directly related to APOEsA 
genotype where reduction in choline acetyl transferase (chAT) activity was 
proportional to the e4 allele copy number (Poirier et al, 1994; Soininen et al, 1995). 
Associated with this is a parallel decrease (40-50%) in choline levels (Nitsch et al, 
1992). These alterations in neurotransmitter may be related to apoE levels in the 
brain. The level of apoE in the brain has been the subject of much debate. The levels 
of apoE in the CSF of AD patients, is significantly lower (3.4mg/L) compared to 
control subjects (4.5mg/L) (Hesse et al, 2000). Total apoE content of brain 
homogenate has also been shown to be lower in the post-mortem tissue of AD 
patients (lOOng/mg protein) compared with control tissue (150ng/mg protein) 
(Bertrand et al, 1995). Some studies dispute this and suggest apoE levels are actually 
elevated or unaffected in the AD brain and that levels only appear to be reduced
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because of a dilution effect, due to an equivalent increase in CSF volume (Terrisse et 
al, 1998). Reduced levels of apoE results in deficient phospholipid delivery to cells 
(Wurtman et al, 1992). This data has significant implications for therapy development 
where the APOEsA genotype of patients undergoing drug therapy has to be taken into 
account. This led to the observation that APOE e4 AD sufferers responded poorly 
when treated with cholinomimetic drugs such as tacrine (Poirier et al, 1995; Farlow et 
al, 1998; Poirier and Sevigny, 1998).
1.4.4.6 LRP receptor and Alzheimer*s disease
Initial interest in this receptor in AD came about with the initial observation, that 
apoE and LRP are co-localized in senile plaques (Rebeck et al, 1993; Poirier et al, 
1995; Hyman et al, 2000) and acts as a receptor for APP (Trommsdorff et al, 1998; 
Van Uden et al, 2000). LRP binds amyloid protein efficiently and internalizes it for 
degradation intracellularly and inhibition of this pathway with the addition of the 
39kDa RAP manifests as an aggregation of p amyloid protein extracellularly (van 
Uden et al, 2000; Hyman et al, 2000; Rebeck et al, 2001). Furthermore, recent 
reports have shown a genetic linkage between LRP and AD (Kang et al, 1997; 
Lendon et al, 1997). Several mutations of the LRP receptor have been studied to 
determine if deficient expression or function of the LRP receptor is central to AD 
pathology. Most recently, studies have demonstrated a linkage of late-onset AD to the 
LRP-1 gene on chromosome 12 and to date approximately 48 polymorphisms of this 
gene have been identified (Zuliani and Hobbs, 1994). Where functional defects in the 
LDL receptor would manifest themselves as familial lipid traits such as 
hypercholesterolaemia, the LRP gene is so large that point mutations may not 
manifest themselves clinically (van Leuven et al, 1998). Several groups have 
examined the 5’ region of the LRP gene where a tetranucleotide repeat polymorphism 
occurs. Recently, two studies identified a polymorphism of a silent mutation in exon 3 
of the LRP receptor (C766T) which was found to be weakly associated with late- 
onset AD (Hollenbach et al, 1998; Beffert et al, 1999). As of yet, no clear association 
has been established between any of the polymorphisms and AD (Chung et al, 1996; 
Clatworthy et al, 1997). However, a site nearby the locus of the LRP gene on 
chromosome 12 is currently under scrutiny, a site which is believed to code for a2-
18
macroglobulin. a2- macroglobulin is a ligand for the LRP receptor, is a proteinase 
inhibitor and in a recent study was genetically linked to AD (Moestrup et al, 1994). 
The study of the mechanics of this receptor and its role in disease and injury is made 
especially difficult as LRP knockout animals cannot be engineered. The LRP gene is 
crucial for foetal development and knockout animals die shortly after birth (Herz et al,
1992). Recently a colony of mice have been engineered with exogenous Lox P sites 
inserted into their genome that allows conditional inactivation after birth. (Mahley and 
Ji, 1999). The engineering of LDL and VLDL receptor knockout mice has been much 
more successful and has outlined other signalling functions which they may be 
involved in (Ishibashi et al, 1994; Trommsdorf et a\, 1999; Umans et al, 1999). Mice 
lacking the RAP protein have also revealed that absence of this protein has significant 
effects on LRP localisation within the brain (Umans et al, 1999).
1.4.4.7 Apolipoprotein J  and Alzheimer*s disease
Many studies have suggested a role for apoJ in AD pathology. ApoJ is expressed at 
high levels in many pathological conditions and acts as an inducer of apoptosis. For 
that reason it is normally expressed in conditions involving transformation of cells 
such as gliomas and Scrapie (Beffert et al, 1998). However, it is also associated with 
AD and functions in a neuroprotectant capacity (Giannakopoulos et al, 1998). 
Probing of post-mortem AD hippocampal tissue revealed increased apoJ mRNA 
expression (May et al, 1990). ApoJ immunoreactivity has been observed in senile 
plaques in the cortex and hippocampus of Alzheimer brain tissue and is also 
upregulated in neurons and reactive astrocytes (Kida et al, 1995; Harr et al, 1996; 
Lidstrom et al, 1997). In human AD postmortem tissue, s4 subjects show low brain 
levels of apoE where apoE levels decrease with increasing number of APOEsA alleles. 
In contrast, hippocampal apoJ protein levels increase with increasing APOEsA allele 
number (60% compared to non-demented control subjects) suggesting a 
compensatory role of apoJ in tissue with low apoE levels (Bertrand et al, 1998).
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1.5 Human Brain Injury
1.5.1 Etiology and statistics
Head injury is the most frequent cause of mortality in individuals aged up to 45 years 
of age. Approximately 1 in 300 families in the UK have a member permanently 
disabled by a head injury as the result of violence (5%), fall (35%), or road traffic 
accident (53%) (Graham and Gennarelli, 1997). 400 patients per 100,000 of the 
population are admitted to hospital every year with a head injury. A survey of 1,000 
patients admitted to hospital following a head injury found 31% died within 6 months, 
30% recovered, 20% were moderately disabled, 16% were severely disabled and 3% 
were vegetative. Regardless of the initial injury, it is evident that recovery of physical 
and cognitive abilities, varies from individual to individual. Some of this may be due 
to environmental factors, such as standard of post-injury rehabilitation. However, it is 
becoming more evident that some individuals may be genetically predisposed to a 
poor recovery following brain injury and the mechanisms involved may be closely 
related to mechanisms previously studied in AD.
1.5.2 Neuropathology of acute human brain injury
Acute brain injury can be divided into categories such as: ischaemic injury as the result 
of cerebrovascular incident or cardiac arrest and traumatic brain injury, the result o f a 
missile and non-missile head injury (Graham et al, 2000). Each year thousands of 
humans suffer from one of these injury types and, although differing in their origin, 
these injuries follow common pathways in secondary damage after the event and in 
subsequent recovery over long periods of time. Ischaemic injury occurs when cerebral 
blood flow is severely reduced as the result of a stroke, or cardiac arrest that in turn 
reduces oxygen supply to the brain. This leads to ischaemic cell death where cells are 
classically pyknotic in appearance and intensely eosinophilic. Macroscopically, brain 
swelling and atrophy are visible where the ventricles become enlarged and midline 
shift, due to raised intracranial pressure, is evident (Forbes et al, 1993). The 
neuropathology of traumatic brain injury is less well defined and consists o f many 
components (Graham et al, 1995; Samatovicz 2000). Brain pathology after head 
injury may be classified in two ways: (1) focal, with injury categorised as skull 
fractures, intracranial haemorrhage and contusions and (2) diffuse, where injury is
20
categorised into ischaemic brain injury, diffuse axonal injury and brain swelling 
(Gentleman et al, 1995, Graham et al, 1995) (Tables 2 and 3).
Focal Diffuse
Skull fracture 
Contusions
Intracranial haemorrhage 
Raised ICP
Diffuse axonal injury 
Ischaemic brain injury 
Brain swelling 
Infection
Table 2 Categories o f brain injury.
Primary Secondary
Lesions
Fracture
Diffuse axonal injury
Haemorrhage 
Ischaemic brain damage
Brain Swelling 
Raised ICP 
Infection
Table 3 Classification o f brain pathology.
Focal injury is most likely to be sustained by physical contact as the result o f a fall 
while diffuse injury is associated with acceleration/deceleration, the type o f injury 
sustained from a road traffic accident (Gennarelli et al, 1982). Within these categories 
primary and secondary pathology has been identified, the primary events being diffuse 
axonal injury and skull fracture (Polvishock and Christman, 1995). The secondary 
events being processes that do not manifest themselves clinically, until a period o f 
time after the initial injury. These include ischaemia, brain swelling and raised 
intracranial pressure. Secondary damage evolves over a period o f  hours, days and 
even a few weeks following the initial injury.
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The secondary damage associated with primary events in common with diffuse and 
focal injury are very often neurochemically driven, caused by fluctuations in ion 
homeostasis (Ca2+ most importantly), cerebral metabolism and breakdown in the 
blood-brain barrier (Graham and Gennarelli, 1997; Maxwell et al, 1997). This 
inevitably leads to breakdown in cytoskeletal elements, primarily microtubules. 
However, of emerging importance are the events that occur months and years 
following the initial injury. Regardless of the original brain injury source, individuals 
who are not dead or vegetative generally follow a process of recovery that can include 
regaining speech skills, learning how to walk again, or even recovering lost cognitive 
capabilities. Recovering these skills requires alterations in the brain to allow the 
formation of new connections and the repair of injured processes, but to achieve this 
certain proteins within the brain must be activated to aid this process.
1.5.3 APOE genotype and acute brain injury: outcome and recovery
1.5,3,1 Traumatic brain injury
The relationship between AD and head injury was made by initial observations in the 
brain tissue of boxers who suffered from being ‘punch drunk’ or dementia pugilistica 
(Corsellis et al, 1973; Roberts et al, 1990). The brains of these individuals displayed 
some of the common neuropathological features associated with AD, including 
neurofibrillary tangles and Ap-containing plaques. Subsequent epidemiological 
studies revealed a significant association between head trauma and a risk of 
developing AD neurodegenerative-like symptoms. Further investigation showed the 
presence of Ap deposits in a large proportion of head trauma victims on postmortem 
examination following short survival periods after the initial injury (Roberts et al, 
1990; 1994). With the association between head injury with AD pathology it was 
examined whether brain pathology after injury was influenced by susceptibility factors 
for AD such APOE genotype. It was found that a history of previous head injury in 
APOEzA survival patients conferred a ten times greater chance of developing AD later 
in life (Mortimer et al, 1991; Mayeux et al, 1993). It was determined that APOEzA 
individuals who died following a head injury were significantly more likely to display 
Ap aggregation (odds ratio of 0.78) than non s4 individuals (odds ratio of 0.15) 
(Nicoll et al, 1995; Horsburgh et al, 2000). This indicated for the first time that
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genotype could modulate the brain’s response to injury. Amyloid deposition has been 
shown as early as 4 hours after injury and these deposits are strongly apoE 
immunoreactive. It was suggested that the amyloid deposits pre-dated the head injury 
because the mean age of the s4+ group was 52 years, whilst it was 28 years for the 84- 
group. However, the criteria for inclusion into the study required death within 30 days 
after the initial injury. This lends to the possibility that the older victims in the non-e4 
group did not die so rapidly after the injury (within 30 days) or alternatively, the 
plaques could develop at an earlier age in individuals possessing an e4 genotype (Roses 
et al, 1997). The issue of whether amyloid deposits were present in head injury victims 
before the injury in that study remains largely unresolved.
Genetic possession of the APOE s4 allele has now been shown to have great 
implications for outcome after traumatic brain injury and further studies have outlined 
an association between the s4 allele and poor recovery from closed head injury 
(Plassman et al, 2000). A higher proportion of APOEzA individuals were found not to 
recover consciousness compared with individuals not possessing an s4 allele. 
Furthermore, 57% of patients with an APOEzA allele had a poor outcome according 
to the Glasgow Outcome Scale, scored as either dead, vegetative, or severely disabled 
compared with 27% in non e4 carriers (Teasdale et al, 1997). Similar studies also 
highlighted a poor outcome in individuals carrying an s4 allele following traumatic 
brain injury and was associated with a greater incidence of prolonged unconsciousness 
(Friedman et al, 1999), a higher incidence of death (Roses et al, 1995) and poorer 
response to rehabilitation (Lichtman et al, 2000). More recently, the presence of 
neurofibrillary tangles has been elucidated in young individuals following repetitive 
head injury (Geddes et al, 1999). The relationship between repetitive head injury and 
APOE genotype was explored in professional boxers and it was shown that those 
possessing an APOEzA genotype displayed greater scores in a clinical scale of chronic 
traumatic brain injury (Jordan et al, 1997). To the present date, no study has defined 
the events that occur at longer survival periods following traumatic brain injury or 
looked at APOE genotype influence on long-term recovery.
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1.5.3,2 Intracerebral haemorrhage, stroke and cardiopulmonary bypass
APOE genotype has been linked to CNS disorders such as cerebrovascular disease 
and stroke. The possession of an APOEzA allele has long been associated with 
atherosclerosis (Hixson et al, 1991) and elevated cholesterol levels (Davignon et al, 
1988). This, combined with the presence of amyloid laden cerebral blood vessels, 
warranted the investigation of APOE genotype in cerebrovascular disease (Namba et 
al, 1991). Work by Schmechel (1993) and others revealed that the APOEzA allele was 
linked to vascular amyloid deposition in a population of AD subjects in a dose 
dependent manner (Greenberg et al, 1995). Subsequent studies have revealed that the 
E4 isoform modulates the severity of cerebral amyloid angiopathy (CAA) by 
promoting the aggregation of A04O around cerebral blood vessels (Alonzo et al, 
1998). Rather unexpectedly, it was found that inheritance of the APOEzl allele posed 
greater risk for blood vessel rupture, this allele had previously been thought of as 
neuroprotective in its role in AD (Nicoll et al, 1997).
The APOEzA allele association with a poor outcome following spontaneous 
intracerebral haemorrhage (Alberts et al, 1995; McCarron et al, 1998; 1999) was then 
identified, an effect which could not be solely explained by larger hematoma volumes 
and more severe oedema in APOEzA individuals (Sorbi et al, 1995). Although there is 
no clear association between APOE genotype and the occurrence of intracranial 
haemorrhage, an apparent link was established between recovery and APOE 
genotype. In a prospective series of patients with nonaneurysmal intracerebral 
haemorrhage, mortality rate was significantly greater for individuals genotypically s4 
and patients without an APOEzA displayed more improved physical and cognitive 
abilities when compared with control groups (McCarron et al, 1998). The APOEz2 
allele has been shown to be beneficial in intracerebral haemorrhage (more favourable 
outcome) (Nicoll et al, 1996, 1997). To date no clear association of the APOEzA 
allele with risk of ischaemic stroke has been determined, however, patients with an 
APOEzA allele are significantly more likely to be functionally and cognitively impaired 
(McCarron et al, 2000). Several groups have actually determined a more favourable 
outcome from ischaemic stroke in APOEzA individuals (McCarron et al, 1998). 
Additionally APOE genotype is also implicated in acute brain injury associated with
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with cardiopulmonary bypass (Newman et al, 1995). Individuals with an APOEzA 
genotype displayed impaired cognitive capabilities compared with a non-s4 control 
group following surgery (Tardiff et al, 1997). These studies all suggest that the 
influence of apoE on recovery from head trauma may depend on the type of insult 
incurred. Neuronal apoE immunoreactivity is increased in the human brain following 
episodes of global ischaemia due to cardiac arrest, where apoE immunoreactivity was 
associated with ischaemic neurons in the vulnerable pyramidal layers of the 
hippocampus (Horsburgh et al, 1999). Upregulation of apoE immunoreactivity also 
occurs in the brains of individuals suffering from hypoglycemia and epilepsy.
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1.6 Animal Models of Brain Injury
1.6.1 Animal models that mimic some of the neuropathological events of human 
brain injury
Several different animal models have been developed which mimic some of the 
neuropathological events that occur in human brain injury. These models include the 
fluid percussion model (Lindgren and Rinder, 1966), the cortical impact model (Dixon 
et al, 1991), closed head injury (CHI) (Chen et al, 1997), stretch models of axonal 
injury (i.e. optic stretch) (Gennarelli et al, 1989), glutamate/excitotoxicity, subdural 
haematoma, focal ischaemia (Tamura et al, 1981; Longa et al, 1989; Macrae et al,
1993) and global ischaemia (Horsburgh et al, 1997; Li et al, 1998). These models 
have been employed primarily in rodents (although higher species have been used) to 
study various components contributing to human brain injury. Using these models, the 
acute (immediate) and chronic (long-term) responses to injury may be assessed. By 
modulating animal survival, the long-term response of the brain to injury may be 
studied and one of the main events, which occur weeks or months after injury, is brain 
plasticity. The contents of this thesis describe the entorhinal cortex lesion model of 
brain injury, which is perhaps, the best characterised model in terms of stimulation of 
plasticity mechanisms. Removal of afferent input into the hippocampus stimulates a 
dramatic plasticity response that is unparalleled in any other region of the brain.
1.6.2 Hippocampal structure and pathways
The hippocampal formation consists of the hippocampus, dentate gyrus and the 
parahippocampal gyrus. In synergy these structures perform valuable functions in 
learning and memory. The formation of new memories requires dendritic remodelling 
and the formation of new synapses to take place within defined regions of the 
hippocampus. This process is termed plasticity and many studies employ the 
hippocampus as a model of CNS plasticity, because of this natural ability to remodel. 
The hippocampus is comprised of highly intricate but well organised circuits, which 
have been relatively well preserved throughout evolution and therefore basic 
hippocampal circuitry is structurally homologous in humans and other mammalian 
species (Barr and Kieman, 1993). The human hippocampus is proportionally smaller
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to the size of the entire brain compared with rodent brain, however the entorhinal 
cortex is geographically closer. The hippocampal formation has four main sources of 
afferent fibres originating in the cortex; the septal nuclei, the contralateral 
hippocampus and the reticular formation and is supplied with blood from the anterior 
choroidal artery. The largest afferent input into the hippocampus is from the 
entorhinal cortex where 80-90% o f the fibres from layers II and III of this region 
project to the molecular layers of the dentate gyrus. Fibres from the entorhinal cortex 
project through the underlying white matter and terminate within the outer two thirds 
of the dentate molecular layer. A proportion of these fibres also project to the stratum 
lacunosum moleculare (Figure 1.5).
The hippocampus proper is composed primarily o f 3 layers. The pyramidal cell layer 
(subdivided into the CA1, CA2, CA3 and CA4), the molecular layers (subdivided into 
inner, middle and outer) and the polymorphic cell layer. The molecular layers of the 
dentate gyrus are composed of the dendritic processes of granule cells. The granule 
cells are the dominant cells of the dentate gyrus, giving it the characteristic ‘V’ shape 
(Figures 1.3 and 1.4)
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Figure 1.3 Diagram derived from The Human Nervous System by Barr and Keirnan, 
1993. The diagram illustrates the structure o f the human hippocampus and highlights 
the intrinsic and extrinsic circuits o f the hippocampus.
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Figure 1.4 Illustrative example o f basic hippocampal structure in a synaptophysin 
immunostained coronal section o f a mouse brain. CA1, 2, 3, 4 are the pyramidal cell 
layers and within the dentate gyrus are the molecular cell layers labelled inner, middle 
and outer. The molecular layers are the main regions o f interest in this thesis.
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Figure 1.5 Diagram illustrating the perforant pathway route from the entorhinal cortex 
to the dentate gyrus.
Intrahippocampal circuitry connections are also shown in the diagram below and 
highlight the feedback nature of these pathways (Figure 1.6). With the development of 
electrophysiological techniques and the use of rodent brain, our knowledge of 
hippocampal circuitry has undoubtedly increased, something that could not be 
achieved using human subjects.
entate Gyrus Mossy fibresPerforant pathway
Entorhinal Cortex CA3
Schaeffer Collaterals
presubiculum,
parasubiculum,
subiculum
CA1
Figure 1.6 Intrahippocampal pathways
The entorhinal cortex receives input from the neocortex of the temporal lobe and 
communicates with sensory areas of the cortex in association with this. In this way the 
hippocampus is kept informed of all sensations and higher brain activities. In this 
capacity it is believed to function in the storage of short-term memories.
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1.6.3 Entorhinal cortex lesion as a model of brain plasticity
The process of neurodegeneration occurs in many human diseases, after brain injury 
and also as an integral part of the ageing process. However, there is some suggestion 
that the human brain is capable of repair and regeneration to a limited extent. This has 
been shown in studies of AD where aberrant sprouting and reactive synaptogenesis 
has been identified within the hippocampus at chronic stages of the disease (Masliah et 
al, 1991, 1992). These phenomena have also been shown following head injury 
(Grady et al, 1989). The entorhinal cortex lesion (ECL) is well characterised and 
allows the study of plasticity within the mature CNS. This model is believed to mimic 
neurodegenerative events characteristic of AD and human head injury (Poirier, 1994; 
Poirier et al, 1995; Danik and Poirier, 1997; Masliah et al, 1996).
Many protocols have been employed to lesion the entorhinal cortex including 
chemical (Cho and Jaffard, 1995) and physical disconnection of the cortical region 
(Masliah et al, 1995) which projects to the hippocampus (see Hippocampal 
Pathways). The mode of lesioning used determines the extent to which 
neurodegeneration occurs within the hippocampus. The most common method used at 
present is aspiration, where the entorhinal region is removed by suction and many 
studies have shown that this leads to degeneration within the outer molecular layer of 
the dentate gyrus (Masliah et al, 1991). The chemical method (achieved by 
administering toxic agent) (Cho and Jaffard, 1995; Scharfinan et al, 1998), 
electrolytic lesion (achieved by injecting small pulses of electricity) (Poirier et al, 
1990; Hardman et al, 1997; Anderson et al, 1998; Terrisse et al, 1999) and cutting 
(using a fine blade) (Ramirez et al, 1996; Haas et al, 1997) all lead to extensive 
neurodegeneration within the middle and outer molecular layers of the dentate gyrus. 
These layers are composed of the dendritic branches from the granule cells (Figure 
1.7). Loss of afferent input onto these cells, results in the breakdown of these 
branches with an associated loss of synapses. This animal model was first 
characterised in the 1960s where tract tracing methods were used to identify the 
projections of the neurons in the entorhinal cortex of the rat and were further mapped 
to define precise projection patterns into the hippocampus (Steward, 1976). To 
confirm these findings the investigators damaged these cells, which resulted in loss of 
fibre definition (60%) in the dentate molecular layers in a time-dependent manner
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(over a period of 14 days) (Cotman et al, 1976; Steward and Vinsant, 1983). 
Evidence for post-lesion sprouting and reactive synaptogensis was initially obtained 
from electron microscopy studies focusing on synapse replacement on denervated 
neurons in the septal nuclei (Raisman et al, 1969). This led to the analysis of 
sprouting in the hippocampus following ECL. Light microscope studies revealed 
proliferation of presynaptic processes from other neighbouring afferent fibre systems. 
The creation of new synaptic contacts was termed reactive synaptogenesis (Cotier and 
Nadler, 1978; Steward et al, 1988) and the proliferation of fibres called sprouting 
(Steward and Vinsant, 1983). Steward and Vinsant (1976) were the first investigators 
to identify the origin of the cells producing the proliferation response and describe a 
time-course for the reinnervation process. Since that discovery, a host of studies have 
employed the ECL to assess CNS plasticity and cellular response to lesions o f this 
kind. Masliah et al (1991) validated an entorhinal cortex lesion model in rat and 
identified specific markers of neurodegeneration and reinnervation, using 
immunohistochemical markers such as synaptophysin and GAP-43. Synaptophysin is a 
synaptic vesicle marker that allows the analysis of synaptic loss and gain. GAP-43 on 
the other hand is the marker of a presynaptic membrane protein involved in 
neurotransmission (Van Lookeren Campagne et al, 1990; Lin et al, 1992; Stroemer et 
al, 1993). This protein is predominately found in the membrane of growth cones and 
therefore this antibody is valuable in identifying not only fibre degeneration but also 
sprouting. Masliahs group noted a significant decrease in both markers by day 7 post­
lesion, however GAP-43 and synaptophysin levels returned towards control levels by 
day 30 post-lesion. To substantiate this finding, several studies have shown that, 
following ECL rats display deficits in memory and learning, which is reduced 
following a suitable period of survival to allow fibre sprouting to occur (Ramirez et 
al, 1996; Hardman et al, 1997; Anderson et al, 1998).
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Molecular Layers o f Dentate G\rus
Ibotenic Acid
Cortical neurons from 
the entorhinal cortex
Figure 1.7 Lesioning the entorhinal cortex. The perforant pathway connecting 
the cortex to the hippocampus can be disconnected via different means i.e 
electrolytically, chemically or aspiratively. Lesioning in the studies included in 
this thesis are achieved chemically. This results in degeneration within the 
molecular layers o f the dentate gyrus (shown on the diagram). The molecular 
layers are comprised of the dendritic branches o f the granule cell layers.
On loss of afferent input to the hippocampus, several other extra and intra 
hippocampal fibre systems have been shown to sprout to compensate (Frotscher et al,
1997). These fibre systems have mainly been identified in animal lesion models, 
primarily the entorhinal cortex lesion (Steward and Vinsant, 1983; Steward etal, 
1988; Masliah et al, 1991). Sprouting has been identified from three main fibre 
pathways (Deller et al, 1996; Frotscher et al, 1997). These are cholinergic fibres from 
the septal nuclei (Deller et al, 1999), crossed temperodentate projections from the 
contralateral hippocampus (Steward and Vinsant, 1983; Deller and Frotscher, 1997) 
and commissural-associational fibre projections from the pyramidal layers of the 
ipsilateral hippocampus (Deller et al, 1996; Deller and Frotscher, 1997). Although 
some groups would argue there is no change in cholinergic markers following 
entorhinal cortex lesion (Aubert et al, 1994; Henderson et al, 1998), compensatory
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sprouting from each of these pathways has been demonstrated in animal models of injury. 
Only projections from the septal nuclei have been clearly shown in human brain. In 
animal models, projections from the commissural-associational fibres have been shown to 
extend up to 10’s of pm into the molecular layers of the dentate gyrus (Steward and 
Vinsant, 1983; Steward et al, 1988) and can be assessed by measuring increases in the 
width of the inner molecular layer (Anderson et al, 1998).
1.6.4 Organotypic hippocampal slice culture: an in vitro model of hippocampal 
plasticity
The ability to maintain a brain slice is an important tool for studying whole brain circuits, 
which is more physiologically relevant than single cells in culture (Gahwiler, 1983, 
1984). In recent years brain slices and in particular hippocampal slices have become 
attractive to electrophysiologists, pharmacologists and biologists because the method 
allows manipulation of the system (drug addition to culture medium) and easy access for 
analysis of current physiological state (electrophysiology). To culture CNS tissue from 
any region successfully, all that is required is sufficient oxygen supply, balanced culture 
medium, and a stable environmental temperature of 36-37°C. Conditions being exact, the 
explant will maintain tissue organisation and cellular connections that resemble the 
original in situ conditions (Stoppini et al, 1991; Gahwiler et al, 1997). In the case of 
hippocampal slices, there are essentially two methods that can be used to maintain 
survival for a period of days, up to months. The tissue is normally sectioned at 100- 
400pm whilst being maintained in a balanced salt solution sufficiently supplied with 
oxygen. The tissue then has to be attached to a substrate that will allow maintenance for 
long periods. In the roller-tube method, slices are embedded in a collagen matrix and 
exposed to continuous changing of the liquid to gas interface. In the membrane culture 
method (interface method), slices are placed on a semi-permeable membrane balanced 
over the culture medium. This allows diffusion of nutrients across the membrane without 
complete submersion in the culture medium. Oxygen is received from above the slice and 
kept completely stationary throughout the entire culture period. Tissue for culturing is 
normally obtained from postnatal animals (<10 days old), as adult tissue generally does 
not survive well due to impaired plasticity capabilities (Stoppini et al, 1991). Many of the 
mechanisms involved in plasticity (GAP-43 expression) may be common to both neonatal 
tissue and adult tissue and is therefore still relevant in these types of studies.
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To allow culturing of hippocampal slices, they require to be dissected from the 
surrounding tissue. This results in removal of the cortical input into the hippocampus 
in a similar manner to that observed in the previously described entorhinal cortex 
lesion (Heimrich and Frotscher, 1990), causing degeneration within the dentate gyrus 
of the hippocampus. Sprouting in hippocampal slices occurs mainly from unlesioned 
intrahippocampal fibre systems (Stoppini et al, 1997; Stoppini et al, 1993). Co- 
culturing the slices with pieces of entorhinal cortex tissue can eliminate this sprouting 
response. In hippocampal slices, survival of neuronal and glial cells is extremely high 
and the morphological appearance of these cells is virtually as found in situ, including 
dendritic structure. Immediately following culture the synaptic density decreases due 
to the deafferentation, however, as found in vivo, reactive synaptogenesis occurs 
(Frotscher and Gahwiler, 1988). Synaptic density tends to remain low in distal 
dendrites due to the lack of extrahippocampal fibre pathways. Therefore, it is evident 
that slices retain a certain capacity for short and long-term plasticity alterations.
The uses for organotypic hippocampal slice culture are wide and varied. 
Electrophysiologists have long been interested in this application as means of 
recording from established neuronal circuitry and this has been particularly useful in 
the study of long-term potentiation (LTP) and in the study of epilepsy. However, this 
culture system is especially relevant for investigations which require the long-term 
survival of the tissue for studies involving chronic administration of drugs (Teter et al,
1999), analysis of synaptogenesis and sprouting (Stoppini et al, 1993), gene 
expression and the long-term influences of ischaemia or hypoxia (Lake et al, 1999). 
This technology combined with the protein analysis systems such as 
immunohistochemistry and Western blotting allows the analysis of behaviour of cells 
and networks in a more physiologically relevant environment.
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1.7 Assessment of ApoE Function and Genotype Influence in Animal
Models of Brain Injury
1.7.1 Human studies versus animal studies
The initial studies linking APOE genotype to AD and head injury were pioneering 
studies and catalysed a vast field of research, which resulted in APOE genotype being 
linked to many other human disorders. However, the majority of these studies were 
human neuropathological or clinical studies. The use of animal models has allowed 
investigators to answer basic fundamental questions, such as cellular localisation of 
apoE before and after brain injury (Poirier et al, 1998). It was not only enough to 
investigate this in normal rodent brain, as they express an apoE isoform structurally 
similar to the human E4 isoform, but systems had to be developed which allowed the 
behaviour of human apoE and its isoforms to be assessed under conditions of brain 
injury. Subsequently, several populations of transgenic mice were engineered which 
expressed the human apoE isoforms. APOE knockout mice were developed which 
addressed the most fundamental question of the primary role of apoE in the CNS.
1.7.2 Genetic engineering of transgenic mice
Transgenic animals are manufactured by a generally common method, using 
embryonic stem cell technology in which the endogenous mouse target gene is deleted 
and the human DNA encoding the appropriate gene sequence inserted by micro­
injection (Gordon et al, 1980; Xu et al, 1996). Human genomic DNA fragments are 
isolated and purified (from homozygous carriers for the APOEz2, s3 and c4 alleles), 
digested, cloned into a vector and transfected into a cell line. Following this, the cell 
lines are screened for presence of the target DNA. Initially, the endogenous gene 
(APOE) is disrupted by gene targeting in the host mouse (Piedrahita et al, 1992). 
Following restriction digestion the purified DNA is micro-injected into the pronucleus 
of single cell embryos, where one parent is a knockout transgenic (Figure 1.8). This 
produces transgenic offspring possessing the target DNA human sequences (Figure 
1.9). The animals can then be backbred with knockout animals, to produce 
heterozygotes, or can be further bred to homozygosity. The presence, integrity and 
copy number of the inserted gene is analysed using polymerase chain reaction (PCR)
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and Southern blotting. Protein expression levels can then be checked using enzyme 
linked immunosorbent assay (ELISA) or Western blotting.
Female Male
SpermEggs
Microinjection 
of gene o f  interest 
into pronuclei of 
single cell embryo
Pronuclei
Southern Blotting confirm 
presence o f  the transgene. Two 
o f the offspring in this case cam  
the gene.
f
Offspring
Figure 1.8 Diagram illustrating the standard procedure for generating transgenic mice 
regardless o f the gene o f interest.
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Figure 1.9 To produce knock-out and transgenic animals before transgene 
introduction the gene is replaced with a gene for neomycin resistance.
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1.7.3 APOE  knockout mice advanced the understanding of basic apoE function 
in the central nervous system
The development of APOE knockout or deficient mice has allowed understanding of 
the basic function of apoE. Several groups have produced APOE knockout mice of 
which some, but not all, display functional or anatomical deficits. The initial findings 
in APOE knockout mice were of abnormalities in the lipid distribution vascularly. 
APOE knockout mice exhibit an hypercholesterolaemic phenotype where cholesterol 
levels are six times higher (577-900mg/dl) compared to wild-type mice (80- 
114mg/dl)(Zhang et al, 1992; Hayek et al, 1998), and arterial lesions develop within 
the proximal aortas by 3 months of age (Reddick et al, 1994). Under normal 
physiological conditions, some ^POZs-deficient mice also display peripheral nerve 
structural defects where the myelin of myelinated axons appears electron dense and 
disordered when compared to the peripheral nerves of wild type animals using 
electron microscopy (Fullerton et al, 1998). In parallel with this, slight motor deficits 
have been detected in these mice (Chen et al, 1997). Within the brain of APOE 
deficient mice, alterations in phospholipid metabolism have been identified where 
levels of membrane phophatidylcholine are significantly lower than in littermate 
controls (Mato et al, 1999; Lomnitski et al, 1999). A similar study also highlighted a 
derangement in the transbilayer distribution of cholesterol in brain synaptic plasma 
membranes (Veinbergs et al, 1999; Igbavboa et al, 1999). In specific brain regions 
synaptic densities of cholinergic, noradrenergic and serotonergic projections are 
significantly lower than control animals. Dopaminergic neuron density is relatively 
unaffected in these animals (Chapman and Michaelson, 1998). In some studies of 
APOE knockouts a reduction in forebrain cholinergic neurons is associated with 
spatial learning deficits when tested in the Morris water-maze (Gordon et al, 1995; 
Krzywkoski et al, 1997; Masliah et al, 1997). Some groups however, have found 
there is no cholinergic deficit in APOE deficient mice (Anderson et al, 1998; 
Bronfman et al, 2000). Aged APOE deficient mice display even greater spatial 
learning problems that are associated with a breakdown in dendritic structure (Masliah 
et al, 1995). In addition to this APOE deficient mice were also shown to have 
abnormal presynaptic terminals, with reduced numbers of synaptic vesicles. The 
microtubule protecting effects of apoE are also highlighted, as in the brains of APOE 
deficient mice the microtubule associated protein tau is hyperphosphorylated, which
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contributes to the abnormal dendritic structural changes (Genis et al, 1995; 1999). 
Immune responses are also altered in APOE knockout mice, suggesting a putative 
role of apoE in cell mediated immunity (Laskowitz et al, 2000). The behavioural 
alterations observed in knockout mice could also be linked to hormonal dysfunction 
due to the disruptions in the hypothalamic-pituitary system. This may also lead to 
metabolic abnormalities (Raber et al, 2000).
1.7.4 APOE transgenic mouse populations and different promoter systems
1.7,4.1 Expression o f  human APOE alleles under the endogenous human 
promoter sequence
There are several populations of APOE transgenic mice that have been engineered. 
The first strain to discuss are the human APOEel and s4 transgenic mice 
manufactured by Xu et al (1996) and developed by Glaxo Research and 
Development. Deletion of the gene was achieved in this case, by removing the APOE 
genes exon and intron 3 and replacing them with the neomycin resistance gene. 
Following homologous recombination, the normal and the modified alleles are 
inherited. The knockout males from this stage are used to fertilise cells from C57BL/6 
female mice. The human APOE genomic DNA (28-30kb) was selected from a 
restriction digest and then injected into the pronucleus of a fertilised embryo. The 
founder mice are then backbred to APOE knockout animals to create animals 
heterozygous for the human APOE genes. Control animals for studies employing 
these transgenics, include littermate APOE knockout controls and wildtype C57BL/6J 
mice. The APOE DNA sequence is inserted in its entirety into the genome including 
the downstream promoter sequences in the creation of these transgenics. This has 
vital implications for the cellular localisation of apoE. APOE expression in these 
transgenic lines has been shown in glial cells throughout the brain, but neuronal apoE 
has also been identified. This corresponds with the endogenous pattern of expression 
in human brain, while rodent APOE expression is strictly glial in nature. This has been 
shown by Xu et al (1998) using high stringency in situ hybridisation that indicated 
neuronal synthesis of apoE. At the present time, these transgenics reflect most 
accurately APOE expression and levels in human brain. Similar study in humans also
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suggests neuronal synthesis of apoE under normal physiological conditions (Han et al, 
1994, Xu et al, 1999).
1.7.4.2 Expression o f  human APOE alleles under a GFAP promoter
A similar set of transgenic mice engineered by Holtzman et al (Sun et al, 1998) at the 
University of Washington, express the human apoE isoforms. However, their 
promoter sequence is an exogenous astrocyte-specific glial fibrillary acid protein 
(GFAP) promoter which, dictates that apoE expression is strictly astrocytic (Sun et 
al, 1998; Holtzman et al, 1999). Following the production of GFAP s3 and s4 mice, 
they were bred with APOE knockout mice and back-crossed onto a C57BL/6J 
background. These animals were heterozygous for the APOEz3 or s4 transgenes and 
expression was determined to be present in astrocytes and neuropil throughout the 
brain.. This pattern o f expression is similar to that found in transgenics produced by a 
group at Duke University in which the APOE gene is under the control of the 
endogenous mouse promoter. The levels of apoE in these line of mice are comparable 
to that in human brain.
1.7.4.3 Expression o f  APOE alleles under a neuronal promoter system
The third population of transgenic mice were generated by Tesseur et al (2000) at the 
Flemish Institute for Biotechnology, Belgium. These mice were manufactured 
originally to investigate axonal degeneration and over-express the APOEzA allele. 
Downstream of the gene, a number of regulatory sequences including the Thyl, 
platelet derived growth factor (PDGF), glial fibrillary acid protein (GFAP) or the 
phosphoglycerate kinase (PGK) promoters were inserted so apoE was expressed 
neuronally in Thyl, PDGF and PGK mice and astrocytically under the GFAP 
promoter. These mice were aged and the brain and spinal cord examined then 
compared in neuron and astrocyte expressing animals. Mice expressing neuronal apoE 
developed severe axonal degeneration and axonal transport was impaired with a 
suggestion of hyperphosphorylation of tau. Levels of apoE in these mice are high 
compared to human brain levels. Another colony of neuronally expressing mice was 
generated by the Gladstone Institute, where the APOE gene is under a neuron specific
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enolase (NSE) promoter (Buttini et al, 1999), however, these mice express similar 
apoE levels to those in human brain.
1.7.5 ApoE and the brains response to injury
7. 7.5.7 ApoE response to acute brain injury in normal rodent brain
The data from the clinical studies indicated APOE alleles had a major role in head 
injury and AD, but very little was known of what apoE was doing in the brain. 
Initially, the response of apoE to brain injury was assessed in rodents following global 
ischaemia. ApoE in rodent brain is localised to glia, not neurons and therefore is 
different to humans. However, the initial studies in rats were undertaken to determine 
cellular localisation and alterations after injury. A global ischaemic insult in rodents 
results in widespread ischaemic cell death within regions such as the caudate and 
specific layers of the hippocampus. In rats, exposed to 15 mins occlusion, apoE 
immunoreactivity was increased at 24 hrs reperfusion within astrocytes and neuropil 
and by 72 hours neuronal cell bodies are intensely stained within the CA1 layer of the 
hippocampus (Kida et al, 1995, Horsburgh et al, 1996). In contrast, at 72 hours apoE 
immunoreactivity in astrocytes had decreased. The results indicated apoE is 
transported to neurons from astrocytes in response to injury. Similar increases in apoE 
have been shown in gerbil brain using in situ hybridisation techniques following global 
ischaemia (Hall et al, 1995; Ah et al, 1996) Intraneuronal accumulation of apoE was 
found to occur within 30 mins in a rat model of subdural haematoma (Horsburgh et 
al, 1997).
7.7.5.2 ApoE response to entorhinal cortex lesion
Before the production of this thesis, a few authors described the response of apoE to 
lesioning in the rat. Poirier et al (1991) first characterised the apoE response in rat 
brain following entorhinal cortex lesion using in situ hybridisation. APOE mRNA was 
increased 7 fold within the hippocampus and expression peaked by day 6 post-ECL. 
ApoE immunoreactivity was largely restricted to cells expressing GFAP mRNA and 
immunoreactivity decreased towards baseline levels by day 30 post-ECL. This study 
however did not include markers of sprouting, although the authors did suggest the 
study displayed a similar time scale to apoE expression following sciatic nerve 
transection and linked this event to remodelling events within the hippocampus.
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Subsequent studies have also shown increased apoE expression (Zarow et al, 1998; 
Anderson et al, 1998). ApoJ immunoreactivity has also been shown to increase within 
the neuropil and glial cells of the dentate molecular layers (Johnson et al, 1996). Prior 
to the production of this thesis, no other studies have investigated the influence of 
APOE genotype on long-term neuronal plasticity.
1.7.5.3 APOE deficient mice and acute brain injury
The primary function of apoE in the brain could be elucidated using APOE deficient 
mice to establish the brain response to injury in the absence of apoE. Exposure of 
APOE deficient mice to a period of global ischaemia, produced significantly greater 
ischaemic neuronal damage when compared to wild type littermate controls 
(Horsburgh et al, 1999; Sheng et al, 1999). This difference is not attributable to 
cerebral blood flow, as blood flow measurements are comparable in APOE knockout 
mice and wild-type mice (Bart etal, 1998). One study highlighted the protective 
effects of apoE in brain injury, by infusing apoE intraventricularly following a period 
of global ischaemia (Horsburgh etal, 2000). Infusion of the exogenous apoE 
significantly reduced the amount of ischaemic neuronal damage in APOE knockout 
and wild-type mice. ApoE deficient mice also display an increased susceptibility to 
focal cerebral ischaemia. Knockout mice sustain larger infarcts compared to wild-type 
mice, with a mortality rate in APOE deficient mice of 40%, compared with 0% in 
wild-type mice following a period of focal ischaemia (Laskowitz et al, 1997). 
Exposure to closed head injury results in widespread neuronal cell death bilaterally 
which is accentuated in APOE deficient mice (Genis et al, 2000). In conjunction with 
this, these mice also display marked motor deficits, cognitive deficits (Chen et al,
1997) and decreased antioxidant activity (Lomnitski et al, 1997) following closed 
head injury, which are significantly more severe than that found in control animals. 
Even milder traumatic brain injury, such as concussive-like injury, renders widespread 
hippocampal damage in APOE deficient mice (Han et al, 2000).
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1.7.5,4 APOE genotype and acute brain injury in transgenic animal models
Studies in APOE knockout mice illustrated that apoE was neuroprotective. The next 
step was to determine APOE genotype influence on human disease. This could be 
addressed, as transgenic animals had been developed expressing human isoforms of 
apoE. It has shown that following a period of global ischaemia, APOEzA mice exhibit 
significantly greater hippocampal neuronal cell damage when compared to APOEzA 
mice exposed to the same episode (Horsburgh et al, 1999). The same is true of 
transgenic mice of the same line exposed to focal cerebral ischaemia (Sheng et al,
1998). After 24 hours of recovery, infarct volume was found to be significantly larger 
in the APOEzA group compared to the APOEzA group. Lesion associated paralysis 
was also less severe in APOEz3 mice, probably as a result of the reduced infarct 
volume. Following exposure to closed injury, APOEzA mice displayed a mortality rate 
of 50% following the injury, where only 25% died in the APOEz3 group. On 
examination 1 hour after the injury all mouse groups (s4, s3, knockout and littermate 
controls) displayed similar severity of injury. Following 11 days of survival, the 
APOEzS mice had significantly smaller lesion sizes and they also exhibited 
significantly smaller neurological scores, compared with the other three groups who 
all displayed similar scores (Sabo et al, 2000). Altogether, these studies showed that 
the APOEzA allele was associated with a poor response to acute brain injury.
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1.8 The Role of ApoE and Influence of APOE genotype on Plasticity
1.8.1 Mechanism of lipid redistribution in CNS plasticity
Neurons have a unique structure, in which the axon terminals may be at a distance of 
a metre or more from the cell soma and therefore not only the anterograde transport 
of lipids is important, but also other means of delivery (Vance et al, 2000). Cells do 
not need to acquire all their lipid material from the cell body, as lipid and cholesterol 
may be taken up from the environment (Fazio et al, 2000) via endocytic receptor 
pathways. Endocytic receptors such as the LRP receptor have been shown to be 
localised dendrosomatically and axonally (Beffert et al, 1998; Page et al, 1998). 
Electron microscopy revealed dense LRP receptor localisation in regions of high 
synaptic density. Many studies highlight a role of apoE (and possibly apoJ) in lipid 
mobilisation for the growth and repair of neurons following injury (Ignatius et al, 
1987; Poirier et al, 1998; Beffert et al, 1998).
The human, and rodent brain retain an amazing ability to maintain neuronal integrity 
under normal physiological conditions, but are also capable of repair and 
compensation under conditions of severe stress (Masliah et al, 1991; Lie et al, 1999; 
Steward and Vinsant, 1976; Arendt et al, 1997). Loss of neuronal input into discrete 
regions of the brain is one of the classic hallmarks of many neurodegenerative 
disorders, such as AD and these neurodegenerative events are also common to head 
injury (Grady et al, 1989). The major constituents of the neuronal structure are lipid, 
cholesterol and water. Combined, these elements form the membranous compartments 
of the nuclear envelope, mitochondria, endoplasmic reticulum, Golgi apparatus and 
the lipid bilayer, which encase the cellular elements. The axon also requires lipid for 
the maintenance of myelin structure and function. As neurodegeneration occurs, the 
cellular structure is degraded releasing vast amounts of lipid and cholesterol debris 
into the extracellular environment (Poirier et al, 1993; Posse de Chaves et al, 1997). 
This material is recyclable and may be scavenged for reutilisation in the construction 
of new cellular components (Fazio et al, 2000), primarily cell membrane. It is in this 
role as a lipid scavenger in which apoE (and possibly apoJ) are thought to excel 
(Poirier et al, 1993). Although the peripheral nervous system (PNS) has been shown 
to be capable of regeneration to a limited extent, the CNS is not capable of
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regeneration per se but rather a process of compensatory sprouting in response to 
denervation. This manifests as dendritic proliferation and sprouting of unlesioned fibre 
pathways (Steward and Vinsant, 1967; Deller and Frotscher, 1997). Growth of a 
neurite occurs at the tip of the fibre at a region called the growth cone (Vance et al,
2000). The progression of a growth cone can occur at a rate of up to 1 mm/day and 
therefore extension of the plasma membrane demands an assiduous supply of 
membrane materials. Electron microscopy studies have shown that lipid is supplied to 
membranes by vesicles, which fiise with the membranes and deliver the lipid encased 
for incorporation into the structure (Posse de Chaves et al, 1997). The source of the 
lipids for this purpose may come from essentially two places. The cell body, axon and 
dendrites of neuronal cells, all contain the apparatus to manufacture proteins that are 
then transported throughout the cell via fast and slow anterograde and retrograde 
transport (Alvarez et al, 2000). Of more importance is the exogenous lipid sources, 
which are transported from other neighbouring cells and from the extracellular 
environment. Mahley et al (1987) first suggested that when a nerve degenerated, lipid 
debris from the membranes is scavenged from the environment, assembled into 
lipoprotein packages and delivered to other cells, which are active in the process of 
sprouting (Vance et al, 2000), and that apoE is heavily involved in this process. 
Evidence confirming this has shown that axonal degeneration products are not cleared 
in APOE knockout mice following injury (Fagan et al, 1998).
1.8.2 ApoE and lipid scavenging
The main hypothesis and one which has prevailed for some time is that on injury, 
apoE protein levels are increased as cells such as astrocytes, microglia and Schwann 
cells upregulate the production and secretion of apoE (Boyles et al, 1985; Stone et al, 
1997; Ignatius et al, 1987). Once trafficked through the extracellular matrix, the 
apoE-lipid complex binds to receptors of the LDL receptor family, which are present 
throughout the nervous system and most importantly are present on neurons (and at 
the tips of growth cones) (Ignatius et al, 1987; Fagan et al, 1996; Narita et al, 1997). 
The complex is then internalised via clathrin-coated pits and the lipid and lipoproteins 
cleaved (Poirier et al, 1993). Lipid is then freely available for incorporation into 
cellular elements (Figure 1.10). The internalised receptor is then thought to be 
recycled to the cell surface. The destiny of apoE following this process is the subject
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of some debate. Under normal physiological conditions, the interaction o f apoE with 
the microtubule-associated proteins is believed to promote cytoskeletal stabilization 
(Roses et al, 1996). However, under conditions o f injury when the process o f neurite 
outgrowth is required, the interaction o f apoE with microtubules is essential for 
extension o f neurite processes (Johnson and Jope, 1992; Pitas et al, 1998). This 
requires escape o f apoE from endosomes and this process will be discussed in the final 
conclusions (DeM attos et al, 1999). A similar process o f lipid scavenging is believed 
to be performed by apoJ because o f its upregulation following brain injury (Tomqvist 
et al, 1996), axonal injury (Tao et al, 1999) and in AD (Bertrand et al, 1995). 
However, the pathways and mechanisms involved have not been clearly demonstrated 
and are confounded by reports that the apoJ receptor, gp330, is very poorly expressed 
or indeed even absent from the human and rat brain (Page et al, 1998, Han et al,
2001 ).
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46
1.8.3 A role for apoE in regeneration was established initially within the 
peripheral nervous system
It is widely accepted, that nerve fibres of the peripheral nervous system (PNS) display 
an amazing ability to regenerate following injury. After peripheral nerve injury, lipid 
and cholesterol materials are released from degenerating axons. ApoE is believed to 
bind to the debris in the extracellular space and transport it to macrophages and 
Schwann cells. Cholesterol from the breakdown of the material can be stored as 
cholesteryl ester for future utilisation (Poirier et al, 1993). The lipid material can also 
be sequestered and used in the reconstruction of various axonal components. ApoE is 
secreted from the macrophage, complexed to an endogenous lipid source and 
transported primarily to the growth cone of the axon engaged in regeneration 
(Ignatius et al, 1987). At the cell surface, the apoE-lipid-complex is internalised via 
receptors of the LDL family. Axons express the LDL receptor along their length and 
increased expression coincides with axonal regeneration and remyelination (Boyles et 
al, 1989).
Initial studies looking at peripheral nerve regeneration, revealed that apoE was 
increased by approximately 200% following optic nerve and sciatic nerve crush and that 
this event paralleled extension and reconnection of the nerve endings (Figure 1.11). 
Increases were so marked, that after 3 weeks the apoE protein levels account for 5% of 
the total protein concentrations in the nerves (from 0.2%) (Ignatius et al, 1986). Much 
of the secreted apoE was associated with lipid and these complexes were internalised 
by receptor mediated endocytosis. Subsequent studies have shown dense expression of 
the LDL receptor on the tips of regenerating nerve fibres. The delivery of lipids and 
cholesterol aid in axonal elongation and may even be involved in the remyelination 
process (Vance et al, 2000). Regeneration was also investigated in dorsal root ganglion 
cells in culture, incubated with lipidated (pVLDL) apoE, and was found to increase 
neurite outgrowth and branching (Handelmann et al, 1992, Nathan et al, 1994). Lipid 
free apoE reduced neurite branching, but neurite extension directed away from the cell 
body was increased. This was thought to occur because apoE reduces the adhesiveness 
of neurites to the extracellular matrix. In the case of PNS injury macrophages enter the 
wound site and synthesise huge quantities of apoE.
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Figure 1.11 Diagram derived from Ignatius et al (1987) illustrating the transport o f 
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This event parallels myelin reabsorption by Schwann cells as axons death progresses 
(Ignatius et al, 1987). 14-21 days after the injury, the process of remyelination begins 
to occur and apoE and apoAI are present within the extracellular matrix and found to 
be associated with large quantities of lipid and cholesterol-like lipids (Boyles et al, 
1989). Ignatius et al (1987) used the injured rat sciatic nerve model to determine if 
neurites are capable of internalising apoE from the environment. They used 
pheochromocytoma (PC 12) cells, which may be stimulated to produce growth cones. 
ApoE labelled with fluorescent dye is endocytosed by the growth cones in a rapid 
manner, suggesting the internalisation was via lipoprotein receptors and not by axonal 
transport. ApoJ too, is upregulated within astrocytes in axotomised processes, 
however its link with regeneration is less well defined and many researchers believe it 
may actually be more involved in the cell death process (Tomqvist et al, 1996; Tao et 
al, 1999).
Work by Bellosta et al (1995) highlighted that the regeneration promoting effects of 
apoE are genotype specific. They demonstrated, that in the presence of very low 
density lipoproteins, apoE E3 and E4 have differential effects on the ability to 
promote neurite outgrowth. When added to the culture medium of dorsal root 
ganglion cells, apoE3, combined with P-VLDL, decreased branching but stimulated 
neurite extension. Cells treated with apoE E4 displayed limited neurite outgrowth. 
Interestingly, apoE added alone to the culture medium had no effect on outgrowth. 
These results suggested that the apoE E4 isoform conferred a poor ability for PNS 
regeneration.
1.8.4 In vitro evidence for a role of apoE in CNS plasticity
Data from studies in the PNS suggesting a detrimental effect of the apoE E4 isoform 
on plasticity lead to interest in the role of apoE in CNS plasticity and whether there 
was an APOE genotype effect. The preliminary studies investigating this were carried 
out in vitro using cell lines derived from the CNS, as opposed to the peripheral nature 
of the dorsal root ganglia (DRG) in the initial studies. Pitas et al (1997) cultured cells 
from a murine neuroblastoma cell line (Neuro-2a) transfected to secrete apoE E3 or 
E4 and, when an exogenous lipid source was added to the culture medium, the apoE
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E3 expressing cells produced neurite outgrowth whilst outgrowth was inhibited in 
apoE E4 expressing cells. It was also found, that this effect could be attenuated using 
blocking agents of the LRP receptor mediated uptake. In contrast, DeMattos (1998) 
suggested that addition of exogenous lipid sources inhibited the inherent outgrowth 
promoting effects of apoE E3 from transfected cells and that apoE E3 and VLDL 
could work independently. In a similar study using untransfected Neuro-2a cells (cells 
do not produce apoE endogenously) it was found that addition of exogenous apoE 
E3, combined with PVLDL, promoted neurite outgrowth whereas addition of apoE 
E4 inhibited it (Fagan et al, 1995; Holtzman et al, 1995). When examined more 
closely it was found that cells incubated with apoE E4 possessed microtubular 
abnormalities, which may contribute to the observed difference in sprouting. 
Hippocampal neurons harvested from C57BL/6J mice were also shown to produce 
extensive neurite outgrowth when grown on a monolayer of astrocytes, cultured from 
transgenic mice expressing APOEs3 under a GFAP promoter sequence (Sun et al,
1998). Outgrowth was inhibited in neurons grown in the presence of apoE E4 
secreting astrocytes. Questions have arisen as to whether the PVLDL lipid source 
employed in the majority of these studies is physiologically relevant, as apoE is found 
endogenously attached to high density-like (HDL) lipoproteins within the CNS. For 
this reason Fagan et al (1996) carried out a study in which apoE E3 and apoE E4 
enriched HDL was incubated with a neuronal cell line (GT1-1 trk9) and again it was 
found that apoE E3 enhanced neurite outgrowth where apoE E4 did not. This effect 
was blocked by an LRP-receptor blocker, indicating that it was a receptor-mediated 
event.
L 8.4.1 LRP receptor function in neurite outgrowth
The LRP receptor mediates apoE-dependent neurite outgrowth, a phenomenon which 
has been identified in a host of in vitro studies (Narita et al, 1997). ApoE E3 
promotes neurite extension in a population of nervous system-derived neuronal cell 
line, an effect which is abolished by the addition of RAP, LRP antibody or lactoferrin 
to the culture medium (Fagan et al, 1996; Williams et al, 1998). It is completely 
feasible that the isoform-specific effect differences are due to differential interactions 
of each apoE isoform at the receptor interface. The single amino acid changes in apoE
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structure for each isoform, is in the LDL/LRP receptor-binding domain and therefore 
it is possible that this would confer binding differences (Mahley et al, 1988). 
However, biochemical studies have revealed that iodinated apoE E3 and E4 have 
similar binding affinities, with apoE E2 displaying the greatest affinity (Weisgraber et 
al, 1993). Ji et al (1998) analysed uptake of 125I-VLDL enriched apoE E2, E3 and E4 
and discovered a 2-3 fold greater accumulation of apoE E3 (and E2 although to a 
lesser extent) than E4 in Neuro-2A cells following 2 hours of incubation, a response 
which was not mediated by either the LDL or LRP receptor since the response 
persisted in cells deficient in both these receptors. The differential accumulation was 
enforced by heparan sulphate proteoglycan (HSPG), a protein closely associated with 
LRP at the membrane surface and responsible for the sequestration of apoE-enriched 
lipoproteins before internalisation by the HSPG-LRP pathway (Mahley et al, 1994). 
On treatment with heparinase, differential accumulation is abolished and thus it is 
evident that the intracellular levels of apoE rely heavily on the presence of the 
receptor associated HSPG (Bellosta et al, 1995). Indeed, some studies have shown 
that HSPG is capable of apoE-complex internalisation in the absence of either the 
LDL or LRP receptors (Mahley et al, 1995). Following the publication of these 
studies, there has been very little literature focussing on the biochemistry of the 
HSPG-LRP pathway. Such work may hold the key to APOE genotype influence on 
cell function.
1.8.5 APOE genotype may influence plasticity in Alzheimer’s disease
In the last 10 years interest in brain plasticity has increased, with the initial realisation 
that long-term potentiation was a basic synaptic plastic mechanism that was primarily 
involved in the acquisition of memory (Gomez-Femandez, 2000). Neurogenesis does 
not occur in the adult mature brain, however, processes of compensatory growth and 
repair are initiated in an endogenous attempt to reduce functional deficit. 
Neuroplasticity is a natural ability of the nervous system to reorganise and alter its 
function in response to environmental changes. Sprouting in the brains of patients 
with temporal lobe epilepsy (TLE) are the best documented cases of plasticity in the 
adult brain. Using a range of markers such as Growth Associated Protein-43 (GAP- 
43) and 5’ nucleotidase, which is a marker of spontaneous synaptic turnover, 
plasticity has been shown in the dentate molecular layers of the hippocampus (Pollard
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et al, 1994; Lie et al, 1999). Neurodegeneration is extensive in AD, resulting in the loss 
of cortical input into the molecular layers of the hippocampus. Several intrahippocampal 
fibre systems are capable of reinnervating the denervated molecular layers, including 
those from the contralateral hippocampus, commissural-associational fibres from the 
CA3 pyramidal layer/hilus region and cholinergic fibres from the septum, as identified in 
rat models. In AD postmortem tissue, mechanisms of compensatory growth have been 
shown especially within the hippocampus, using antibodies such as GAP-43 (Masliah et 
al, 1991 and 1992; Bogdanovic et al, 2000). The sprouting observed in these AD cases 
tends to be aberrant with respect to their localisation and neurotransmitter composition, 
however the intensity of dendritic changes is apoE genotype dependent. The brains of 
Down’s syndrome patients with marked dementia related neuronal loss, also exhibit 
neuronal sprouting (Ohara et al, 1999). Data from a study by Arendt et al (1997) 
suggested that plastic remodelling is severely impaired in APOE s4 carriers. The s4 allele 
dose was also shown to have significant effects on the severity of the initial degeneration, 
degeneration which was not restricted to cholinergic neurons, suggesting a more 
widespread effect of apoE.
1.8.6 APOE genotype and brain plasticity after head injury
Cortical plasticity in humans after brain injury has been documented (Robertson and 
Murre, 1999). Following unilateral perinatal brain injury, the brain switches its 
functions to the healthy cortex, this results in ipsilateral motor control using ipsilateral 
corticospinal projections and the contralateral cerebellum. Patients with this disorder 
produce mirror limb movements (Nirkko et al, 1997). The hippocampus of patients 
who have undergone uncal herniation due to raised intracranial pressure, display 
sprouting within the termination field of the entorhinal cortex (Grady et al, 1989). 
Reorganisation of the CNS is crucial if lost modalities such as speech and motor 
functions are to be returned after injury. Several studies have shown synaptic change, 
tracked electrophysiolgically, could contribute to functional recovery after traumatic 
brain injury and stroke (Lee and van Donkelaar, 1995; Ivanco and Greenough, 2000; 
Kempermann et al, 2000). The first study suggesting APOE genotype may modulate 
long-term plasticity after traumatic brain injury was carried out by studying clinical 
outcome, 6 months after traumatic brain injury. APOEz3 and s4 head injured
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individuals over a range of ages were recruited and assessed over a period of 6 
months following a traumatic brain injury. Initially, it appeared there was no genotype 
effect on outcome, however when the groups were broken down into age categories, 
it was found that the APOEz3 <15 years group exhibited significantly better clinical 
outcome compared to APOEzA carriers when controlled for severity of initial injury 
(Teasdale et al, 2000). This would suggest that the differences in outcome may be 
more related to genotype effects on plasticity and not age related effects, such as 
amyloid deposition.
1.8.7 A role for apoE in plasticity mechanisms in other human diseases
The vital role of apoE in the transport of lipids and cholesterol and the isoform 
specific differences in this role has implications for many other human diseases and 
disorders, particularly those which are primarily neurodegenerative disorders. 
Although a topic of some debate, it appears that multiple sclerosis (MS) may have a 
significant genetic component. Studies in the past have failed to detect any APOE 
genotype influence, until recently, with the advancement of MRI technology 
(Weatherby et al, 2000). A recent study of 83 MS patients revealed subjects with an 
e3/s4 genotype showed a greater T2-LL than patients with the e2/e3 genotype, 
supporting speculation on an APOE genotype influence on MS severity (Fazekas et 
al, 2000). The authors suggest this may be attributed to more extensive destruction or 
less efficient repair. It has also been shown that the frequency of the APOEzA allele is 
significantly higher in MS patients compared with a control group (P<0.05) and the 
rate of progression was significantly greater in APOEzA individuals (Hogh et al,
2000). Conversely, a study by Carlin et al (2000) highlighted that remyelination was 
defective in patients genotypically APOEz2. ApoE immunoreactivity was increased 
within demyelinated regions localised to macrophages and astrocytes. More severe 
white matter degeneration has been shown in AD associated with the APOEzA allele 
(Bronge et al, 1999). In subsequent studies the APOEzA genotype has been linked to 
several other neurodegenerative conditions, such as AIDS related neuropathy, 
diabetic neuropathy and motor neuron disease (MND) (Bedlack et al, 2000). 
Possession of an APOEzA allele in patients with MND results in rapid deterioration 
and a significantly lower age of onset. Average survival, from the onset of the disease
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to death, was not found to be statistically different in c4 individuals however, in 
clinical, terms this equates to a mean survival time of 36 months compared to 49 
months. The data concerning Huntington’s disease is less well defined but highlights, 
in contrast, a more rapid progression of the disease in APOEzl carriers and this was 
particularly noted in females (Kehoe et al, 1999). The reason for this adverse effect of 
s2 is unknown although may be related to estrogen levels. Parkinson’s disease (PD) is 
one of the most common neurodegenerative disorders manifesting itself in 1% of 
Western populations and therefore is a major economic burden. Several authors have 
investigated whether the APOEzA allele is associated with PD and Parkinson’s related 
dementia, considering that PD dementia possesses many of the neuropathological 
features of AD. PD patients show a trend for greater s4 allele frequency than control 
subjects, however dementia was not significantly greater in those individuals 
(Inzelberg et al, 1998; Oliveri et al, 1999). More recently it has been suggested that 
individuals have an increased susceptibility to sporadic PD when an APOEzA 
genotype is combined with a polymorphism of allele 1 of the alpha-synuclein promoter 
(Kruger et al, 1999). The APOEzA allele has also been shown to predispose patients 
to a greater degree of dopaminergic drug induced hallucinations (Inzelberg et al, 
2000).
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Aims of Thesis
The APOEzA allele confers an increased risk for the development of AD and more 
exaggerated neuropathology (plaque load and tangle density), when compared with 
individuals not in possession of an APOE e4 allele. The APOE s4 allele has also been 
shown to be associated with a poor outcome following brain injury. The introduction 
of this thesis, has highlighted a role for apoE in the modulation of the brains response 
to acute injury. However, there is evidence that apoE may play a role in long-term 
recovery and repair processes.
The aims of this thesis are to:
1. Establish a model of entorhinal cortex lesion using C57BL/6J wild-type mice and 
characterise the acute and chronic cellular and protein alterations following the 
injury (Chapter III).
2. Analyse APOE genotype influence on CNS plasticity, in a line of APOE transgenic 
mice, expressing human APOEzl or c4 alleles under the endogenous human 
promoter sequence following entorhinal cortex lesion (Chapter IV).
3. Analyse APOE genotype influence on CNS plasticity, in a line of APOE knockout 
and transgenic mice, expressing human APOEzl or s4 alleles under a GFAP 
promoter sequence following entorhinal cortex lesion (Chapter V).
4. Analyse APOE genotype influence on ageing in the brains, of a line of APOE 
knockout and transgenic mice expressing human APOEzl or s4 alleles under a 
GFAP promoter sequence (Chapter VI).
5. Establish an organotypic hippocampal slice culturing model and use this to 
characterise the sprouting response in hippocampal slices derived from C57BL/6J 
and APOE transgenic mice and analyse Herpes Simplex Virus as a potential vector 
for apoE gene delivery (Chapter VII).
6. Analyse microtubular binding of apoE E3 and apoE E4 protein and determine if 
there is an isoform specific difference (Chapter VIII).
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Chapter II 
Materials and Methods
2.1 Mice
2.1.1 Wild type C57 BL/6J mice
Male C57BL/6J mice were obtained from Harlan Olac and maintained in an animal 
unit at the University of Glasgow.
2.1.2 APOE transgenic mice on a human promoter
APOE e3 and s4 heterozygous transgenic mice were generated as previously 
described (Xu et al, 1996). Briefly, the coding and promoter sequences of human 
APOE were inserted into the genome of apoE knockout mice. The mice were 
backcrossed at least six times to C57BL/6J mice in the USA, before transportation to 
the UK and further backcrossing at Glaxo Wellcome. In the present study, APOE s3- 
437 and APOE e4-81 lines were used which carry two copies of the appropriate gene. 
These lines were selected as they were best matched for apoE levels. The mice were 
obtained from Glaxo Wellcome and maintained in an animal facility at the University of 
Glasgow.
2.1.3 APOE transgenic mice on a GFAP Promoter.
APOEzA and s4 heterozygous transgenic mice were generated as previously described 
(Sun et al, 1998). Briefly, the coding sequences of human APOE were inserted into 
the genome of B6/CBA mice. An exogenous glial promoter sequence was attached to 
the APOE DNA sequences, so expression is driven astrocytically. Integration of the 
transgene was determined by PCR and Southern blotting analysis. The mice were 
imported from Dr D. Holtzman, maintained and bred in an animal unit at the 
University of Glasgow. These mice were also employed in the in vitro studies used as 
7 day neonates.
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2.2 APOE Genotyping
2.2.1 Restriction Digest of Mouse Tissue
The genotype of transgenic animals was confirmed by PCR analysis (Nicoll et al, 
1995). Tail tip samples (carried out by Dr K. Horsburgh) were collected from each 
transgenic mouse aseptically and placed in DNA/RNA free tubes filled with sterile 
ethanol. The genotypes were then analysed at the Southern General Hospital (by 
Janice Stewart). DNA was isolated in an enzyme digest mix containing proteinase K 
overnight at 56°C. The samples were then incubated at 95°C for 10 mins to inactivate 
the proteinase K. 0.8pi of the target DNA was then added to 14.2pl master mix 
(containing deoxynucleotide bases, primers L3 and R3+ and Amplitaq Gold 
polymerase) (see appendix) and transferred to a thermal cycler (Techne GENIUS). 
Briefly the cycler progressed through a series of temperatures, 35°C (to denature the 
target DNA), 95°C (to anneal the primers) and 65°C (for new DNA synthesis). To the 
final PCR product, restriction enzyme was added (Hhal) and incubated overnight at 
37°C. This restriction enzyme cleaves at ‘GCGC’ sites on the DNA sequence (i.e. 
arginine residues) and therefore at positions 112 and 158 where the residue 
substitutions occur that are responsible for apoE isoform structural differences.
2.2.2 PCR Gel Electrophoresis
To 15pi of PCR product, 4pl of loading gel was added before loading the samples 
onto a gel for electrophoretic separation. A Hinf 1 marker was also loaded onto the 
gel as a DNA ladder. The gel was run at 200 volts for 40 mins. The electrode 
assembly was removed from the tank and carefully prised from between the glass 
plates. The gels were then incubated in ethidium bromide solution (lOmg/ml) for 4 
mins, the bands visualised on a ultra violet light box and photographic images 
collected (Figure 2.1).
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Figure 2.1 PCR analysis o f  APOE genotype from human brain tissue
2.3 Entorhinal Cortex Lesion
2.3.1 Surgery
All animals employed in these studies were approximately 12 weeks o f  age at the time 
o f  procedure and weighed approximately 25-30g in weight. Animals were fed on the 
same diet and housed under identical conditions. Anaesthesia was induced by a 
combination o f  3% halothane in 70% N20 /  30% 0 2. The animals were fixed in a 
K opf stereotaxic frame, with anaesthesia maintained at the above levels. Each animal 
was ventilated mechanically throughout the entire procedure. Body temperature was 
monitored by a rectal probe and regulated by a heat lamp to 37°C.
All surgical procedures were carried out under sterile conditions. A rostrocaudal 
incision was made above the right eye extending to the ear, revealing the cranium. 
The skull overlying lambda was drilled away, with the aid o f an operating microscope, 
to expose the occipital lobe and the dura removed. Ibotenic acid (8)(a-amino-3- 
hydroxy-5-isoazoleacetic acid (Sigma)) (lOmg/ml in phosphate buffered saline (PBS)) 
was injected using a Hamilton syringe. Co-ordinates for the injection site were 
determined from Bregma (AP 4.72mm; L 4.75mm; A 17° from vertical). The needle 
was lowered vertically 1.5mm through the cortex to the entorhinal region. A total 
volume o f  0.5pi o f  ibotenic acid was injected at a rate o f  0.1 pi/ min. The needle was 
left in place for a further 5 mins to allow diffusion through the tissue. Following the 
procedure the wound was sutured and 0.5ml o f  saline administered subcutaneously, to
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keep the animal hydrated throughout the recovery period. The animals recovered from 
anaesthesia in an incubator for 2 hours, and returned to the animal unit. Control 
animals (0 days) underwent an identical procedure but were terminated immediately 
after the surgery.
2.3.2 Processing of Tissue
Following the appropriate survival period, the animals were perfused transcardially 
under halothane anaesthesia with heparinised saline (lOmls), followed by buffered 4% 
paraformaldehyde (20mls). The brains were post-fixed in the skull for 24 hours, to 
prevent artefacts due to mechanical damage, removed and post-fixed for a further 2 
hours and processed for paraffin embedding. The brain was cut into two 3mm coronal 
blocks containing the occipital cortex for lesion assessment and the other, at the level 
of the lateral habenula, for visualisation of the hippocampus. The blocks were placed 
into plastic cassettes, dehydrated through a graded series of alcohols and cleared in 
xylene. This processing had been optimised previously. Following submersion of the 
cassettes in liquid paraffin for 24 hours at 60°C, the blocks were embedded in paraffin 
and left to harden at 4°C. 6pm coronal sections were cut on a microtome and 
collected onto polylysine coated slides.
2.3.3 Assessment of Lesion
2.3.3.1 Haematoxylin and Eosin Staining
Sections from the occipital cortex containing the entorhinal region were stained with 
haematoxylin and eosin to confirm correct needle placement and the presence of the 
lesion. Briefly, sections were dewaxed in histoclear, dehydrated in absolute alcohol 
and rinsed in water, before submersion in haematoxylin for a period of between 1-10 
mins. The sections were then rinsed in water and differentiated in acidic methylated 
alcohol (1% HC1). Following another rinse in water the sections were placed in Scot’s 
tap water substitute (STWS) for 1 min, rinsed again and placed in eosin (aqueous) 
for 3 mins. After a final wash in water the sections were dehydrated through a graded 
series of alcohols, cleared in histoclear and coverslips mounted with histomount.
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2.3.4 Immunohistochemistry
2.3.4.1 Single Labelling Immunohistochemistry
Paraffin sections were placed in an oven at 60°C for 15 mins, dewaxed in histoclear 
for 30 mins and dehydrated in absolute alcohol (2x10 mins). Endogenous peroxidase 
was eliminated by incubating the sections with 3% H2 O2  in methanol for 30 mins. 
Sections were washed in PBS (phosphate buffered saline), non-specific binding 
reduced using blocking agent (10% normal serum/ 2% bovine serum albumin (BSA) 
in PBS) for 1 hour and primary antibody was applied overnight at 4°C. 
Concentrations of antibodies applied are shown in Table 4. Sections were then 
incubated in biotinylated secondary antibody (1:100) for 1 hour and processed with a 
Vectastain ABC (avidin biotin complex) standard kit. Diaminobenzadine 
(DAB)(Vector) was employed as the chromagen in the visualisation step (Figure 2.2). 
The reaction was allowed to proceed for exactly 3 mins and the reaction stopped by 
submerging the sections in distilled water. The sections were then thoroughly washed 
in water before being dehydrated through a graded series of alcohols, cleared in 
histoclear and coverslipped. Negative controls were generated by omission of primary 
antibody (Figure 2.3). Optimal working dilutions were determined for each antibody.
2.3.4.2 Double Labelling Immunohistochemistry
The same basic method as above was applied. Following the DAB stage from the first 
antibody, blocking solution is then applied and the next primary antibody applied. The 
procedure continues by addition of the appropriate secondary antibody for the second 
primary antibody and ABC application for 1 hour. SG was employed as the second 
chromagen and the sections were incubated in this for exactly 3 mins. SG appears 
grey in colour microscopically.
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A  Primary antibody
Secondary antibody
Biotin 
Avidin 
☆  Peroxidase
Antigenic
Epitope
Add substrate for 
peroxidase i.e. DAB 
or SG
1. Primary antibody binds to antigen
2. Secondary antibody with biotin attached 
binds to the primary antibody
3. Biotinylated enzyme peroxidase and av idin 
form a complex (ABC)
4. ABC binds biotin on secondary antibody
5. Chromagen ie DAB used for visualisation
Figure 2.2 Diagram illustrating the chemical interactions involved in 
immunohistochemistry.
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Antibody
Cone'1 used for 
Immunohistochemistry
1. Primary antibody
2. Blocking serum
3. Secondary antibody
Source of primary 
antibody
Synaptophysin 1:200 1. Mouse monoclonal
2. Normal horse serum
3. Anti-mouse (horse)
Sigma
GAP-43 1:500 1. Mouse monoclonal
2. Normal horse serum
3. Anti-mouse (horse)
Sigma
MAP-2 1:750 1. Mouse monoclonal
2. Normal horse serum
3. Anti-mouse (horse)
Sigma
ApoE 1:5000 1. Goat polyclonal 
2 Normal horse serum 
3. Anti- goat (horse)
Chcmicon
ApoJ 1:50 1 Goat polyclonal
2. Normal horse serum
3. Anti- goat (horse)
Chemicon
GFAP 1:1000 1. Mouse monoclonal
2. Normal horse serum
3. Anti-mouse (horse)
Sigma
LRP
(Lipoprotein
receptor-related
protein)
1:1000 1 Rabbit polyclonal
2. Normal goat serum
3. Anti-rabbit (goat)
Gift:Dr D 
Strickland
LRP 1:1000 1 Rabbit polyclonal
2. Normal goat serum
3. Anti-rabbit (goat)
Gift : Dr J Herz
Tubulin 1:500 1. Mouse monoclonal
2. Normal horse serum
3. Anti-mouse (horse)
Sigma
mrf-1
(microglial 
response factor)
1:20 1. Rabbit polyclonal
2. Normal goat serum
3. Anti-rabbit (goat)
Gift : Dr S. Tanaka
Table 4 Data table illustrating information on the antibodies used in all studies.
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Figure 2.3 Illustrative example of a negative control for immunohistochemical 
staining. This was achieved by omission of the primary antibody acting as a control 
for non-specific staining.
2.3.4.3 Quantification o f  Immunohistochemistry
Multiple controls were carried out to ensure consistency of optical density 
measurement. Immunohistochemistry for each antibody was carried out on all sections 
in a series batch simultaneously to eliminate differences in the immunohistochemistry 
process. Relative optical density (ROD) values for immunostaining were measured 
using an M4 image analysis system (MCID) connected to a microscope. All 
measurements for a single antibody series were rigorously recorded in the dark, on the 
same day and at the same microscope light intensity, to eliminate light variation 
effects. Optical density readings were taken from the inner, middle and outer 
molecular layers (IML, MML, OML) of the dentate gyrus of both the ipsilateral and 
contralateral hippocampus using a 1cm2 sampling box. The box was placed randomly, 
six times within each layer (IML, MML and OML) and an average taken for each 
layer. The averages from each subject entered into a statistical program (Graphpad 
Prism) for analysis.
Density measurements were also taken from subcortical white matter regions to act as 
a control for intensity of immunohistochemical staining. ANOVA was also carried out 
on contralateral readings to ensure that staining was of an identical intensity in every 
section of a series.
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2.3.5 Statistical Analysis
2.3.5.1 C57BL/6J mice
One way ANOVA was carried out on the contralateral hippocampal readings and the 
ipsilateral and contralateral readings were compared using a Student’s paired /-test. 
All data is represented graphically as the mean +/- standard error of the mean 
(S.E.M.).
2.3.5.2 APOE transgenic mice (human promoter)
One way ANOVA was carried out on the contralateral optical density readings and 
the percentage difference between the ipsilateral and contralateral readings was 
compared using a Student’s unpaired /-test. Bonferroni correction for multiple 
comparisons was carried out where necessary and is specified in the legend to specific 
graphs. All data is represented graphically as the mean +/- S.E.M.
2.3.5.3 APOE transgenic mice (GFAPpromoter)
ANOVAR was carried out on the groups and the genotypes compared using a 
posthoc Student’s unpaired /-test with Bonferroni correction for multiple 
comparisons. All data is represented graphically as the mean +/- S.E.M
2.3.5.4 Ageing study
ANOVAR was carried out on the data at 3 months of age and then at 1 year. The 
genotypes in each group were then compared using a Student’s unpaired /-test with 
Bonferroni correction for multiple comparison. All data is represented graphically as 
the mean +/- S.E.M.
2.3.6 Quantification of IML Width
The width of the inner molecular layer was measured in GAP-43 immunostained 
sections to give an indication of the sprouting index. Expansion of this layer is 
indicative of sprouting from the commissural-associational fibre pathway, an 
important source for reinnervation of the molecular layers (Anderson et al, 1998). 
The MCID analyser was calibrated to measure distance in millimetres using a stage 
graticule and measurements were taken from the ipsilateral and contralateral IML of 0 
day control animals and 90 day survival animals. ANOVAR was carried out on the
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contralateral readings to ensure no significant variance in width. In C57BL/6J mice 
the ipsilateral and contralateral IML width at day 90 post-ECL was compared using a 
Student’s unpaired /-test. The width of the IML in knockout and APOE s3 and c4 
transgenic mice was compared using a Student’s unpaired /-test with Bonferroni 
correction for multiple comparisons.
2.3.7 Western Blotting
2.3.7.1 Tissue Collection
The entorhinal cortex was lesioned in male C57BL/6J mice and the animals allowed to 
survive for periods of 0, 7 and 28 days (n= 5 per timepoint). The animals were culled 
by anaesthetic overdose and the brains removed. The ipsilateral and contralateral 
hippocampus was dissected out from each brain and rapidly frozen in liquid nitrogen.
2.3.7.2 Tissue Homogenisation and Protein Assay
The hippocampal tissue was weighed and a 5X volume of homogenisation buffer 
added to the eppendorf. Hippocampal homogenates were produced by 
homogenisation of the tissue with a polytron in a buffer (2.5mM Tris-HCl: pH6/ 3mM 
MgCL/ lOOmM NaCl). The samples were centrifuged for 15 mins (10,000 rpm) in a 
bench top centrifuge and the supernatant removed for protein assay. The protein 
content was determined using Bio-Rad protein assay reagent. Briefly, light absorbancy 
measurements from bovine serum albumin standards were determined in a 
spectrophotometer at a wavelength of 595nm (Table 5). The homogenate samples 
were then loaded into the spectrophotometer and absorbancy readings taken from 
these. Using linear regression analysis, the protein concentrations of each sample were 
determined (Figure 2.4). Appropriate volumes of H20  and Laemelli buffer were then 
added to the correct volume of homogenate to gain the appropriate protein 
concentration (lOpg/ml).
2.3.7.3 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
All gel apparatus was washed and cleaned in ethanol before construction. Spacers 
were placed between the glass plates and a tight seal was ensured before
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commencement. Resolving gel (10%) was poured gently between the glass plates and 
a thin layer o f 0.1 % SDS added on top before setting. After leaving to set for 1 hour, 
the SDS was poured off and the stacking gel poured between the plates. The combs 
were carefully added making sure no air bubbles formed between the teeth and gel. 
The stacker was allowed to set for 1V2 hours, the combs were removed and the wells 
rinsed with running buffer. Finally the reservoir was connected and filled with running 
buffer. The samples were boiled for 5mins and immediately placed on ice. 1 Opig of 
protein was then loaded into the wells using a Hamilton syringe and separated 
overnight at 12mA. A prestained molecular weight marker was included onto each gel 
for identification o f protein bands. Cross gel controls were introduced due to multiple 
gel running.
Table 5 Standard Curve Generation from BSA Samples
Volume BSA (pi) Volume Water (pi)
0 800
1 799
2 798
5 795
10 790
15 785
1.00-1
EcIO
o> 0.75-  io
2kO
c  0.50-coJQi_O
jg 0.25-  
<
0.00
150 5 10
Bovine Serum Albumin Content 
us/ml
Figure 2 .4 Standard curve for determining protein content o f  unknown samples.
2.3.7.4 Protein Transfer
Following electrophoresis, the gels were removed from between the plates and the 
stacking gel discarded. The gels were floated in transfer buffer (see appendix for
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recipe) and the polyvinylidene flouride membrane (PVDF) (Amersham Pharmacia) 
placed in methanol, whilst transfer apparatus was assembled. The membrane was 
finally equilibriated in water and sandwiched in the apparatus (Mesh, Sponge, Card, 
Gel, PVDF membrane, Card, Sponge, Mesh). The apparatus was submerged into the 
buffer filled transfer tank ensuring the gel was nearest the negative electrode. Proteins 
were then transferred for 3 hours at 75volts.
2.3.7.5 Immiinoblotting
Following transfer, the blots were placed overnight in blocking solution consisting o f 
Tris-buflfered saline containing 3% non-fat dried milk to reduce non-specific binding 
before incubation in primary antibody for 1 hour at 4°C (Table 6). The blots were then 
rinsed in T-TBS (6x5mins) (0.2% tween/ TBS) before incubation in secondary 
antibody (horseradish peroxidase conjugated anti-mouse (Promega) and anti-goat 
(SAPU) 1:1000 in 3% non-fat dried milk/TBS) for 1 hour on a shaker. After vigorous 
washing in TBS (6x5mins), the blots were then developed using ECL 
chemiluminescence detection and exposed to Fuji-RX film.
Antibody Concentration Used Purchased
Synaptophysin 1:100,000 Sigma
GAP-43 1:5000 Sigma
ApoE 1:1000 Chemicon
Tubulin 1:1000 Sigma
Table 6 Illustrating information on the antibody concentrations for immunoblotting.
2.3.7.6 Semi-Quantification o f  Protein Levels and Statistical Analysis 
Protein bands were assessed as relative optical density values using an M4 image 
analysis system (MCID). ANOVAR was carried out on the readings from the 
contralateral hippocampus. The ipsilateral and contralateral density readings were 
then compared using a Student’s paired t-test. In determining apoE protein 
expression, the protein bands were compared in APOEz3 and s4 transgenic mice 
using a Student’s unpaired /-test.
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2.3.7.7 Reprobing o f  Western Blots
Following immunohistochemistry for a single antibody the membranes were stripped 
using stripping agent (lOOmM mercaptoethanol/ 2% SDS/ 625mM Tris-HCl pH6.7 in 
water). The membranes were agitated in this solution for 30 mins at 50°C, following 
which they were placed in blocker to begin the immunoblotting steps again for a 
different antibody.
2.3.8 Silver Staining
2.3.8.1 Fink-Heimer Silver Staining o f  Degenerating Terminals
Fink-Heimer (Fink and Heimer, 1967) silver staining was employed to determine the 
degeneration product clearance within the lesioned hippocampus. This stain allows 
specific labelling of degenerating axon terminals. Paraffin sections awere initially 
dewaxed and dehydrated before pretreatment with 0.1% potassium permangate 
(KMnC>4 ) to produce a distinctive brown hue, following which they were incubated in 
decolourizing solution (1% hydroquinone/ 1% oxalic acid) until colourless in 
appearance. The tissue was then processed through a series of silver impregnation steps 
(0.5% uranyl nitrate (U0 2 (N0 3 )2 / 2.5% AgNCb) in which silver particles were 
deposited onto the tissue. Following a third impregnation step in ammonical silver 
nitrate, reducing agent (10% formalin/ 1% citric acid/ 95% alcohol) was then used to 
develop these silver particles. The sections were then dehydrated through a graded 
series of alcohols, cleared in histoclear and coverslips mounted.
2.3.8.2 Semi-Quantification o f  Silver Staining
Levels of silver labelled degeneration products within the hippocampus were assessed 
semi-quantitatively using a scoring method (0= no staining, 1= minimal, 2= moderate 
and 3= extensive) and differences between APOEzi and s4 mice compared using a 
Mann-Whitney test for comparing non-parametric data. The data is represented 
graphically using the median +/- standard deviation (S.D.)
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2.4 Organotypic Hippocampal Slice Culture
2.4.1 Preparation of Hippocampal Slices
2.4.1.1 Preparation o f  Cell Wells
All procedures are carried out under aseptic conditions, in a culture cabinet, unless 
otherwise stated. Cell culture dishes were prepared approximately an hour before 
culturing the hippocampal slices to allow the medium to attain the correct 
temperature. Briefly, membrane inserts (0.4pm pore size, Becton Dickinson) were 
inserted into the culture dish wells using only four wells per plate to avoid 
contamination. 1ml of culture medium consisting of 96% minimum essential medium 
with balanced salt solution (GIBCO), 6.5mg/ml glucose, penicillin/streptomycin (50 
U/ml), glutamax (0.5%) and the serum substitute TCM (final concentration 2%; ICN 
Biomedicals) was added to each cell well between the insert and culture well (derived 
from that of Teter et al, 1999). This interface method was derived from that of 
Stoppini et al (1991), in which the slice is not bathed in medium but forms an 
interface with the membrane insert which being in contact with the culture medium 
allows diffusion of nutrients. The prepared plates were then transferred to an 
incubator to equilibriate to the desired temperature before culturing commenced (5% 
CO 2 / 37°C).
2.4.1.2 Tissue Harvesting
Mice were derived from a breeding colony of C57BL/6J or GFAP transgenic mice 
(knockout v e3 v s4) maintained in an animal unit in the University of Glasgow. Male, 
7 day old neonatal mouse pups were anaesthetised by intra-peritoneal injection of 
euthatal and their brains removed rapidly using curved forceps. Tail tips were 
collected from the pups for APOE genotyping. The cerebellum and forebrain were 
removed and the brain adhered, forebrain down, onto a vibratome stage and fixed into 
a vibraslicer. The tissue was then submerged in ice cold Geys balanced salt solution 
(Life Technologies) for slides and oxygenated using a pipe connected to an oxygen 
cylinder. The reduced temperature and oxygenation kept the slices living until fully 
cultured. 300pm hippocampal slices were collected into a petri dish on ice, containing 
ice cold, oxygenated Geys solution. Approximately 8 slices were collected from each 
brain.
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2.4.1.3 Culturing o f  Hippocampal Slices
The excised hippocampi were then transported to the clean hood and placed onto a 
black surface in the petri dish for visualisation. A sterile spatula was then used to 
retrieve a slice from the petri dish and placed into a cell well by washing it off with a 
drop of Geys salt solution using a Pasteur pipette. The slice was then orientated 
within the cell well and the excess Geys medium surrounding the slice removed using 
a pipette. Two slices were placed in each cell well. The plates were then returned to 
the incubator. The medium was changed every 3 DIV (days in vitro) for the desired 
culture period. Cultures were maintained for 7 or 18 DIV in C57BL/6J studies 
(n=5/timepoint) and in transgenic studies (n=8/timepoint).
Following the desired culture period, the medium was removed and the slices 
submersion fixed in 4% paraformaldehyde for 2 hours, at which point the slices float 
from their membrane. The fixative was then removed, phosphate buffer added and the 
tissue stored at 4°C.
2.4.2 Hippocampal Slice Immunohistochemistry
2.4.2.1 Immunohistochemistry
The slices were transferred into a 24 welled culture dish (1 slice/ well) and 
permeabilised by submersion in PBS containing 0.2% Triton X-100 for 1 hour. Non­
specific binding was eliminated by applying blocking solution (10% normal serum/ 2% 
BSA in PBS) and the tissue was incubated overnight in primary antibody (made in 
blocking serum) (Table 7). Following 3X5 min rinses in PBS, biotinylated secondary 
antibody was applied for 1 hour and processed with a Vectastain ABC standard kit. 
Diaminobenzadine was employed as the chromagen in the visualisation step. The 
slices were then dehydrated through a graded series of alcohols (30 mins in each of 
70%, 90%, 100% X2), cleared in histoclear for 10 mins, mounted onto slides and 
coverslipped.
71
Antibody Concentration Used 1. Primary antibody
2. Blocking serum
3. Secondary antibody
Primary
antibody
supplied
Synaptophysin 1:2000 1. Mouse monoclonal
2. Normal horse serum
3. Anti-mouse
Sigma
GAP-43 1:2000 1 Mouse monoclonal
2. Normal horse serum
3. Anti-mouse
Sigma
MAP-2 1:5000 1. Mouse monoclonal
2. Normal horse serum
3. Anti-mouse
Sigma
ApoE 1:1000 1 Goat polyclonal
2. Normal horse serum
3. Anti-goat
Chemicon
ApoJ 1:1000 1. Goat polyclonal
2. Normal horse serum
3. Anti-goat
Chemicon
Table 7 Table showing concentration o f antibodies used in hippocampal s ices
2.4.2.2 Quantification o f Immunohistochemistry and Statistical Analysis 
Relative optical density (ROD) values for immunostaining were measured using an 
image analyser (MCID) connected to a microscope. All controls were applied as for 
immunohistochemistry on sections. Optical density readings were collected from the 
dentate molecular layers and from CA1 pyramidal cell layer to ensure consistency of 
immunostaining. Ten readings were collected randomly across the expanse o f  the 
molecular layer using a 1cm2 sampling box, and an average o f  the ten readings taken. 
In C57BL6 derived tissue, optical density readings were compared in the 7 and 18 day 
slices using a Student’s unpaired t-test. In the tissue derived from the transgenic 
mouse lines, optical density measurements were compared in APOE s3, e4 and 
knock-out animals also using ANOVAR with a posthoc Student’s unpaired /-test with 
Bonferroni correction for multiple comparisons.
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2.4.3 Herpes Simplex Virus 1716 as a Viral Vector
2.4.3.1 Production o f  Genetically Modified Herpes Simplex Virus 1716
The genetically modified virus employed in this study was produced in the laboratory 
of Prof Moira Brown (Southern General Hospital). Briefly the virus was made by 
targeting the ICP34.5 protein which is a specific determinant of virulence. ICP34.5 
null mutants are avirulent unlike the wildtype virus and may only replicate in cells 
actively undergoing proliferation/ differentiation. The virus employed in this study 
possesses a green fluorescent protein (GFP) reporter gene that results in the 
expression of GFP if the virus is replicated within the cell. Other reporter genes have 
also been used, including luciferase and p-galactosidase, although not employed in 
this study.
2.4.3.2 Addition o f Herpes Simplex Virus 1716 to Hippocampal Slice Preparations 
Hippocampal slices were prepared from C57BL/6J wild-type mice and APOEz$ 
transgenic mice as previously described and transported to the Neurovirology Unit at 
the Southern General Hospital. All virus handling was carried out within a category 2 
culture hood. Following virus use, all instruments were submerged in detergent and 
the culture hood exposed to U. V. radiation for at least half an hour to exterminate any 
stray virus particles. 106 and 105 virus particles were diluted in culture medium and 
added directly onto the slices as a single dose of lOpl of the mixture pipetted directly 
onto the surface of the slices. The slices were then returned to an incubator and 
maintained for a period of 3, 7, 12 or 18 DIV with changing of the medium every 3 
DIV. Control cases received no infection by HSV1716 virus. GFP labelled wild-type 
virus was also employed.
2.4.3.3 Fluorescence Microscopy
Following the appropriate survival period, the slices were submersion fixed in 4% 
paraformaldehyde for 2 hours. The slices were mounted onto glass slides and 
coverslipped, submerged in hardening medium or the slices were removed unfixed, 
attached to the membrane and visualised without the addition of a coverslip. A 
fluorescence microscope was used to visualise the GFP and the image captured using 
a camera attached to the microscope.
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2.5 Microtubule Binding
2.5.1 Preparation of Lipidated ApoE
Human plasma samples were obtained from human APOE s3/3 and s4/4 donors, 
pooled and processed to isolate high density lipoprotein (HDL) with the appropriate 
apoE isoform attached (in collaboration with Dr Muriel Caslake, Dept of Pathological 
Biochemistry, Glasgow Royal Infirmary). To obtain HDL bound apoE, the plasma 
samples were cushioned with potassium bromide (KBr) solution (density 1.063g/ml) 
and centrifuged overnight at 39,000 rpm at 15°C. The intermediate and low-density 
lipoprotein component (IDL, LDL) were discarded (1.006-1.063g/ml) KBr added 
again and centrifuged for a further 36 hours to give HDL at a density of 1.063- 
1.21g/ml. All samples were then dialysed and concentrated. The apoE concentration 
of each of these samples was confirmed using an ELISA and the HDL and cholesterol 
concentrations.
2.5.2 Microtubule Associated Protein Assay
2.5.2.1 Microtubule Assembly
Tubulin protein is reconstituted in 210pl of tubulin dilution buffer containing GTP 
solution (5mg/ml), divided into lOpl aliquots and stored at -70°C for future use. An 
aliquot of this tubulin was thawed out and transferred to ice adding 2.5pl of 
microtubule cushion buffer and incubated at 35°C for exactly 20 mins. 180jul of 
tubulin dilution buffer and 40pM of taxol (stabilises microtubules) were mixed 
together and incubated at 35°C. 180pl of this solution was then added to the 
polymerised tubulin and mixed thoroughly but gently. The microtubules were now at 
a concentration of lx l0 12/ml and 5-10pm in length.
2.5.2.2 Microtubule Binding Activity
A preliminary experiment to determine if a protein of interest shows microtubule 
binding activity is described (Table 8).
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Eppendorf Protein Microtubules (pi) TDB/taxol solution 
(ftO
1 MAP-2 (4pl) 20 26
2 BSA (1 5pl) 20 28.5
3 0 20 30
4 MAP-2 (4pl) 0 46
5 BSA (1.5pl) 0 48.5
6 Test Protein
(ApoE):5pg/ml/20pg/
ml
20 50pl final volume
Table 8 Initial test for microtubule binding activity
These reactions were then left at room temperature for 20 mins to attain equilibrium. 
1 OOpl o f cushion buffer was placed in eight ultracentrifuge tubes at room temperature 
and 20pM  taxol added to each tube. The reaction product was carefully pipetted on 
top o f the corresponding cushion. This mixture was then centrifuged at 48,000 rpm 
(100,000 xg) at room temperature for 20 mins.
The supernatant was removed and a volume o f  50pl removed, equal to the original 
reaction volume. To this, an equal volume o f 2xSDS gel loading buffer was added 
(lOOmM Tris pH 6.8, 5% SDS, 10% beta-mercaptoethanol, 20% glycerol, 0.2% 
bromophenol blue). The pellet fraction can then simply be resuspended in lxSDS 
sample buffer. The supernatant and pellet fractions were then separated on an SDS- 
PAGE gel (see Western Blotting protocol), transferred and visualised using a 
polyclonal antibody to apoE (1:1000) (with goat HRP secondary 1:1000) and 
detected using an enhanced chemiluminescence detection system (ECL). The presence 
o f microtubules in the pellet fraction and absence in the supernatant was confirmed 
using tubulin immunohistochemistry (1:1000).
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2.5.2.3 Analysis o f  Microtubular Binding
Multiple microtubule preparations containing either apoE E3/HDL or apoE E4/HDL 
at concentrations of 5pg/ml and 20pg/ml were then run on a gel as described and 
apoE immunohistochemistry performed. For analysis purposes it was initially 
determined whether apoE was present in the supernatant or pellet fraction. Any 
protein that is microtubule bound should be present within the pellet fraction. Any 
unbound protein remains within the supernatant fraction. Protein bands were then 
analysed as relative optical density values using a 1cm2 sampling box. Optical density 
values from the pellet fraction were then compared between apoE E3 and apoE E4 
containing samples using a Student’s unpaired t-test.
2.5.3 Fluorescent Microtubule Binding
2.5.3.1 Preparation ofTaxol Stabilized Fluorescent Microtubules 
The correct fluorescence intensity of the microtubule assemblies should be determined 
before beginning this experiment. All components of this kit were stored at -70°C. To 
obtain fluorescent microtubules with a final labelling stoichiometry of 0.33 labels per 
tubulin heterodimer, one aliquot of rhodamine labelled tubulin (2pi) was thawed and 
placed on ice and was diluted in 4pl of unlabelled tubulin. This solution was divided 
into 2pl aliquots and frozen for future use. 20pl of microtubule cushion buffer and 
40pl of general tubulin buffer were then added together to produce a solution called 
polymerisation buffer and this solution was placed on ice. 2pl of the polymerisation 
buffer was then added to the 0.33 tubulin and incubated at 35°C for 20 mins. While 
the tubulin was polymerising 500pl of general tubulin buffer was placed at 35°C and 
after 15 mins at this temperature 5pi of taxol was added (20pM). This solution was 
stored at room temperature and labelled taxol/microtubule buffer. The polymerised 
tubulin was removed from the incubator and immediately had lOOpl of 
taxol/microtubule buffer added mixing thoroughly but gently, using a Pasteur pipette. 
This preparation should now contain a population of taxol stabilized microtubules that 
average 6.5pm in length at a concentration of 7xl010/ml. The microtubules can then 
be visualised microscopically by diluting lp l of the microtubule preparation in lOpl of 
taxol/microtubule buffer containing 20pl of antifade solution. This preparation is then 
smeared onto a slide, coverslipped and visualised using fluorescence microscopy.
76
2.5.3.2 Addition o f  Lipidated Human ApoE E3 and E4 to Microtubule Preparations 
After preparing a population of stabilised microtubules, the solution was split so the 
apoE isoforms were being tested in a homogenous population of microtubules. This 
solution was incubated with HDL lipidated apoE E3 or E4 derived from human CSF 
samples at a concentration of 5pg/ml or 30jug/ml for 20 mins at room temperature to 
allow binding to occur.
2.5.3.3 Immunohistochemistry on Microtubule Preparations
An apoE polyclonal antibody was added to the mixture at a concentration of 1:100 
and incubated for 30 mins and the goat secondary antibody applied for 30 mins 
proceeding this (1:100). Avidin D fluorescein was then added to the preparation for 
30 mins at a concentration of 1:100. To visualise microscopically lp l of this final 
solution was dissolved in lOpl of taxol/microtubule buffer and lOpl of antifade and 
smeared onto a microscopy slide. The microtubules appear red (rhodamine) and the 
bound apoE appears green (fluorescein).
2.5.3.4 Confocal Image Analysis
Microtubules with bound apoE were analysed qualitatively using confocal 
microscopy.
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Chapter III
Investigation of ApoE in Relation to Degeneration/ Regeneration Using a 
Mouse Model of Entorhinal Cortex Lesion
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3.1 Introduction
ApoE has been shown to play a role in acute brain injury in humans and in animal 
models of brain injury (Horsburgh et al, 1996, 1999). However, the role of this 
protein in chronic brain injury is less well understood. At the outset of this thesis, no 
models of chronic brain injury had been established. However, in rats, the entorhinal 
cortex lesion model was well characterised as a model of degeneration and 
regeneration (Cotman et al, 1975, 1976; Steward and Vinsant, 1983). It was realised 
that following a suitable recovery period, certain fibre systems were capable of 
sprouting to compensate for the primary deafferentation (Steward and Vinsant et al, 
1976, 1983). The hypothesis in this study was that apoE would be upregulated post- 
ECL and be associated with the plasticity response at long-term survival periods.
3.2 Aims
(1) to establish a model of hippocampal degeneration and regeneration by entorhinal 
cortex lesion (ECL)
(2) to define temporal alterations in apoE and related proteins after ECL
3.3 Materials and Methods
3.3.1 Entorhinal cortex lesion
The entorhinal cortex was lesioned using male C57BL/6J mice (12 weeks old, 
weighing approximately 30g) (as described in chapter II). The mice were allowed to 
survive of 1, 3, 7, 28 or 90 days (n=8 per timepoint). Control animals underwent an 
identical procedure but were terminated immediately after the procedure. Sections 
from the entorhinal cortex were histologically stained using haematoxylin and eosin to 
confirm lesion placement. Immunohistochemistry for synaptophysin, GAP-43, apoE, 
apoJ, LRP, MAP-2, GFAP and mrf-1 was performed on hippocampal sections. 
Double labelling was also performed to determine cellular localisation of apoE and 
apoJ. Fink Heimer silver staining was carried out to assess terminal degeneration 
products and to determine a time-course for clearance. I ML width was measured in 
GAP-43 sections and analysed as outlined in chapter II.
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In a separate group, mice underwent ECL to generate tissue for Western blotting 
(n=5/ timepoint). Following the appropriate survival periods of 0, 7 and 28 days the 
ipsilateral and contralateral hippocampus were harvested and frozen in liquid 
nitrogen. 1 Opg of protein was separated by gel electrophoresis and immunoblotting 
for synaptophysin, GAP-43 and apoE was carried out.
3.3.2 Quantification of immunohistochemistry and statistical analysis
Relative optical density values for immunostaining were collected from the inner, 
middle and outer molecular layers from both the ipsilateral and contralateral 
hippocampus using an M4 image analysis system connected to a microscope. Six 
optical density readings were collected from each layer using a 1cm2 sampling box 
and an average taken. One way analysis of variance (ANOVA) was carried out on the 
contralateral hippocampal readings and the ipsilateral and contralateral readings 
compared using a Student’s paired Mest. Readings were taken from a reference area 
to ensure consistency of staining. Western blots were also analysed by collecting 
optical density measurements. Data is represented graphically using the mean 
+/- S.E.M. (standard error of the mean).
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3.4 Results
3.4.1 Characterisation of a mouse model of entorhinal cortex lesion
3.4.1.1 Setting up the model: technical considerations
The C57BL/6J mouse strain was chosen because it is the background strain of the 
transgenic lines to be employed in the following studies. Primarily, the method to 
lesion the cortex was considered. In rats, a number of methods were available 
including aspiration and electrolysis. Pilot studies were initially carried out to 
determine the stereotaxic placement of the injection. Precise stereotaxic co-ordinates 
were determined from the mouse brain atlas and transposed onto the surface of the 
skull. The final location for the injection was chosen on the basis that it was a site 
which would not incorporate the hippocampus itself when the lesion was fully 
developed and the entorhinal cortex is at its largest in size in a coronal view. The 
concentration of ibotenic acid employed was determined from a study by Cho and 
Jaffard (1995). Differing amounts of ibotenic acid were injected into the brain (0.5pi 
and 1 pi) to produce the optimal lesion.
Concentration curves were generated for all antibodies employed in this study and the 
dilution chosen which optimally displayed the protein alterations. Synaptophysin (a 
synaptic vesicle marker) and GAP-43 (presynaptic membrane protein also found on 
growth cones) were chosen to assess the temporal profile of degeneration and 
regeneration because they would most accurately highlight not only synaptic loss and 
fibre degeneration respectively, but also synaptogenesis and fibre sprouting. These 
antibodies had been employed and validated in previous rat studies of CNS plasticity. 
When the pilot tissue was stained with these antibodies they accurately reflected 
degeneration and reinnervation within the molecular layers of the dentate gyrus. The 
MAP-2 antibody was chosen to highlight cytoskeletal changes and was included 
because it would be relevant in the future studies of apoE genotype and mictrotubule 
interaction.
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3.4.1.2 Lesion assessment
Haematoxylin and eosin staining was used to assess lesion placement within the 
entorhinal cortex. The lesion appeared as an area o f pallor, engulfing the entire 
entorhinal region in which all cell types were pyknotic in appearance (Figure 3.1).
Lesion
Injection
ite
• s•>
Figure 3.1 Entorhinal cortex lesion
Illustrative example o f the entorhinal cortex lesion as shown in haematoxylin and 
eosin histologically stained sections. The lesion was induced by intracortical injection 
o f ibotenic acid at specific stereotactic co-ordinates. This produces excitotoxic cell 
death and a change in pallor within the cortex. This pattern o f staining is typical o f 
that produced throughout the studies regardless o f genotype.
More sections were taken rostral to the injection site and histologically stained to 
ensure the lesion did not directly involve the hippocampus. If  no visible lesion was 
apparent, the animal was excluded from the study although this was extremely rare.
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3.4.2 Temporal Profile of Degeneration and Reinnervation
3.4.2.1 Alterations in synaptophysin immunoreactivity
Synaptophysin immunoreactivity displayed a time-dependent loss and increases in 
synapse density within the hippocampus following injury. Synaptophysin 
immunoreactivity in unlesioned animals displayed a regular dense pattern of staining 
throughout all regions of the hippocampus. The molecular layers take on a trilaminar 
pattern with the inner staining most intensely. After ECL, synaptic alterations were 
most apparent within the MML and OML with very few alterations within the I ML. 
Synaptophysin immunoreactivity in the MML decreased gradually and at day 7 the 
ipsilateral MML showed a significant decrease in staining when compared to the 
contralateral hippocampus (p<0.0001). Maximal synaptic loss was achieved by day 28 
post-ECL (p<0.0001) where levels were approximately 40% of control levels (Figure
3.2 and 3.4). At day 90 synaptophysin immunoreactivity in the ipsilateral MML had 
returned towards baseline levels and was not significantly different to the contralateral 
hippocampus. The optical density was approximately 80% of control levels at this 
time. Synaptic decline within the OML was not observed until day 28, when the 
ipsilateral hippocampus displayed a slight decrease compared to the contralateral side 
(p<0.05). At 90 days post-ECL the ipsilateral hippocampus staining had increased and 
was not significantly different to that in the contralateral hippocampus. Analysis of 
variance on the contralateral hippocampal density measurements revealed no 
statistically significant variance and therefore all significant changes observed in the 
paired r-tests were attributed to alterations in the ipsilateral hippocampus.
Western blotting data revealed that synaptophysin levels were similar in the ipsilateral 
and contralateral hippocampus. At day 7 synaptophysin levels had decreased by 25% 
in the ipsilateral hippocampus (p<0.01) (Figure 3.5). By day 28 synaptophysin 
immunoreactivity had increased within the ipsilateral hippocampus and was 
approximately 25% greater than baseline control values. These data did not accurately 
reflect alterations within the small discrete regions of the molecular layers. These data 
highlights the inability Western blotting to analyse small localised alterations of 
proteins.
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3.4.2.2 Alterations in growth associated protein-43 (GAP-43) immunoreactivity
GAP-43 immunoreactivity displayed a time-dependent loss and gain of synapses 
within the hippocampus. In unlesioned control animals, GAP-43 labelled the 
hippocampus intensely compared to other brain regions. The I ML was most intensely 
stained, with the outer two thirds stained equally. The most significant alterations 
occurred within the outer two thirds of the molecular layer. Within the MML fibre 
density progressively decreased and maximal fibre loss was achieved at day 7 post- 
ECL, where GAP-43 levels were found to be approximately 25% of control levels and 
40% of contralateral levels (p<0.01) (Figure 3.3 and 3.4). At day 90 post-ECL, GAP- 
43 immunoreactivity increased towards baseline levels and there was no significant 
difference between the ipsilateral and contralateral hippocampus. GAP-43 levels at 
this time were approximately 70% of control values. The OML exhibited a similar 
pattern of alterations to the MML but were delayed in comparison. At day 90 post- 
ECL ipsilateral hippocampal GAP-43 staining had increased and was not significantly 
different to that in the contralateral hippocampus. The IML did not exhibit any loss of 
fibre density, but at day 90 post-ECL fibre density increased and was significantly 
greater than that of the contralateral hippocampus (p<0.05). Analysis of variance on 
the contralateral hippocampal density measurements revealed no statistically 
significant variance and therefore all significant changes observed in the paired /-tests 
were attributed to alterations in the ipsilateral hippocampus.
Western blotting data revealed GAP-43 levels were similar in the ipsilateral and 
contralateral hippocampus. At day 7, GAP-43 levels had decreased by 40% in the 
ipsilateral hippocampus compared to the contralateral hippocampus (p<0.01) (Figure 
3.5). At day 28, GAP-43 immunoreactivity had increased within the ipsilateral 
hippocampus and was approximately 25% greater than baseline control values. These 
data did not accurately reflect alterations within the small discrete regions of the 
molecular layers and are more a representation of GAP-43 behaviour within the entire 
hippocampus.
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Figure 3.2 Quantification of synaptophysin immunoreactivity within the inner, middle 
and outer molecular layers (IML, MML, OML) of the hippocampal dentate gyrus at 
0, 1, 3, 7, 28 and 90 days post-lesion measured as relative optical density values. The 
ipsilateral and contralateral optical density measurements were compared using a 
Student’s paired /-test. ***p<0.0001 and *p<0.05
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Figure 3.3 Quantification of GAP-43 immunoreactivity within the inner, middle and 
outer molecular layers (IML, MML, OML) of the hippocampal dentate gyrus at 0, 1, 
3, 7, 28 and 90 days post-lesion measured as relative optical density values. The 
ipsilateral and contralateral optical density measurements were compared using a 
Student’s paired t-test. **p<0.01 and *p<0.05
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Synaptophysin GAP-43
90 day 90 day
Figure 3 4 Degeneration and regeneration post-ECL
Illustrative examples o f  ipsilateral synaptophysin and GAP-43 immunoreactivity at 0, 
7 and 90 days post-ECL within the hippocampal dentate gyrus. Contralateral 
immunoreactivity (not shown) remained relatively unchanged post-ECL and is similar 
to that shown in the 0 day control illustrations. The arrows indicate the regions 
affected by the lesion. x50 magnification
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3.4.2.3 IML width alterations post-ECL
The IML width was measured at days 0 and 90 post-ECL in GAP-43 immunostained 
sections to determine if sprouting from the commissural-associational fibres had 
occurred. In 0 day control animals the width of the IML was similar in the ipsilateral 
and contralateral hippocampus (55pm). At day 90 post-ECL the width of the 
ipsilateral IML had expanded by approximately 30% compared to the contralateral 
IML (90pm) (p<0.0001) (Figure 3.6).
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Figure 3.6 Quantification of the width of the inner molecular layer (IML) of the 
dentate gyrus as assessed in GAP-43 immunostained section. Expansion of this layer 
gives an indication of the sprouting index from the commissural-associational fibre 
pathway. The ipsilateral and contralateral IML width was compared using a Student’s 
paired t-test. ***p<0.0001
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3.4.3 Apolipoprotein Response to Injury
3.4.3.1 Apolipoprotein E
Cellular immunoreactivity
In unlesioned control animals only faint neuropil staining was present and was similar 
within both the ipsilateral and contralateral hippocampus. No neuronal cell body 
staining was present at any time. At day 7 post-ECL, intense cellular apoE 
immunoreactivity was noted which was exclusively confined to cells that had the 
morphological appearance of glia (Figure 3.9). At day 28 post-ECL, very little cellular 
apoE immunoreactivity was evident. No cellular immunostaining was present by day 
90 post-ECL. The contralateral hippocampus exhibited no increase in glial 
immunoreactivity. Labelling with GFAP (astrocytes) and mrf-1 (microglia), indicated 
a marked astrocytic and microglial proliferation response within the injured 
hippocampus. Double labelling of adjacent sections at day 7 post-ECL with GFAP 
and apoE confirmed that apoE was localised to some GFAP-positive astrocytes. 
Double labelling with apoE and mrf-1 indicated localisation of apoE in microglia 
(Figure 3.10).
Neuropil immunoreactivity
Alterations in neuropil apoE immunoreactivity were measured within the molecular 
layers as relative optical density values. By day 1 post-ECL, apoE immunoreactivity 
increased within the MML and OML of the ipsilateral hippocampus by approximately 
20% (p<0.05 and p<0.01 respectively) compared to the contralateral hippocampus 
(Figure 3.7 and 3.9). Levels remained relatively elevated within these layers compared 
to control values, however the contralateral hippocampal apoE levels increased also 
so there was no statistically significant difference between the ipsilateral and 
contralateral hippocampus. At day 28, apoE immunoreactivity had declined to below 
baseline levels in all layers. At day 90 post-ECL, only within the OML neuropil, apoE 
had increased to the highest levels observed at any time-point. At that time apoE 
immunoreactivity had increased to approximately 40% above baseline levels. This was 
significantly different to the immunoreactivity in the contralateral hippocampus 
(p<0.0001). ApoE increased within the IML at day 7 post-ECL to approximately
90
20% above baseline levels and then declined to below baseline levels by day 28. 
ANOVA revealed variance in both hemispheres. Contralateral apoE may be elevated 
slightly because a small percentage of entorhinal fibres project contralaterally.
Western blotting data revealed apoE levels were similar in the ipsilateral and 
contralateral hippocampus. At day 7 GAP-43 levels had increased 4 fold in the 
ipsilateral hippocampus and was significantly greater than that of the contralateral 
hippocampus (p<0.01) (Figure 3.5). At day 28 apoE levels still remained elevated. 
These data did not accurately reflect alterations within the small discrete regions of 
the molecular layers and are more a representation of apoE behaviour within the 
entire hippocampus. This data also highlights how inefficient Western blotting 
performs in the analysis of small localised alterations.
3.4.3.2 Apolipoprotein J
Cellular immunoreactivity
In unlesioned control animals, neuropil immunoreactivity was faint and did not 
significantly differ from that observed in the contralateral hippocampus. Light apoJ 
neuronal immunoreactivity was evident, but was similar in the ipsilateral and 
contralateral hippocampus. At day 7 post-ECL, the MML and OML were densely 
populated with apoJ-immunopositive cells with the morphological appearance of glia 
(Figure 3.9). At day 28 post-ECL, these cells remained intensely immunolabelled, 
however by day 90 no glial cell immunoreactivity was evident. Double labelling of 
sections from 7 day survival subjects with apoJ and GFAP confirmed apoJ was 
localised predominantly to GFAP-positive astrocytes. There were no additional cells, 
which displayed apoJ immunoreactivity and double labelling of sections with apoJ and 
mrf-1 indicated that very few microglia were apoJ immunopositive (Figure 3.10).
Neuropil immunoreactivity
Neuropil alterations were also evident for apoJ. Immunostaining within the MML and 
OML increased by approximately 20% at day 3 post-ECL, in the ipsilateral 
hippocampus compared to the contralateral hippocampus (p<0.05) (Figure 3.8 and 
3.9). Immunoreactivity declined thereafter, towards or below baseline levels at day 90 
post-ECL except within the OML, in which at day 90, apoJ immunoreactivity was
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dramatically increased to 40% above control levels within the ipsilateral hippocampus 
and this was significantly greater than that of the contralateral hippocampus 
(p<0.0001). ApoJ immunoreactivity did not significantly alter except that at day 90 
post-ECL, intensity declined and was approximately 50% of control levels. Analysis 
of variance revealed no significant variance in the hippocampal immunoreactivity.
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Figure 3.7 Quantification of neuropil apoE immunoreactivity in the inner, middle and 
outer (IML, MML, OML) molecular layers of the hippocampal dentate gyrus at 0, 1, 
3, 7, 28 and 90 days post-lesion measured as relative optical density values. ApoE 
immunoreactivity in the ipsilateral and contralateral hippocampus was compared using 
a Student’s paired t-test. ***p<0.0001, **p<0.01 and *p<0.05
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Figure 3.8 Quantification of neuropil apoJ immunoreactivity in the inner, middle and 
outer (IML, MML, OML) molecular layers of the hippocampal dentate gyrus at 0, 1, 
3, 7, 28 and 90 days post-lesion measured as relative optical density values. ApoJ 
immunoreactivity in the ipsilateral and contralateral hippocampus was compared using 
a Student’s paired (-test. ***p<0.0001 and *p<0.05
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Figure 3 9 Increased apolipoprotein E and apolipoprotein J  post-ECL
Illustrative examples o f apoE and apoJ immunoreactivity in the ipsilateral 
hippocampus at day 0, 7 and 90 post-ECL. Increased glial and neuropil 
immunoreactivity is evident at day 7 post-ECL. In contrast, at day 90 post-ECL only 
intense neuropil immunoreactivity is evident. xlOO magnification
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Figure 3 10 Cellular localisation of apoE and apoJ
(1) Illustrative examples o f astrocyte (GFAP) and microglial (mrf-1) proliferation 
post-ECL in the contralateral (a,c) and ipsilateral (b,d) respectively. x25 magnification 
(microglia black arrows and astrocytes red arrows)
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3.4.4 Cytoskeletal Alterations Post-Lesion
3.4.4.1 Alterations in MAP-2 immunoreactivity
In unlesioned control animals, MAP-2 characteristically labelled the soma of neurons 
and the associated dendritic networks most intensely. This resulted in the molecular 
layers of the dentate gyrus being heavily labelled but of a similar intensity across all 
molecular layers. Over days 1 and 3 post-ECL, MAP-2 immunoreactivity increased in 
a stepwise fashion in increments of 10% within all layers. This was also observed 
contralaterally. At days 7 and 28 post-ECL, MAP-2 immunoreactivity decreased 
within the ipsilateral MML and was significantly different to the contralateral 
immunoreactivity (p<0.0001). At day 90 post-ECL, MAP-2 immunoreactivity 
increased greatly within both the ipsilateral and contralateral hippocampus where 
immunoreactivity was approximately 20% greater than baseline levels. Similarly to the 
MML, MAP-2 immunoreactivity increased within the OML at day 90 post-ECL, but 
was not significantly different to the contralateral side (Figure 3.11 and 3.12). 
Analysis of variance on the contralateral hippocampal optical density values revealed 
statistically significant variance in these readings, suggesting both the ipsilateral and 
contralateral hemisphere contribute to the statistically significant difference found.
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Figure 3.11 Quantification of MAP-2 immunoreactivity within the inner, middle and 
outer molecular layers (IML, MML, OML) of the hippocampal dentate gyrus at 0, 1, 
3, 7, 28 and 90 days post-lesion measured as relative optical density values. The 
ipsilateral and contralateral optical density measurements were compared using a 
Student’s paired Mest. ***p<0.0001, **p<0.01 and *p<0.05
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Figure 3.12 MAP-2 immunoreactivity post-ECL
Illustrative examples o f MAP-2 immunoreactivity in the ipsilateral hippocampus at 
day 0, 7 and 90 post-ECL. MAP-2 immunoreactivity decreases at day 7 post-ECL 
and is increased at day 90 post-ECL. Contralateral MAP-2 immunoreactivity did not 
significantly alter post-ECL. The arrows indicate the region o f the hippocampus 
affected post-ECL. Ocassionally increased staining was seen in pyramidal layers with 
injury and this has been noted in other models o f injury x50 magnification
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3.4.5 Clearance of Degeneration Products Post-Lesion
This method of labelling degeneration products specifically highlighted the time 
course of deposition and clearance of lipid and cholesterol (lipid laden lysosomes) 
materials from terminals. The stain appeared as a rich brown background with the 
degenerating processes labelled with an intense black deposit. In 0 day control animals 
and at day 1 post-ECL there were no silver deposits indicating there were no 
degeneration products. In contrast, at day 3 post-ECL, an intense black punctate 
deposit was present throughout all regions of the molecular layer in the ipsilateral 
hippocampus (n=8/8) (Figure 3.13). Deposition was also evident in the ipsilateral 
stratum lacunosum moleculare. At day 7 post-ECL only a thin band of degeneration 
material staining remained, localised specifically within the MML of the ipsilateral 
hippocampus (n=7/8). This band was still present at day 28 however at day 90 post- 
ECL, no silver labelled degeneration products were present.
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Figure 3 13 Degeneration product deposition and clearance
Fink-Heimer silver staining o f lipid laden degeneration products at day 0, 3, 7, 28 and 
90 post-ECL. The contralateral hippocampus displayed no degeneration products.
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3.4.6 LRP Receptor Expression Post-Lesion
Cellular immunoreactivity
In 0 day control mice no astrocytic LRP immunoreactivity was evident. At day 7 post- 
ECL the MML and OML were densely populated by LRP immunoreactive astrocytes 
(Figure 3.15). At day 28 post-ECL, the number of immunoreactive astrocytes 
declined until, at day 90, no glial immunoreactivity was evident. Neuronal 
immunoreactivity did not significantly alter with the injury.
Neuropil immunoreactivity
In unlesioned control animals, LRP immunoreactivity was evident on neuronal cell 
bodies and in the neuropil but was similar in the ipsilateral and contralateral 
hippocampus. LRP neuropil immunoreactivity did not alter within the molecular layers 
of the dentate gyrus post-ECL (Figure 3.14). Analysis of variance on the contralateral 
hippocampal optical density values revealed no statistically significant variance in 
optical density values.
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Figure 3.14 Quantification of LRP receptor immunoreactivity in the inner, middle and 
outer molecular layers (IML, MML, OML) of the hippocampal dentate gyrus at 0, 1, 
3, 7, 28 and 90 days post-lesion measured as relative optical density values. LRP 
immunoreactivity was compared in the ipsilateral and contralateral hippocampus using 
a Student’s paired t-test. *p<0.05
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*Figure 3 15 Increased astrocytic LRP receptor immunoreactivity at day 7 post- 
ECL
Illustrative example o f LRP immunoreactivity in the ipsilateral hippocampal molecular 
layer at day 7 post-ECL. No astrocytic staining is evident at day 0 or 90 post-ECL. 
x200 magnification
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3.5 Discussion
This study demonstrated that upregulation of apoE and apoJ occurs in the 
hippocampus after ECL and this parallels the immediate response and long-term 
recovery to injury. The data supports the hypothesis that both apolipoproteins E and J 
may be involved in the clearance and redistribution of lipid and cholesterol material 
from the site of injury, for reutilization in the reconstruction of neuronal cell elements, 
such as membrane in the regeneration process (Holtzman and Fagan, 1998). This 
function may be crucial in long-term plasticity alterations following brain injury.
3.5.1 Experimental deafferentation: an animal model for studying CNS 
plasticity
Mechanical lesioning of the entorhinal cortex has been employed in a number of 
studies to illustrate the role of apolipoproteins in relation to plasticity within the adult 
CNS after injury (Masliah et al, 1991; Poirier et al, 1991; Anderson et al, 1998). In 
the present study, chemical lesioning of the mouse entorhinal cortex results in 
degeneration of the perforant pathway to the hippocampus that causes time- 
dependent structural alterations within specific layers of the hippocampus. The 
C57BL/6J mouse strain is the background strain of the transgenic mice to be 
employed in the proceeding studies and therefore, it was essential to characterise 
plasticity in these mice in response to injury. Synaptic decline, as assessed using 
synaptophysin immunoreactivity, became apparent 7 days post-ECL and maximal loss 
was achieved at day 28 post-ECL where immunoreactivity was approximately 40% of 
that of the unlesioned side and control mice. However, at day 90 post-ECL, 
synaptophysin immunoreactivity had increased within the ipsilateral hippocampus and 
was similar to that observed in the contralateral hippocampus, indicating 
compensatory reactive synaptogenesis had occurred. Other groups have reported 
increases in synaptophysin levels reaching 80% recovery within the ML by day 30 
(Masliah et al, 1991; Poirier et al, 1990, 1991). Synaptic loss is accompanied by fibre 
and terminal degeneration within the same region as determined using GAP-43 
immunohistochemistry (Lin et al, 1999) (MAP-2 data also reflects fibre loss via 
cytoskeletal breakdown). GAP-43 immunoreactivity decreased within the MML and 
OML and fibre density loss was maximal at day 7 post-ECL. At day 28 post-ECL
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immunoreactivity had begun to increase, suggesting terminal proliferation and 
collateral sprouting and at day 90 post-ECL, immunoreactivity had increased to 70% 
of control levels. These findings contrast with other groups, who witnessed partial 
recovery as early as day 7 post-ECL and fiill recovery to pre-lesion levels at day 28 
(Anderson et al, 1998). The differences in neuropathology may reflect the inherent 
differences in the method applied to induce the lesion. Chemical lesioning of the EC 
ablates afferent input into the hippocampus via extensive cellular death rostrocaudally, 
whereas mechanical methods render only partial severance of the pathway (Cho and 
Jaffard, 1995). This allows compensation by the entorhinal cortex itself, which occurs 
over a shorter time course consequently in these less severe models, compensatory 
plasticity alterations may occur earlier post-ECL. In addition, there are innate 
differences in the behaviour of each layer within the molecular layers. The most 
striking differences were found, in our hands, to occur within the MML, a finding that 
agrees with the results of Anderson et al using the electrolytic lesion model in mice. 
Others analyze the MML and OML as a single entity. In the present study, the results 
accentuate the innate divide in behaviour in the two layers and a need for separate 
analysis. Several intra and extrahippocampal fibre systems are capable of reinnervating 
the denervated granule cells and this study has shown this from the commissural- 
associational fibre system by expansion of the IML. Other fibre systems, such as 
cholinergic fibres from the septum and crossed temperodentate fibres, may also 
participate in this response and have been identified in rat models (Steward and 
Vinsant, 1983; Fagan and Gage, 1994; Deller et al, 1996; Deller and Frotshcer,
1997).
There is information, albeit limited, to suggest that analogous sprouting processes 
may occur in the human brain. Grady et al (1989) reported evidence of reinnervation 
in the hippocampus of two patients who had died following an intracerebral 
haemorrhage which had caused uncal herniation with subsequent damage to the 
entorhinal cortex. The study mentioned only presented two cases, however our group 
is presently assessing hippocampal sprouting in a larger cohort of patients who have 
experienced a similar injury. Aberrant sprouting witnessed in AD postmortem brains 
also suggests that the human CNS is capable of reinnervation (Masliah et al, 1991; 
Arendt et al, 1998; Danik and Poirier, 1998).
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3.5.2 Apolipoprotein E is upregulated in the neuropil and glia following injury
Upregulation of apoE in the brain in experimental animal models of injury has been 
well documented (Horsburgh etal, 1996; Poirier etal, 1991) as in human brain injury 
(Horsburgh et al, 1999). In the present study apoE was markedly increased within the 
neuropil when synaptic loss was first detected and later apoE was increased and 
localised to glial cells. Most surprisingly, a dramatic increase in apoE occurred by day 
90 post-ECL specifically within the OML neuropil. In rodent brain apoE is localised 
exclusively to glia (Boyles et al, 1985). ApoE protein and mRNA increases have been 
identified in astrocytes associated with GFAP mRNA following ECL (Poirier et al, 
1990; Zarow et al, 1998). Glial staining within the present study peaked at day 7 
post-ECL within the molecular layers of the dentate gyrus in the present study. It is 
possible this cellular staining has resulted from the reuptake of apoE from the local 
environment (Poirier et al, 1993; Ji et al, 1998), or indeed it could represent a 
secondary upregulation for functioning in the progressive plasticity changes which 
occur over a period of months following injury (Masliah et al, 1991; Danik and 
Poirier, 1998; Holtzman et al, 1998). This is substantiated by the occurrence of 
elevated apoE levels within the OML even by day 90 post-ECL. Levels were higher 
than at any other survival point post-ECL. This supports a role for its involvement in 
long-term repair.
Although no increase in neuronal cell body staining was evident in this study, it is 
possible apoE is endocytosed into neurons, but via receptor interactions on terminals 
and dendrites (Mahley et al, 1988). Neuronal cell bodies, dendrites, and proximal 
axons express the endogenous apoE receptor; LRP (Rebeck et al, 1993). Several 
groups have shown dendrosomatic localisation of the receptor and suggest it is likely 
to be expressed in regions of high synaptic density (Page et al, 1998; Stockinger et al,
1998), where uptake would be required for the reconstruction of cellular elements in 
membrane maintenance and repair following injury. Since it is not required by the cell 
body in this type of injury it may be trafficked to the region of most need. It has been 
shown in this study that the LRP receptor displays a dense neuropil localisation in 
conjunction with expression on astrocytes and neurons.
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In this study, the majority of apoE-positive cells were not GFAP-positive but 
appeared to be localised to microglia. In situ hybridisation studies have also indicated 
localisation of apoE to microglia (Stone et al, 1997). We have used the antibody mrf- 
1, which is a well characterised antibody raised against a microglial gene (Tanaka et 
al, 1998) (this antibody is the only microglial marker for paraffin tissue at present). 
The main aim of this study was to determine if apolipoproteins played a role in long­
term repair processes following injury when sprouting and synaptogenesis are 
occurring.
3.5.3 Apolipoprotein J is upregulated in the neuropil and glia following injury
Under normal physiological conditions apoJ is expressed at low levels within neurons, 
glia and the neuropil (Rebeck et al, 1993) and indeed faint neuronal staining was 
evident in control tissue. Neuronal cell body immunoreactivity did not alter with the 
injury. Upregulated expression of apoJ occurs when the CNS is stressed (Michel et al, 
1997). Lampert-Etchells et al (1991), who first determined increases in apoJ 
following ECL, employed the protien as a marker of neurodegeneration. In the 
present study, apo J immunoreactivity increasd within the neuropil and also within glial 
cells of dentate molecular layer, a finding in agreement with others (Johnson et al, 
1996). This suggests that, like apoE, apoJ is present within the extracellular space 
around terminals with subsequent increases in reactive glia (Danik et al, 1995) either 
via uptake or de novo synthesis. All apoJ-positive cells were astrocytes (GFAP- 
positive) in contrast to apoE. At day 28 post-ECL, apoJ cellular immunoreactivity 
remained intense, a time when apoE immunoreactivity had declined to below baseline 
levels. Similarly, apoJ immunoreactivity significantly increased within the OML at day 
90 post-ECL (p<0.0001). It is thought that apoJ functions predominantly in lipid 
transport, but also that it performs similar functions in maintenance and repair to apoE 
and thus warranted its investigation in this thesis (Jordan-Starck et al, 1992). This is 
especially important in the later chapters when APOE knockout mice will be 
investigated (Bertrand et al, 1995). ApoJ uptake is mediated mainly via the gp330 
receptor (Beffert et al, 1998; Page et al, 1998; Niemeier et al, 1999), however the 
presence and functionality of this receptor in the brain has not been fully elucidated 
(De Silva et al, 1990).
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3.5.4 Alterations in apoE and apoJ parallel clearance of cellular debris from the 
environment
Both apolipoproteins E and J are involved in the transportation and redistribution of 
lipids and cholesterol. Poirier (1993) suggested apoE was mobilised to clear cellular 
breakdown products from the site of injury. In the present study was illustrated a 
time-course for the deposition of degeneration products using silver staining. 
Deposition was maximal at day 3 post-ECL. Clearance of material coincided with the 
increased expression of both apoE and apoJ, thus at day 7 post-ECL only a thin band 
of degeneration material remained within the MML. At day 90 post-ECL, no 
degeneration products were evident within the dentate molecular layers. This 
temporal profile of alterations in apolipoproteins in redistribution suggests that both 
apoE and apoJ may be involved in the ongoing, long-term plasticity changes post- 
ECL (Holtzman and Fagan, 1998). In this study we have also identified a range of 
markers, which accurately reflect degeneration and reinnervation in this mouse model. 
Using wild-type mice we have studied endogenous mouse apoE and apoJ function in 
the clearance of cellular debris.
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Chapter IV
Analysis of APOE Genotype Influence on CNS Plasticity in Transgenic 
Mice Expressing Human APOE s3 and s4 Alleles (Under a Human 
Promoter Sequence) Following Entorhinal Cortex Lesion
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4.1 Introduction
Animal models are an essential tool for the study of human disease and injury (Roses 
et al, 1997). However, alone they do not allow the study of genetic components of 
human disease and injury. Rat models of global ischaemia were initially used for 
determining the role of apoE in acute brain injury, where it was determined that apoE 
was upregulated primarily in astrocytes and then translocated to neurons following 72 
hours of survival (Horsburgh et al, 1996). However, rodents do not have the APOE 
allelic heterogeneity which humans express. Transgenic animals were produced which 
had the endogenous mouse APOE gene deleted but human APOE gene sequences 
inserted which encode the s2, s3 or e4 human alleles.
The transgenics that will be discussed in this chapter, have human e3 and e4 inserts 
that are driven by the human promoter sequence (Xu et al, 1996). This gives these 
mice an apoE expression pattern similar to that observed in human brain tissue, in that 
apoE is expressed in astrocytes, microglia and oligodendrocytes (Boyles et al, 1985). 
The influence of APOE genotype has been investigated using animal models of acute 
brain injury, where it has been found that the E4 isoform confers a poor outcome and 
accentuated brain damage (Sheng et al, 1998; Horsburgh et al, 1999; Sabo et al, 
2000). However it is now evident that apoE may modulate the progression of chronic 
brain injury possibly through a process affecting CNS plasticity and that this process 
may be influenced by APOE genotype. The next step was to use the entorhinal cortex 
lesion model to study APOE genotype influence on long-term plasticity post-ECL.
4.2 Aims
To test the hypothesis that the possession of an APOEzA genotype is associated with 
an impaired long-term reparative response post-ECL.
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4.3 Materials and Methods
4.3.1 APOE transgenic mice on a human promoter
APOE&3 and e4 heterozygous mice were generated as previously described (Xu etal, 
1996). The mice were transported to Glasgow according to Home Office Regulations, 
acclimatised and maintained in an animal unit at the University of Glasgow. The 
genotype of the transgenic mice was confirmed using PCR analysis.
4.3.2 Entorhinal cortex lesion
The entorhinal cortex was lesioned in male transgenic mice (12 weeks old) which 
were allowed to survive for periods of 7, 28 or 90 days (n=l 1/time-point). 0 day 
control animals received ibotenic acid injection but were terminated immediately after 
the procedure. Sections from the entorhinal cortex were histologically stained using 
haematoxylin and eosin to confirm lesion placement. Immunohistochemistry for 
synaptophysin, GAP-43, apoE, apoJ, LRP and MAP-2 was performed on 
hippocampal sections (see chapter II). IML width was measured in GAP-43 
immunostained sections. Separate tissue was dissected out from nai've animals for 
Western blotting to check expression levels of apoE between the two genotypes.
4.3.3 Quantification of immunohistochemistry and statistical analysis
Relative optical density values were collected from the inner, middle and outer 
molecular layers from both the ipsilateral and contralateral hippocampus using an 
MCID image analysis system connected to a microscope. For each antibody, six 
optical density readings were collected from the expanse of each layer using a 1cm2 
sampling box and an average taken. Readings were taken from a reference area to 
ensure consistency of staining. Two way ANOVA was carried out on the contralateral 
hippocampal readings to allow changes in immuno staining to be attributed to the 
ipsilateral hemisphere. Percentage difference between the ipsilateral and contralateral 
hippocampus was compared in APOEe3 and s4 mice using a Student’s one-tailed 
unpaired /-test. Bonferroni correction for multiple comparisons was applied where 
appropriate. All data is represented graphically using the mean +/- S.E.M.
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4.3.4 Silver staining
Fink Heimer silver staining was carried out to assess terminal degeneration products 
and to determine a time-course for clearance (see Chapter II). Deposition of silver 
labelled degeneration products within the ipsilateral hippocampus was semi-quantified 
using a scoring method (0= no staining, 1= minimal, 2= moderate and 3= extensive). 
Differences between APOEe3 and APOEeA mice were compared using a Mann 
Whitney U statistical test for non-parametric data.
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4.4 Results
4.4,1 APOE levels
The brains o f 12 week old APOEz3 and 84 mice were harvested, the hippocampus 
dissected and frozen in liquid nitrogen. Tissue homogenates were produced and 1 Opig 
o f protein separated by SDS-PAGE gel electrophoresis. Immunoblotting for apoE 
was then carried out as previously described (see Chapter II). Protein bands were 
assessed as relative optical density values using an image analyser (MCID). The 
average optical density value for the apoE protein bands was 0.6405 in APOEz3 mice 
and 0.7762 \n APOEzA mice. The protein levels m APOEzA mice being approximately 
19% greater than that o f APOEz3 mice (Figure 4.1). This is similar to the difference 
observed in baseline optical density values obtained from immunostained sections.
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Figure 4.1 Western blotting showing the levels o f apoE in the 83 and 84 transgenic 
lines. The apoE band appears as a doublet because in the CNS it exists in the 34 kDa 
form and a differently sialyated form at 36kDa.
4.4.2 Statistical design
Taking the percentage difference between the ipsilateral and contralateral 
hippocampal optical densities allowed for correction o f differences which may be due 
to the variance in baseline levels o f apoE between APOEz3 and APOEzA animals. A 
one-tailed /-test was employed, as the hypothesis was that APOEzA mice would 
display a long-term impaired recovery to injury.
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4.4.3 Lesion Assessment
Lesion placement was assessed histologically and appeared as an area of pallor in 
which cells were pyknotic in appearance. The lesions were restricted to the entorhinal 
cortex with no involvement of adjacent structures. Control animals displayed no 
excitotoxic damage to the entorhinal region, only the site of the needle placement was 
visible. No observable difference was evident between the lesion volumes of APOEz3 
and z4 mice.
4.4.4 Temporal Profile of Degeneration and Regeneration Post- 
Lesion
4.4.4.1 Alterations in synaptophysin immunoreactivity
Synaptic alterations during degenerative and reinnervative events within the 
hippocampal dentate gyrus were assessed using synaptophysin immunohistochemistry. 
Percentage difference between the ipsilateral and contralateral hippocampus was 
compared for APOEz3 and c4 mice. Synaptophysin immunoreactivity in 0 day control 
animals displayed a regular dense pattern of staining throughout the dentate gyrus and 
did not differ between the APOEzA and e4 mice. Synaptic alterations occurred within 
the outer two thirds of the molecular layer with little or no change within the IML. 
Synaptic density declined progressively and maximal synaptic loss was evident at day 
28 post-ECL within the MML and OML (Figure 4.2 and 4.3). Ipsilateral hippocampal 
synaptophysin levels were approximately 60% of contralateral at this time-point. 
Synaptic loss was similar within the MML of both APOEzA and s4 mice but was 
significantly greater within the OML o f APOEz3 mice compared to s4 mice (p<0.05). 
At day 90 post-ECL, synaptophysin immunoreactivity had returned almost to pre­
lesion levels in APOEz3 mice. In contrast, in APOEzA mice, synaptophysin 
immunostaining levels remained well below pre-lesion levels and this was significantly 
different to the APOEz3 mice (p<0.05). No significant difference in synaptic density 
was observed between the APOEz3 and c4 mice within the OML, although a similar 
trend was observed. Two way ANOVA on the contralateral hippocampal optical 
density values revealed no statistically significant difference.
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4.4.4.2 Alterations in growth-associated protein immunoreactivity
In 0 day control animals, GAP-43 immunoreactivity exhibited a regular punctate stain 
within the outer two thirds of the molecular layer and denser labelling within the IML, 
however baseline GAP-43 immunoreactivity was significantly greater in APOEz3 
mice compared to APOEzA mice (p<0.05). The percentage differences between the 
ipsilateral and contralateral hippocampal optical density readings were taken to 
correct for this. Within the MML, GAP-43 immunoreactivity declined and maximal 
degeneration was observed at day 7 post-ECL where levels were approximately 40% 
below control levels (Figure 4.4 and 4.5). At day 90 post-ECL, the reduction in GAP- 
43 immunoreactivity had increased towards pre-lesion levels in APOEzA mice. In 
contrast, fibre density remained below pre-lesion levels in APOEzA mice, and this was 
significantly different to that of APOEz3 mice (p<0.05). A similar progressive 
reduction in GAP-43 immunoreactivity occurred within the OML and at day 28 post- 
ECL, reduction in fibre density was maximal at approximately 40% of contralateral 
levels. At day 90 post-ECL, GAP-43 immunoreactivity in the OML of APOEzA mice 
had returned to, or was greater than, pre-lesion levels and this was significantly 
different to that observed in the OML of APOEzA mice. Two way ANOVA revealed 
no statistically significant variance in the contralateral readings from each genotype.
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Figure 4.2 Quantification o f synaptophysin immunoreactivity within the inner, middle 
and outer molecular layers (IML, MML, OML) o f  the hippocampal dentate gyrus at 
0, 7, 28 and 90 days post-lesion measured as relative optical density values. 
Percentage difference between the ipsilateral and contralateral hippocampus 
immunoreactivity was compared in APOEzA and APOEzA mice using a Student’s 
unpaired Mest. *p<0.05
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Figure 4.3 Impaired synaptic recovery in APOEzA mice post-ECL
Illustrative examples o f synaptophysin immunoreactivity in transgenic mice expressing 
human APOEz3 and 84 alleles at day 0, 7 and 90 post-ECL. The contralateral 
hippocampus displays no significant synaptic alterations. The arrows delineate the 
region o f  the hippocampal dentate gyrus which experiences synaptic change post- 
ECL. x50 magnification
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Figure 4.4 Quantification o f  GAP-43 immunoreactivity within the inner, middle and 
outer molecular layers (IML, MML, OML) o f  the hippocampal dentate gyrus at 0, 7, 
28 and 90 days post-lesion measured as relative optical density values. Percentage 
difference between the ipsilateral and contralateral hippocampus immunoreactivity 
was compared \nAPOEz3 and APOEzA mice compared using a Student’s unpaired t- 
test. *p<0.05
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Figure 4 5 Impaired sprouting response in APOEzA transgenic mice post-ECL
Illustrative examples o f GAP-43 immunoreactivity in transgenic mice expressing 
human APOEz3 and s4 alleles at day 0, 7 and 90 post-ECL. The contralateral 
hippocampus displays no significant fibre density alterations. The arrows delineate the 
region o f the hippocampal dentate gyrus that experiences fibre density changes ppost- 
ECL. x50 magnification
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4.4.4.3 IML width alterations post-lesion
The width o f  the IML in GAP-43 immunostained sections was measured in each 
animal to reflect the degree o f  sprouting from the commissural-associational fibres. In 
0 day control animals, the width o f  the IML did not significantly differ between 
APOEzA and c4 mice. At day 90 post-ECL, statistical analysis revealed the ipsilateral 
IML width increased significantly compared to that observed in the contralateral IML 
and this was noted for both genotypes (p<0.0001) (Figure 4.6). Comparison o f  the 
ipsilateral IML width o f  the APOEzA and 84 mice revealed the width was significantly 
greater in APOEz3 mice compared to that for APOEzA mice (p<0.0001). The width 
in APOEzA animals expanded by approximately 45% (to 100pm) whereas it increased 
by only 20% (to 75 pm) in zA mice.
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Figure 4.6 Quantification o f the width o f  the inner molecular layer (IML) o f the 
dentate gyrus as assessed in GAP-43 immunostained section. Expansion o f this layer 
gives an indication o f  the sprouting index from the commissural-associational fibre 
pathway. The ipsilateral and contralateral hippocampus was compared using a 
Student’s paired /-test. Sprouting in APOEzA and APOEzA mice was compared using 
a Student’s unpaired /-test. ***p<0.0001
121
4.4.5 Apolipoprotein Response to Injury: APOE Genotype
Differences
4.4.5.1 Apolipoprotein E
(a) ApoE levels in APOE transgenic mice
ApoE levels in these mice APOEz3 and c4 transgenic lines were not exactly matched. 
In control animals, assessment of immunohistochemistry indicated significantly 
greater levels of apoE in the APOEzA line compared to the s3 line (ROD- s3: 0.1265 
vs zA: 0.1562: * p<0.05). Data has been published illustrating apoE levels in these 
lines (Xu et al, 1996, Horsburgh et al, 2000). The increased apoE levels in s4 mice 
was found to be correlated with the increased GAP-43 immunoreactivity in control 
animals (MML: p<0.01 and OML: p<0.05) but no correlation existed between apoE 
and synaptophysin levels (Figure 4.7).
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Figure 4.7 Graphical representation of data correlating GAP-43 and synaptophysin 
immunoreactivity to apoE immunoreactivity in APOEE3 and APOEzA, 0 day control 
animals. ApoE immunoreactivity was correlated with GAP-43 immunoreactivity in 
APOEzA mice but not in APOEz3 mice. Synaptophysin and apoE immunoreactivity 
were not correlated in either APOEzi or APOEzA mice. R-squared values and p 
values are represented on the graphs. **p<0.01 and *p<0.05
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(b) Alterations in cellular immunoreactivity
Intense apoE immuno-positive glial cells were evident within the molecular layers of 
the dentate gyrus by day 7 post-ECL and was similar in both APOEs3 and s4 mice 
(Figure 4.9). No glial staining was evident in the contralateral hippocampus. Faint 
neuronal staining was present in all animals but did not alter with the injury.
(c) Alterations in neuropil immunoreactivity
The percentage difference between the ipsilateral and contralateral hippocampus was 
taken to determine any difference between the APOEzl and s4 mice. In 0 day control 
animals immunostaining was faint and was similar in pattern in both the ipsilateral and 
contralateral hippocampus. Ipsilateral neuropil apoE immunoreactivity increased 
within the IML and MML at day 7 post-ECL similarly in both APOEz3 and s4 mice 
(increases of 50% and 25% respectively) (Figure 4.8 and 4.9). ApoE 
immunoreactivity then declined towards pre-lesion levels at day 90 post-ECL. OML 
apoE immunoreactivity followed a similar pattern where apoE immunostaining 
increased and was maximal at day 7 post-ECL although levels were significantly 
greater in APOEzA mice (p<0.05) (increase of 35% approximately). ApoE 
immunoreactivity declined thereafter towards pre-lesion levels at day 90 post-ECL. 
Two way ANOVA revealed no statistically significant variance in contralateral ROD 
values for each genotype.
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Figure 4.8 Quantification o f  apoE neuropil immunoreactivity within the inner, middle 
and outer molecular layers (IML, MML, OML) o f  the hippocampal dentate gyrus at 
0, 7, 28 and 90 days post-lesion measured as relative optical density values. 
Percentage difference between the ipsilateral and contralateral hippocampus 
immunoreactivity was compared in APOEz3 and APOEzA mice using a Student's 
unpaired t-test. *p<0.05
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Figure 4.9 ApoE is increased at day 7 within the dentate molecular layers post- 
ECL
Illustrative examples o f apoE immunoreactivity in transgenic mice expressing 
APOEz3 and s4 at day 0, 7 and 90 post-ECL. ApoE was increased within the 
neuropil and within some astrocytes. The contralateral hippocampus displayed no 
change in apoE immunoreactivity. The arrows highlight the region where apoE is 
upregulated. x50 magnification
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4.4.5 Apolipoprotein J
(a) Cellular immunoreactivity
At day 7 post-ECL, apoJ immunoreactive glial cells were evident within the molecular 
layers of the dentate gyrus, but the extent was similar in APOEzi and s4 mice (Figure 
4.11).
Neuropil immunoreactivity
In 0 day control animals apoJ immunoreactivity was punctate and stained the 
molecular layers in a pattern similar to that observed for apoE. Pre-lesion apoJ optical 
density measurements were similar in APOEC3 and APOEz.4 mice. Percentage 
difference between the ipsilateral and contralateral hippocampus was taken. ApoJ 
immunoreactivity increased within the molecular layers and was maximal at day 7 and 
28 post-ECL, but was not statistically different between APOEe3 and e4 mice (Figure 
4.10 and 4.11). ApoJ immunoreactivity then declined towards pre-lesion levels at day 
90 post-ECL and was not statistically different in APOEC3 and e4 mice. Two way 
ANOVA on the contralateral hippocampal readings revealed no statistically significant 
variance.
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Figure 4.10 Quantification of apoJ neuropil immunoreactivity in the inner, middle and 
outer molecular layers (IML, MML, OML) of the hippocampal dentate gyrus at 0, 7, 
28 and 90 days post-lesion measured as relative optical density values. Percentage 
difference between the ipsilateral and contralateral hippocampus immunoreactivity 
was compared in APOEe3 and APOEe4 mice using a Student’s unpaired Mest. 
*p<0.05
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Figure 4 11 ApoJ immunoreactivity is increased in astrocytes and the neuropil 
and is similar in both AP()Ez3 and s4 mice
Illustrative examples o f apoJ immunoreactivity in the ipsilateral hippocampus at day 0, 
7 and 90 post-ECL in APOEz3 and 84 mice. ApoJ immunoreactivity is increased in 
astrocytes and the neuropil by day 7 post-ECL. At day 90 post-ECL apoJ 
immunoreactivity has declined within astrocytes however it remains elevated within 
the neuropil o f the OML. There is no significant difference in apoJ immunoreactivity 
between e3 and s4 mice. x50 magnification
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4.4.6 Cytoskeletal Alterations Post-Lesion
4.4.6.1 Alterations in MAP-2 immunoreactivity
One mechanism by which apoE isoforms may affect their differences in plasticity is by 
differential interaction with cytoskeletal components. It was hypothesised that there 
would be differences in the degree of MAP-2 immunoreactivity post-ECL. In 0 day 
control animals, MAP-2 characteristically labels the soma of neurons and the 
associated dendritic networks most intensely. Baseline MAP-2 immunohistochemistry 
was not significantly different between APOEs3 and s4 mice. Little or no alteration in 
MAP-2 was observed in the IML until day 90 post-ECL where the density of MAP-2 
immunohistochemistry was increased within the ipsilateral hippocampus of APOEz3 
mice compared to e4, however this was not a significant difference. Within the MML 
and OML, MAP-2 immunoreactivity declined slightly until day 28, however this was 
similar in both APOEz3 and s4 mice. MAP-2 staining then increased towards pre­
lesion levels by day 90 post-ECL (Figure 4.12). At this time-point MAP-2 
immunoreactivity was greater than contralateral levels in APOEE3 mice however, in 
contrast, MAP-2 immunoreactivity remained below baseline levels in APOEzA mice 
(p<0.05). A similar pattern was observed within the OML, but at day 7 APOEz3 mice 
displayed greater loss of MAP-2 immunohistochemistry compared to e4 mice. At day 
90 post-ECL MAP-2 levels had increased in APOEz.3 mice to above baseline levels 
and was significantly greater than that in APOEz4 mice (p<0.05). Two way ANOVA 
revealed there was no statistically significant variance in the contralateral hippocampal 
immunostaining.
4.4.6.2 Alterations in microtubule organisation
These sections were also analysed using high power light microscopy to assess 
dendritic structure following the insult. It was found that in 0 day control animals, 
dendritic structure was uniform and similar in both APOEz3 and e4 mice. Fine fibrils 
run in parallel through the molecular layers in an well-organised fashion. At day 90 
post-ECL, the dendritic networks in APOEz3 mice recovered and were similar to that 
observed in 0 day control animals. In contrast, the dendritic networks in the molecular 
layers of APOEzA mice are very disarrayed. The MAP-2 labelled fibrils are 
fragmented and the fine fibrils normally observed are ill defined (Figure 4.14).
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Figure 4.12 Quantification of MAP-2 immunoreactivity within the inner, middle and 
outer molecular layers (IML, MML, OML) of the hippocampal dentate gyrus at 0, 7, 
28 and 90 days post-lesion measured as relative optical density values. Percentage 
difference between the ipsilateral and contralateral hippocampus immunoreactivity 
was compared in APOEz3 and APOEzA mice using a Student’s unpaired Mest. 
*p<0.05
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Figure 4.13 Dendritic disorganisation in s4  mice at day 90 post-ECL
Illustrative examples o f MAP-2 immunoreactivity in the ipsilateral hippocampus at 
day 0 and 90 post-ECL in APOEe3 and s4 mice. By day 90 post-ECL the dendritic 
networks in e3 mice are well-organised and fine fibrils can be seen passing through the 
molecular layers. In contrast, in s4 mice, the dendritic networks are very disorganised, 
as highlighted by the arrows. x200 magnification (Inset x400 magnification)
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4.4.7 Clearance of Degeneration Products Post-Lesion
It was hypothesised that differences in plasticity between APOEz3> and s4 mice may 
be dependent on the ability of the different isoforms to clear neuronal degeneration 
products. Sections from each subject were scored microscopically for degeneration 
product deposition. No degeneration products were present in 0 day control animals. 
No degeneration products were evident within the contralateral hippocampus, except 
for a thin band within the stratum lacunosum moleculare and thus only ipsilateral 
scores are represented graphically. From the studies in Chapter III it was shown that 
maximal degeneration product staining was achieved at day 3 post-ECL. For this 
reason two 3 day survival animals for each genotype were included in the study. 
Maximal accumulation of degeneration products was achieved by day 3 post-ECL. By 
day 7 post-ECL, degeneration products were cleared to leave only a thin band of 
material within the MML (Figure 4.14 and 4.15). This state persisted until day 28 
post-ECL and thereafter degeneration products were cleared, until by day 90 post- 
ECL only minimal or no degeneration products were present within the dentate gyrus. 
No statistically significant difference in clearance was determined between APOEz3 
and e4 mice at any time.
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Fig 4.14 Quantification of Fink Heimer silver staining used to label degeneration 
products from axon terminals. Staining was scored on a scale of 0-3. 0- no 
degeneration products, 1-minimal, 2-moderate and 3-maximal. Scores from APOEz.3 
and s4 mice were compared using Mann-Whitney U test. No significant difference in 
clearance of degeneration products was detected. Bar indicates the median in each 
group +/- standard deviation.
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Figure 4.15 Equal rate of clearance of degeneration products in AP()Ez3 and s4 
mice post-ECL
Illustrative examples o f Fink-Heimer silver staining o f degeneration products in 
human APOEe3 and e4 mice at day 0, 7, 28 and 90 post-ECL. The contralateral 
hippocampus displayed no degeneration products at any time. The arrows mark 
regions where degeneration products are present. x50 magnification
90 day
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4.4.8 LRP Receptor Expression Post-Lesion
Cellular immunoreactivity
In 0 day control animals only minimal astrocytic LRP immunoreactivity was observed. 
At day 7 post-ECL (Figure 4.17), LRP immunoreactivity increased on reactive 
astrocytes within the dentate molecular layers, but was not present at day 28 post- 
ECL and astrocytic immunoreactivity was similar in both APOEs3 and s4 mice.
Neuropil immunoreactivity
In 0 day control animals LRP receptor immunoreactivity was evident on neuronal cell 
bodies and in the neuropil but was similar in APOEE3 and e4 animals. In general, 
there were no significant alterations in neuropil LRP immunoreactivity and certainly 
no statistical difference in staining between APOEC3 and e4 mice (Figure 4.16). Two 
way ANOVA revealed no significant variance in the contralateral hippocampal 
readings.
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Figure 4.16 Quantification of LRP receptor neuropil immunoreactivity in the inner, 
middle and outer molecular layers (IML, MML, OML) of the hippocampal dentate 
gyrus at 0, 7, 28 and 90 days post-lesion measured as relative optical density values. 
LRP immunoreactivity in APOEe3 and c4 mice was compared using a Student’s 
unpaired f-test.
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Figure 4.17 Increased LRP receptor immunoreactivity in astrocytes by day 7 
post-ECL but similar in APOEz3 and c4 mice
Illustrative examples o f LRP immunoreactivity at day 7 post-ECL in APOEz3 and s4 
mice. 0 day LRP immunoreactivity is similar in 83 and e4 mice. By day 7 post-ECL, 
LRP immunoreactivity is increased in reactive astrocytes within the molecular layers 
but is similar in e3 and 84 mice (x200). At day 7 and 90 no astrocytic LRP 
immunoreactivity was evident.
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4.5 Discussion
The e4 allele of the APOE gene is associated with sporadic and late-onset AD 
(Corder et al, 1993; Saunders et al, 1993; Hyman et al, 1996; Roses et al, 1996; 
Roses et al, 1997) and a poor recovery after head injury in humans (Jang et al, 1996; 
Teasdale et al, 1997; Horsburgh et al, 2000). The present study indicates that long­
term neuronal repair mechanisms are impaired in transgenic mice possessing human 
APOEzA alleles compared to APOEz3 after denervative injury (Xu et al, 1996, 1998,
1999).
4.5.1 APOE  genotype influence in the acute response to brain injury
In this study we hypothesised that APOEzA mice would have a poorer reparative 
capacity than APOEz3 mice after ECL. This was primarily based on previous studies 
of these mice that highlighted an adverse influence of the s4 allele to acute brain injury 
types. One of these studies which was carried out by our group, showed that APOEzA 
mice incurred a greater level of neuronal cell injury following a period of global 
ischaemia (Horsburgh et al, 2000). However contrary to this, the data indicated that 
in the acute phase after ECL, the APOEz3 mice had a greater degenerative response 
than APOEzA mice, the s3 mice experiencing greater fibre and synapse loss in the 
acute phase of the injury (28 days). One potential explanation for this is that the levels 
o f apoE present may be crucial in the acute stage after injury. The APOEzA mice in 
this transgenic line express approximately 20% more apoE than the s3 line and 
therefore this may cause an inherent difference in the initial response to injury. This is 
reflected in studies using APOE deficient mice, which show a markedly poorer 
response to an episode of global ischaemia compared to wild-type littermate controls 
(Horsburgh et al, 1999). However, increasing the levels of apoE by intraventricular 
infusion, greatly ameliorates this response in apoE deficient mice (Horsburgh et al,
2000). It has also been suggested that low levels of apoE, found in APOEzA 
individuals (Bertrand et al, 1995), underlie their susceptibility for the development of 
AD and potentially to the effects of trauma. Another possibility is that it could be a 
detrimental effect of the s3 isoform in the acute response to ECL. However, there is 
no data to indicate that apoE E3 has a detrimental effect on neuronal integrity. 
Despite this initial poor response, APOEz3 mice were able to compensate and
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promote sprouting, unlike the APOEzA mice which demonstrated a poorer ability to 
recover post-ECL.
4.5.2 APOE genotype and its influence in the long-term response to brain injury
Most recently it has been determined by our group that, following a head trauma, 
individuals with an s4 genotype have a significantly impaired recovery. This results in 
a greater number of these individuals being severely disabled or scoring lower on 
cognitive assessments compared to s3 individuals on a 6 month outcome analysis. 
These findings were particularly important considering the individuals in question 
were under the age of 15 years and therefore, ruled out any of the amyloid depositon 
theories to isoform differences which had previously reigned (Teasdale et al, 2000). 
Inefficient plastic remodelling in AD patients possessing s4 alleles of the APOE gene 
(Arendt et al, 1997) has also been shown. We found that plastic neuronal remodelling 
was impaired in APOEzA mice. In this study we analysed sprouting from the 
commissural-associational neurons by measuring the width of the IML as previously 
described (Anderson et al, 1998). At day 90 post-ECL, the IML of APOEzA mice had 
expanded by almost 45% compared to only 20% in c4 mice. This is consistent with 
the poor recovery of the MML and OML shown in s4 mice.
The present study substantiates other studies, which have indicated a role for apoE in 
the response of the brain to trauma (Poirier et al, 1993; Posse de Chaves et al, 1997). 
ApoE is produced and secreted by astrocytes, microglia (Boyles et al, 1985; Stone et 
al, 1997) and neurons (Han et al, 1994; Roses et al, 1997; Xu et al, 1998, 1999), and 
it functions primarily in the transport of lipids and cholesterol to cells requiring the 
material for remodelling (Holden, 1998; Holtzman and Fagan, 1998; Pitas et al, 
1998). Lipid is essential for the long-term remodelling events after injury. This 
includes reconstruction of cellular elements (i.e. membrane) (Poirier et al, 1993; 
Poirier et al, 1995), if neurite outgrowth and dendritic field reorganisation is to occur. 
Further support for the involvement of apoE in long-term plasticity comes from 
studies employing APOE-dtficient mice, in which entorhinal cortex lesioning is 
associated with severe neurodegenerative changes and compromised compensatory 
sprouting (Masliah et al, 1995; Anderson et al, 1998).
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4.5.3 Alterations in apoE expression in transgenic mice post-ECL
In this study, apoE increased within the neuropil post-ECL equally for both APOEzA 
and s4 mice and at day 90 post-ECL, apoE immunoreactivity had returned to baseline 
levels. Glial apoE within the dentate gyrus was also evident after the injury (Poirier et 
al, 1991; Boyles et al, 1995). This pattern of apoE expression has been identified 
within human AD brains (Kida et al, 1995; Harr et al, 1996; Hesse et al, 1999) and 
also in previous animal studies (Masliah et al, 1996; Terrisse et al, 1999). The 
transient increase in apoE immunoreactivity corresponded with the time period during 
which sprouting and synaptogenesis began to occur.
It has been suggested that the effects of APOE genotype on plasticity may be 
mediated by differences in the levels of apoE in the brain, rather than differences in the 
isoform of the protein. Support for this idea has come from the suggestion that brain 
levels are lower among AD patients possessing the APOEzA allele (Bertrand et al, 
1995). This seems unlikely to explain the findings of this study, because baseline apoE 
levels were initially greater in APOEzA mice compared to s3 yet they recovered 
poorly from the insult. Therefore the data would seem to suggest an isoform effect 
rather than a level effect in the chronic response to injury. This isoform hypothesis is 
supported in a study by Buttini et al (2000), which shows that APOEzA homozygotes 
recover poorly from excitotoxic injury compared to APOEzVzA heterozygotes. In the 
present study, the greater baseline levels of apoE in s4 mice was found to correlate 
with increased GAP-43 immunoreactivity in control mice. This raises the possibility 
that fibre density in humans may be influenced by APOE genotype and this would 
suggest greater fibre density under normal physiological conditions however this does 
not have any implications for its behaviour in injury. In the present study, neither 
APOE genotype nor apoE levels had an influence on baseline synaptic density. 
Genotype influences on baseline fibre density have not been identified in humans as of 
yet.
4.5.4 Alterations in apoJ expression in transgenic mice post-ECL
It is hypothesised that apoJ may perform a similar function in lipid transportation and 
neuronal repair as apoE (Poirier et al, 1995). Recent studies in humans have shown
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that apoJ is increased in senile plaques in the brains of AD sufferers (Kida et al, 
1995), and that apoJ levels in the brain are associated with APOE genotype (Bertrand 
et al, 1995). The authors stipulated that apoE protein levels decreased with increasing 
number of inherited e4 alleles, but apoJ protein levels increased. This suggests that 
apoJ increased perhaps as a function of apoE levels in the brain and not purely 
because of genotype. This is consistent with the finding that in this study, APOEz3 
mice displayed higher levels of apoJ immunoreactivity compared to that in c4 mice but 
they also expressed lower levels of apoE. ApoJ increased similarly for both genotypes 
by day 7 and 28 post-ECL. However, at day 90 post-ECL apoJ immunoreactivity was 
significantly decreased in APOEz3 mice compared to e4. This would seem plausible, 
considering the e4 mice are in an uphill struggle to repair.
4.5.5 ApoE isoform influence on factors which may modulate CNS plasticity
4.5.5.1 Lipid clearance post-ECL
The clearance of debris from the site of an injury is essential if the lipid materials are 
to be recycled for incorporation into cellular elements such as membrane. In apoE 
knockout mice, lipid clearance is deficient mainly due to the absence of apoE (Fagan 
et al, 1998) and thus these mice display deficient regenerative capabilities. Isoform- 
effects on this mechanism have not been addressed. However, in this study APOEzi 
and e4 mice exhibited similar rates of clearance of degeneration products and by day 
90 post-ECL, all debris had been cleared from the dentate gyrus in both lines. 
Therefore, this suggests both isoforms efficiently clear lipid and another mechanism 
may underlie the adverse effects of the apoE E4 protein (Jolivalt et al, 2000).
4.5.5.2 Actions on the LRP receptor
The neurotrophic effects of apoE have been directly demonstrated in vitro. Addition 
of lipidated apoE to a population of cultured neuronal cells enhances neurite 
outgrowth (Fagan et al, 1998, Pitas et al, 1998). The outgrowth promoting effects of 
apoE have been determined to be isoform specific such that neurite outgrowth in 
cultured cells was stimulated by apoE E3, but attenuated by apoE E4 (Nathan et al, 
1994; Bellosta et al, 1995; DeMattos et al, 1998). This has been shown to be 
modulated via apoE interaction with the LRP receptor, an effect that may be
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attenuated by administration of an LRP blocker. In this study there were no major 
alterations in LRP receptor neuropil immunoreactivity after the injury and staining 
was similar in APOEe3 and s4 mice. However, astrocytic LRP expression was 
increased at day 7 post-ECL but the levels were similar in APOEeA and e3 mice. This 
type of analysis does not allow the functioning and binding of apoE to be determined 
however other groups have endeavoured to analyse this and will be discussed in 
chapter IX. Recent data has suggested that interaction of apoE with the LRP receptor 
modulates intracellular signalling pathways which may, in turn modulate intracellular 
proteins i.e. those affecting cytoskeletal structural alterations (Herz, 2001). These 
mechanisms will be elaborated upon in the final discussion.
4.5.5.3 Actions on the cytoskeleton
It is thought that the action of apoE on the neuronal cytoskeleton may play a large 
role in the plasticity response. In this study it was found that MAP-2 protein was 
reduced following the injury but increased towards baseline levels mAPOEeS mice. In 
contrast, MAP-2 protein remained severely reduced in APOEe4 mice. More 
importantly, it was found that dendritic structure was severely disrupted in APOEeA 
mice compared to APOEe3 mice. ApoE plays a major role in maintaining the integrity 
of the microtubular system (Roses et al, 1996; Scott et al, 1998) and this relationship 
may be iso form-dependent (Sun et al, 1998). This adverse influence of apoE E4 on 
neurite outgrowth has been attributed to its function in microtubule depolymerisation 
and destabilization (Nathan et al, 1995; Pitas et al, 1998), an effect not favourable 
during neuronal remodelling and outgrowth. Although reorganisation of the 
cytoskeleton is important in the remodelling process the E4 isoform appears to cause 
significant depolymerisation without polymerisation and may not protect the 
microtubule from phosphorylative enzymes.
In summary, this data shows that long-term neuronal remodelling is impaired in 
APOEeA transgenic mice (on a human promoter) after injury and supports a role for 
apoE isoform influence on plasticity.
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Chapter V
Analysis of APOE Genotype Influence on CNS Plasticity in APOE 
Knockout and Transgenic Mice Expressing Human APOE s3  and s4 
Alleles (GFAP Promoter) Following Entorhinal Cortex Lesion
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5.1 Introduction
In the previous study it was demonstrated that APOEzA mice display poor neuronal 
repair capabilities following injury. The transgenic mice discussed in the previous 
chapter had the entire human APOE gene inserted, including promoter sequence, into 
their genome that resulted in expression of apoE similar to that found in human brain, 
that is they expressed apoE in neurons and glia. However, the contribution of 
endogenous neuronal apoE to plasticity was unclear. A different line of transgenics 
became available which possess an exogenous GFAP promoter sequence downstream 
of the gene, which drives astrocytic apoE expression (Sun et al, 1998). The 
investigation of these transgenic mice allows other questions to be addressed in terms 
of apoE expression and function after injury. This study was undertaken to determine 
if the APOEzA allele exerted its adverse effects on plasticity when it is expressed 
endogenously in astrocytes only. The hypothesis was that possession of the APOEzA 
genotype in these transgenic mice would result in impaired repair processes after 
injury.
5.2 Aims
To analyse APOE genotype on CNS plasticity in a line of APOE knockout mice and 
transgenic mice expressing human APOEz3 and zA under an exogenous GFAP 
promoter sequence following entorhinal cortex lesion.
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5.3 Materials and Methods
5.3.1 APOE transgenic mice on a GFAP promoter
APOEzA and s4 heterozygous transgenic mice were generated as previously described 
(Holtzman et al, 1998). The coding sequences of the human APOE gene were 
inserted into the genome of B6/CBA mice. Mice were obtained from Dr Holtzman 
and transported to the UK according to Home Office Regulations and bred in an 
animal unit at the University of Glasgow. Knockout littermates are also produced in 
the breeding of these animals. The genotypes of all animals bred were checked using 
PCR analysis (see Chapter II).
5.3.2 Entorhinal cortex lesion
The entorhinal cortex was lesioned in male knockout, transgenic APOEz3 and s4 
mice. The mice were then allowed to survive for periods of 90 days (KO/n=12, 
c3/n=8, e4/n=7). 0 day control animals underwent an identical procedure but were 
terminated immediately after the procedure (KO/n=ll, s3/n=8, s4/n=8). Tissue was 
also harvested from naive mice and homogenised for separation by gel 
electrophoresis. Sections from the entorhinal cortex were histologically stained using 
haematoxylin and eosin to confirm correct lesion placement. Immunohistochemistry 
for synaptophysin, GAP-43, apoE, apoJ, LRP and MAP-2 was performed on 
hippocampal sections. The IML width, in GAP-43 immuno stained sections, was 
measured and analysed as outlined in chapter II.
5.3.3 Quantification of immunohistochemistry and statistical analysis
Relative optical density values were collected from the inner, middle and outer 
molecular layers of both the ipsilateral and contralateral hippocampus using an MCID 
image analysis system connected to a microscope. Six optical density readings were 
collected from the expanse of each layer using a 1cm2 sampling box and an average 
taken. The percentage difference between the ipsilateral and contralateral 
hippocampus was taken for comparison between the genotypes. The groups were 
compared using ANOVAR and the genotypes compared using a post-hoc Student’s
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unpaired /-test with Bonferroni correction for multiple comparisons. All data is 
represented graphically using the mean +/- S.E.M.
5.3.4 Silver Staining
Fink Heimer silver staining was carried out to assess terminal degeneration products 
and to determine a time-course for clearance (see chapter II). Deposition of silver 
labelled degeneration products within the ipsilateral hippocampus was semi-quantified 
using a scoring method (0= no staining, 1= minimal, 2= moderate and 3= extensive). 
Scores were tested for variance using a Kruskal Wallis test and the genotypes 
compared using a Mann Whitney U statistical test for non-parametric data.
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5.4 Results
5AA APOE  levels
The brains o f 12 week old APOEz3 and s4 mice were harvested, the hippocampus 
dissected and rapidly frozen in liquid nitrogen. Tissue homogenates were produced 
and 10p.g o f protein separated by SDS-PAGE gel electrophoresis. Immunoblotting for 
apoE was performed as previously described (chapter II). Protein bands were 
assessed as relative optical density values using an image analyser (MCID). ApoE 
levels were found to be comparable in the e3 and 84 mice (Figure 5.1).
s3 s4
Figure 5.1 Western blotting bands showing apoE levels in APOEe3 and s4 transgenic 
mice Levels are comparable in e3 and z4 mice.
5.4.2 Lesion assessment
Lesion placement was assessed histologically and appeared as an area o f  pallor in 
which cells were pyknotic in appearance. The lesions were restricted to the entorhinal 
cortex, with no involvement o f  the adjacent structures. Control animals displayed no 
excitotoxic damage to the entorhinal region, only the site o f  the needle placement was 
visible. No observable difference was evident between the lesion volumes o f 
knockout, APOEzA or e4 mice.
5.4.3 Temporal Profile of Degeneration and Regeneration Post- 
Lesion
5.4.3.1 Alterations in synaptophysin immunoreactivity
Synaptic alterations during degenerative and reinnervative events within the 
hippocampal dentate gyrus were assessed using synaptophysin immunohistochemistry. 
Percentage difference between the ipsilateral and contralateral hippocampus was 
compared in knockout, APOEz3 and APOEzA mice. Synaptophysin immunoreactivity 
in 0 day control mice displayed a regular dense pattern o f staining throughout the
1 4 6
dentate gyrus and did not differ significantly between the genotypes. At day 90 post- 
ECL, ipsilateral synaptophysin immunoreactivity was significantly reduced in all layers 
(20-30%). There was no statistically significant difference between APOE knockout, 
s3 and s4 mice (Figure 5.2 and 5.4).
5.4.3.2 Alterations in growth-associated protein immunoreactivity
In 0 day control mice, GAP-43 immunoreactivity exhibited a regular dense, punctate, 
stain within the outer two thirds of the molecular layer and denser labelling within the 
IML and there was no statistically significant difference in GAP-43 levels between the 
genotypes. At day 90 post-ECL, GAP-43 immunoreactivity was not significantly 
altered in the ipsilateral hemisphere in APOE knockout and s3 mice in the IML, but 
e4 mice displayed a deficit. In the MML and OML, APOE knockout, s3 and s4 mice 
displayed a deficit in GAP-43 immunoreactivity in the ipsilateral hemisphere 
compared to the contralateral at 90 days. This deficit was most marked in the e4 mice 
(p<0.05) (Figure 5.3 and 5.5).
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Figure 5.2 Quantification of synaptophysin immunoreactivity in the inner, middle and 
outer molecular layers (IML, MML and OML) of the hippocampal dentate gyrus 
measured as relative optical density values at 0 and 90 days post-lesion. Percentage 
difference between the ipsilateral and contralateral hippocampus immunoreactivity 
was compared in APOE knockout, s3 and s4 transgenic mice using a Student’s 
unpaired r-test with Bonferroni correction for multiple comparisons.
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Figure 5.3 Quantification of GAP-43 immunoreactivity in the inner, middle and outer 
molecular layers (IML, MML and OML) of the hippocampal dentate gyrus, measured 
as relative optical density values at 0 and 90 days post-lesion. Percentage difference 
between the ipsilateral and contralateral hippocampus immunoreactivity was 
compared in APOE knockout, e3 and s4 transgenic mice using a Student’s unpaired t- 
test with Bonferroni correction for multiple comparisons. *p<0.05
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Figure 5 4 Synaptophysin immunoreactivity in APOE knockout (K O ), s3 and s4  
mice post-ECL
Illustrative examples o f synaptophysin immunoreactivity in the ipsilateral 
hippocampus at day 0 and 90 post-ECL in APOE knockout, 83 and s4 transgenic 
mice. Contralateral synaptophysin immunoreactivity does not alter post-ECL. x50 
magnification
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Figure 5 5 Impaired sprouting in APOEz4 mice at day 90 post-ECL
Illustrative examples o f GAP-43 immunoreactivity in the ipsilateral hippocampus at 
day 0 and 90 post-ECL in APOE knockout, s3 and s4 mice. GAP-43 
immunoreactivity in the contralateral hippocampus did not alter post-ECL. The 
arrows delineate the region o f the hippocampus affected by the lesion. x50 
magnification
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5.4.3.3 IML width alterations post-lesion
The width of the IML in GAP-43 immunostained sections was measured in each 
animal to give an indication of the degree of sprouting from the commissural- 
associational fibres. In 0 day control animals there was no statistically significant 
difference in IML width between the genotypes. At day 90 post-ECL, IML width 
increased in mice of all genotypes, but more so in APOEe3 mice (30%) and knockout 
mice (25%) compared to APOEe4 mice (20%). Comparison of the IML widths at day 
90 revealed IML width was significantly greater in APOEe3 mice compared to 
APOEe4 but was not significantly different to that of knockout mice (p<0.05) (Figure 
5.6).
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Figure 5.6 Quantification of hippocampal IML width in GAP-43 immunostained 
sections from APOE knockout and APOEe3 and e4 transgenic mice at 0 and 90 days 
post-lesion. The width was compared between the genotypes using a Student’s 
unpaired /-test with Bonferroni correction for multiple comparisons. ***p<0.0001, 
**p<0.01 and *p<0.05
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5.4.4 Apolipoprotein Response to Injury
5.4.4.1 Apolipoprotein E
(a) Alterations in cellular immunoreactivity
No apoE immunoreactivity was evident in APOE knockout mice. 0 day control APOE 
transgenics displayed astrocytic immunostaining throughout the entire brain. At day 
90 post-ECL astrocytic apoE was increased slightly but was similar in APOEe3 and 
e4 mice.
(b) Neuropil immunoreactivity
The percentage difference between the ipsilateral and contralateral hippocampal apoE 
immunoreactivity was taken. APOE knockout mice displayed no immunoreactivity. In 
0 day control APOEe3 and c4 mice apoE immunoreactivity was faint and similar in 
both APOEe3 and e4 mice. At day 90 post-ECL, apoE immunoreactivity was 
increased within the MML and OML of both APOEe3 and e4 mice. At this time s4 
mice displayed slightly greater apoE immunoreactivity compared to s3 mice, however 
this was not statistically significant (Figure 5.7 and 5.8).
5.4.4.2 Apolipoprotein J
(a) Cellular immunoreactivity
In 0 day control mice, neuronal apoJ immunoreactivity was present within mice of all 
genotypes. No astrocytic immuno staining was present. By day 90 post-ECL minimal 
astrocytic immunoreactivity was evident.
(b) Neuropil immunoreactivity
In 0 day control animals, apoJ neuropil immunoreactivity was punctate and stained the 
molecular layers in a dense pattern of staining which was similar across all genotypes. 
Percentage difference between the ipsilateral and contralateral hippocampus was 
taken. At day 90 post-ECL, apoJ immunoreactivity was no different in the IML and 
MML compared to 0 day control mice. In contrast, apoJ immunoreactivity was 
intense within the OML but did not differ significantly between genotypes (Figure
5.9).
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Figure 5.7 Quantification of apoE neuropil immunoreactivity in the inner, middle and 
outer molecular layers (IML, MML and OML) of the hippocampal dentate gyrus 
measured as relative optical density values at 0 and 90 days post-lesion. Percentage 
difference between the ipsilateral and contralateral hippocampus immunoreactivity 
was compared in s3 and e4 transgenic mice using a Student’s unpaired t-test with 
Bonferroni correction for multiple comparisons.
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Figure 5 8 ApoE is elevated at day 90 post-ECL
Illustrative examples o f apoE immunoreactivity in the ipsilateral hippocampus at day 0 
and 90 post-ECL in s3 and z4 transgenic mice. Knockout mice do not display any 
apoE immunoreactivity at any time. In 0 day control mice, apoE immunoreactivity is 
light within the neuropil and immunoreactive astrocytes are evident throughout the 
entire brain. ApoE immunoreactivity is increased in s3 and s4 mice at day 90 post- 
ECL but is sightly more elevated in c4 mice, x 50 magnification
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Figure 5.9 Quantification of apoJ neuropil immunoreactivity in the inner, middle and 
outer molecular layers (IML, MML and OML) of the hippocampal dentate gyrus 
measured as relative optical density values at 0 and 90 days post-lesion. Percentage 
difference between the ipsilateral and contralateral hippocampus immunoreactivity 
was compared in APOE knockout, s3 and s4 transgenic mice using a Student’s 
unpaired Mest with Bonferroni correction for multiple comparisons.
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5.4.5 Cytoskeletal Alterations Post-Lesion
5.4.5.1 Alterations in MAP-2 immunoreactivity
In 0 day control mice MAP-2 immunoreactivity displayed a regular pattern of 
staining, with dendritic processes being visible throughout the entire molecular layer. 
At day 90 post-ECL MAP-2 immunoreactivity was reduced in all layers compared to 
0 day, however this deficit was similar in APOEzS, s4 and knockout mice (Figure
5.10).
5.4.5.2 Alterations in microtubule organisation
Sections were analysed using high power light microscopy to assess dendritic 
structure following the insult. In 0 day control animals of all genotypes, microtubule 
organisation was well-organised and fine fibrils were evident running through the 
entire molecular layer. At day 90 post-ECL, although there was a clear reduction in 
MAP-2 immunoreactivity, dendritic structure did not differ significantly between 
APOE knockout, s3 and e4 mice (Figure 5.11).
5.4.6 Clearance of Degeneration Products
Silver stained sections from each subject were scored microscopically for the presence 
of degeneration product deposition. No silver labelled degeneration products were 
present at day 0 or day 90 post-ECL in any APOE knockout, s3 or s4 mice (Figure 
5.12). Silver labelled degeneration products were present within a 3 day control 
mouse brain used as a positive control.
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Figure 5.10 Quantification of MAP-2 immunoreactivity in the inner, middle and outer 
molecular layers (IML, MML and OML) of the hippocampal dentate gyrus measured 
as relative optical density values at 0 and 90 days post-lesion. Percentage difference 
between the ipsilateral and contralateral hippocampus immunoreactivity was 
compared in APOE knockout, s3 and c4 transgenic mice using a Student’s unpaired t- 
test with Bonferroni correction for multiple comparisons.
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Figure 5.11 High power MAP-2 immunoreactivity
There is no difference in MAP-2 immunoreactivity between APOE knockout, 83 and 
c4 transgenic mice at day 90 post-ECL. x400 magnification
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Figure 5 12 Silver labelled degeneration products
Illustrative examples o f degeneration products silver staining in the ipsilateral 
hippocampus at day 0 and 90 post-ECL in APOE knockout (KO), s3 and 84 
transgenic mice. No injury related degeneration products were present at any time in 
either APOE knockout, s3 or s4 mice.
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5.4.7 LRP Receptor Expression Post-Lesion
(a) Cellular immunoreactivity
In 0 day control mice, LRP immunoreactivity was evident on neurons with minimal 
astrocytic immunoreactivity and this pattern was similar in APOE knockout, e3 and e4 
mice. No astrocytic immunoreactivity was present by day 90 post-ECL. Neuronal cell 
body LRP immunreactivity did not alter with the injury.
(b) Neuropil immunoreactivity
In 0 day control mice, LRP immunoreactivity optical density values were found to be 
comparable in APOE knockout, s3 and s4 mice. At day 90 post-ECL, LRP 
immunoreactivity was slightly elevated within all layers but was statistically similar 
between APOE knockout, s3 and b4 mice (Figure 5.13).
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Figure 5.13 Quantification of LRP neuropil immunoreactivity in the inner, middle and 
outer molecular layers (IML, MML and OML) of the hippocampal dentate gyrus 
measured as relative optical density values at 0 and 90 days post-lesion. Percentage 
difference between the ipsilateral and contralateral hippocampus immunoreactivity 
was compared in APOE knockout, b3 and s4 transgenic mice using a Student’s 
unpaired t-test with Bonferroni correction for multiple comparisons.
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5.5 Discussion
ApoE is involved in the long-term plasticity changes that occur in the weeks to 
months following brain injury. In the previous chapters, a role for apoE in neuronal 
cell maintenance was established. Using a line of transgenic mice, with both neuronal 
and glial cell apoE expression, it was shown that the human APOEzA allele was 
associated with impaired neuronal cell plasticity following injury (White et al, 2001). 
In this study we have employed the same animal model but have assessed recovery 
from chronic brain injury in APOE knockout and transgenic mice possessing human 
APOEz3 and s4 alleles under an astrocytic promoter. This dictates that apoE 
expression is strictly astrocytic in nature. The present study suggests that there may be 
an impairment of long-term neuronal repair mechanisms in transgenic mice possessing 
the human APOEzA genotype compared to APOEz3 transgenic mice. However, the 
extent of this impairment is more pronounced than that observed in the transgenic 
mice expressing apoE protein neuronally.
5.5.1 APOE genotype and the acute response to brain injury
It is becoming increasingly clear that the localisation of apoE within the brain may be 
crucial to the way in which it influences recovery. In contrast to the mice employed in 
the previous study, this line of transgenic mice express apoE astrocytically and this 
could have vital implications for recovery from brain injury. If apoE is not expressed 
neuronally can it modulate neuronal plasticity? The acute response to injury was not 
the focus of this study. Following the injury, apoE was increased within the neuropil 
and also within glia in the dentate molecular layer. A study by Horsburgh et al (2001) 
found that following a period of global ischaemia, there was no statistically significant 
difference in the extent of ischaemic cell death between APOEz3 and s4 mice. In this 
study, a marked increase in apoE levels was determined after ischaemia. There is little 
data on acute brain injury in these transgenic mice, other than the study mentioned, 
however the results from that would suggest that at least in the acute phase, APOE 
genotype does not influence outcome. Traditionally it has been thought, that to 
function in neuronal repair mechanisms, apoE would be required to enter the neuronal 
cell, or at the very least interact with its receptors on the neuron cell surface. 
Although no neuronal cell body staining was evident at any time, it would seem
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unlikely that the dramatic increase in neuropil staining observed in the dentate 
molecular layers would be due solely to the presence of apoE in astrocyte processes. 
It would seem possible that at least some of the protein was present within neuronal 
cell processes, or in the extracellular space, ready for utilisation in membrane 
biosynthesis. This issue would need to be resolved using electron microscopy.
5.5.2 APOE genotype and the chronic response to brain injury
The present study is the first to use this transgenic mouse line in the study of chronic 
brain injury. We have found that APOEzA mice recover poorly from the injury 
compared to APOEz3 and APOE knockout mice. At 90 days post-ECL, APOEzA 
mice display significant deficits in GAP-43 immunoreactivity compared to APOE 
knockout and z3 mice. No genotype effect on synaptic density was evident. As 
previously described the width of the IML serves as an efficient indicator of the 
sprouting response from the commissural-associational neurons. The IML width 
increased by approximately 25-30% in APOEz3 and knockout mice but only increased 
by 15-20% in APOEzA mice. ApoE immunoreactivity was elevated at 90 days post- 
ECL within all layers but to a greater extent in APOEzA mice compared to s3. This 
increase in apoE at 90 days post-ECL is a similar finding to that observed in the 
C57BL/6J mice (see chapter III). In contrast, the transgenic mice expressing apoE in 
neurons do not experience this late increase post-ECL. Wild-type mice express apoE 
in glial cells but not neurons similar to the mice in this chapter and therefore the late 
expression of apoE post-injury could be dependent on the initial localisation of 
expression. It must also be noted that although the mice in this study display a certain 
ability to repair, even at 90 days there remains a significant deficit in fibre and synapse 
density (20-30%) compared with 0 day control levels in each genotype. This is in 
contrast to the previous neuronally expressing mice where all mice displayed a 
complete recovery by day 90 post-ECL. This could indicate the importance o f the 
presence of neuronal apoE in brain injury.
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5.5.3 Uptake of the apoE/Iipid complex by the LRP receptor
The entrance of apoE into neuronal cells is primarily mediated by the LRP receptor. 
This receptor is expressed on neuronal cell bodies and also on neurite processes, 
especially in regions of high synaptic density (Herz et al, 1990, Rebeck et al, 1993, 
Bu et al, 1994). The most common hypothesis, based on its basic function, is that, in 
response to stress, apoE is released by astrocytes into the extracellular space to 
scavenge lipid material from degenerating neurons (Poirier et al, 1993). ApoE may 
only bind efficiently to its receptor when lipid bound. Once taken up, the lipid is 
cleaved from the particle (for membrane integration) and apoE may be recycled to the 
cell surface or interact with cytoskeletal proteins (Roses et al, 1996). This process is 
particularly important in the model described in this chapter, since it is the only means 
by which apoE could possibly enter the cell. It would therefore take longer for apoE 
to reach the neuron than if synthesised endogenously. This also has implications for 
the pathway by which the apoE travels. In a study by DeMattos et al (1999) it was 
shown that apoE fails to escape the endocytic/lysosomal pathway intracellularly as 
previously thought and suggests that direct expression of apoE in the cytosol is toxic. 
The authors suggest that the signalling events at the cell surface are the crucial factors 
in the function of apoE in plasticity. This is corroborated by studies released recently 
by Herz et al, (2001) which have shown the activation of extensive signalling 
pathways on binding of apoE to the LRP receptor. These pathways are detailed in 
chapter IX.
5.5.4 Brain injury in APOE knockout mice
Several studies have shown the poor outcome of APOE knockout mice after acute 
brain injury. This has been demonstrated following closed head injury (Chen et al, 
1997; Genis et al, 2000), focal cerebral ischaemia (Laskowitz et al, 1997) and global 
ischaemia (Horsburgh et al, 1999; Sheng et al, 1999) when compared to wild-type 
C57BL/6J mice. Studies of chronic brain injury have also been carried out using 
APOE knockout mice. Anderson et al (1998) used the entorhinal cortex lesion model 
to assess plasticity in APOE knockout mice and wild-type C57BL/6J mice. The 
authors found that following 140 days of survival post-injury, both APOE knockout 
and wild-type groups showed immunohistochemical evidence of reactive 
synaptogenesis although the APOE knockout group initially displayed greater synaptic
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loss. In the present study we also found that APOE knockout mice displayed a 
significant degree of plasticity which was more substantial in some layers than that 
observed in APOEzA. The finding that APOE knockout mice are capable of plasticity 
suggests that another protein may compensate for the absence of apoE. Could this be 
the function of apo J in the brain?
5.5.5 Alterations in apoJ expression in transgenic mice post-ECL
It is hypothesised that apoJ may perform a similar function in lipid transportation and 
neuronal repair, to apoE (Poirier et al, 1995). In conditions where apoE is absent or 
reduced, apoJ is thought to compensate (Anderson et a\, 1998). Bertrand et al (1995) 
showed that apoE levels in human brain were reduced with the increasing e4 allele 
number and apoJ levels were found to increase. In the present study we have found 
that apoJ is slightly greater in 0 day control, APOE knockout mice, although not 
significantly so when compared to APOEz3 and s4 mice. By day 90 post-ECL, apoJ 
immunoreactivity was comparable in the IML and MML to control levels but was 
elevated within the OML. Again no significant difference in immunoreactivity could 
be detected between the genotypes. The fact that APOE knockout mice display 
slightly greater baseline apoJ levels may suggest that it is elevated to compensate for 
the lack of apoE. However, apoJ levels are comparable between the genotypes post- 
ECL may suggest that levels expressed post-injury are not dependent on the presence 
or absence of apoE.
5.5.6 ApoE isoform influence on factors that may influence CNS plasticity
5.5.6.1 Clearance o f degeneration products
There are several factors that may account for the isoform differences observed in this 
study. Initially it was important to determine if E3 and E4 both cleared degeneration 
material from the site of the injury efficiently. In the present study it was found that at 
day 90 post-ECL, there was no evidence of lesion induced degeneration products in 
APOEz3 or e4 mice. Most surprisingly, it was also found that degeneration products 
were efficiently cleared in APOE knockout mice. The only study which found 
impaired degeneration product clearance is that by Fagan et al (1998) who found that 
knockout mice displayed impaired clearance of degeneration products but only when
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aged. The clearance of degeneration material post-injury has not previously been 
analysed in these mice before the carrying out of this study.
5.5.6.2 LRP receptor expression
The outgrowth promoting effects of apoE from this line of transgenic mice have been 
shown in vitro. It was noted that hippocampal neurons grown on a monolayer of 
astrocytes, derived from these astrocyte-expressing mice, produced long neurites 
when the astrocytes were derived from APOEz3 expressing mice. Outgrowth was 
inhibited when hippocampal neurons were grown on APOEzA expressing astrocytes 
(Holtzman et al, 1995; Sun et al, 1998). In addition it was found that by blocking the 
LRP receptor, the outgrowth promoting effects of apoE E3 could be attenuated 
(Holtzman et al, 1995). APOE knockout mice express the LRP receptor throughout 
the brain even in the absence of apoE expression (Ishibashi et al, 1994). However, the 
LRP receptor has a host of ligands and functions in a number of other processes. No 
significant difference in LRP expression between the genotypes was noted at any time 
in this study, however, this does not reflect functional variations of the isoforms at the 
receptor. Although LRP was increased on reactive astrocytes, generally endocytic 
receptors are shown not to increase expression significantly under stress but increase 
turnover, therefore it is not surprising that increased neuropil expression was not 
witnessed.
5.5.6.3 Cytoskeletal structure
In the neuronally expressing transgenic mice it was found that dendritic structure, as 
labelled with the MAP-2 antibody, was disrupted and disorganised in APOEzA mice 
post-ECL compared to e3 mice. This was not the case in this study. No genotype 
effect on MAP-2 immunoreactivity density was observed. Additionally, there was no 
observable difference in dendritic structure in APOE knockout, e3 or zA mice post- 
ECL. This could reflect the role of intraneuronal apoE interaction with the 
cytoskeleton. If E3 and E4 behave differently when they enter the neuron i.e. E3 
escapes the endosomal pathway but E4 does not, this could mean that E3 is able to 
interact with microtubules to promote polymerisation and extension. In neuronally 
expressing mice the apoE is readily available intraneuronally for immediate
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interactions with the cytoskeleton, without the added complication of cell entry 
primarily. This could reflect why the neuronally expressing mice repair so efficiently 
and the astrocytically expressing mice do not.
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Chapter VI
APOE Genotype Influence in the CNS of Aged APOE Knockout, s3 and 
s4 Transgenic Mice (GFAP Promoter).
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6.1 Introduction
At birth the normal human brain is composed of 1012 cells, approximately 20,000 cells 
for every 1mm3 of brain mass (Principles of Behavioural Neuroscience, 1995). This 
population of cells is composed predominately of neurons and glial cells of various 
types. Glial cells of the brain are capable of dividing however, neurons are unique, in 
that, unlike cells of other major organs, they are not capable of division. New 
neuronal cells cannot be manufactured in the CNS, a process call neurogenesis. Thus, 
we are bom with a full complement of brain cells. In the process of ageing, brain cells 
are lost and this combined with the associated loss of synaptic contacts can have a 
devastating effect on function, an exaggerated example of this being Alzheimer’s 
disease (AD). The brain is capable of compensating for this to a certain extent 
through a process of synaptic plasticity. Existing fibres produce outgrowth in an 
attempt to form new contacts. Isoform specific effects on brain ageing have not been 
clearly elucidated and in this chapter the APOE genotype influence on the ageing 
process, will be assessed in APOE knockout, e3 and s4 transgenic mice. The 
hypothesis of this study is that APOEe4 mice will display impaired hippocampal 
plasticity with increasing age.
6.2 Aims
This study will assess APOE genotype influence on CNS plasticity with ageing in 
APOE knockout, human APOEe3 and s4 transgenic mice (GFAP promoter).
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6.3 Materials and Methods
6.3.1 APOE transgenic mice on a GFAP promoter
APOEel and s4 heterozygous transgenic mice were generated as previously described 
(Sun et al, 1998). Homozygous knockout littermates are also produced in the 
breeding of these animals. The APOE genotypes of all animals bred were checked 
using PCR analysis (see Chapter II).
6.3.2 Tissue
APOE knockout, c3 and s4 transgenic mice were bred and maintained in an animal 
house until the age of either 3 months (knockout: n=5, e3: n=5, s4: n=5) or 1 year 
(knockout: n=12, c3: n=6, s4: n=7). The mice were halothane anaesthetised and 
perfused transcardially with heparinised saline followed by buffered 4% 
paraformaldehyde. The brains were processed and paraffin embedded and 6pm 
coronal sections were cut on a microtome. Immunohistochemistry for GAP-43, 
synaptophysin, apoE, apoJ and MAP-2 was performed on tissue sections from each 
subject. IML width was measured in GAP-43 immunostained sections and analysed as 
outlined in chapter II.
6.3.3 Quantification of immunohistochemistry and statistical analysis
Relative optical values for immunostaining were collected from the inner, middle and 
outer molecular layers of the dentate gyrus from both the ipsilateral and contralateral 
hippocampus of each subject using an MCID image analysis system. Six optical 
density readings were taken from each layer using a 1cm2 sampling box and averaged 
to give a representative reading from the layer. The measurements from the ipsilateral 
and contralateral hippocampus were averaged for each subject. ANOVAR was carried 
out on the measurements taken from each antibody of both the 3 month and 1 year 
old mice. The genotypes were then compared using a post-hoc Student’s unpaired t- 
test with Bonferroni correction for multiple comparisons. Histograms are presented as 
the mean +/- S.E.M.
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6.4 Results
6.4.1 Temporal Profile of Degeneration
6.4.1.1 APOE genotype and synaptic loss in ageing
Synaptophysin immunoreactivity displayed a regular, dense, trilaminar pattern of 
staining with the IML most intensely stained. In 3 month old mice, there was no 
statistically significant difference in synaptophysin immunoreactivity. Genotype 
differences in synaptophysin immunoreactivity were compared between APOE 
knockout, e3 and s4 mice. In 1 year old mice, synaptophysin immunoreactivity was 
not significantly altered compared to those at 3 months of age. There was a trend for 
greater synaptophysin immunoreactivity in 1 year old, APOEz3 transgenic mice 
compared to the other genotypes although this did not achieve statistical significance 
(Figure 6.1).
6.4.1.2 APOE genotype and fibre degeneration in ageing
GAP-43 immunoreactivity displayed a regular punctate staining with the IML being 
most densely immunoreactive. In 3 month old mice, a statistically significant 
difference in GAP-43 immunostaining was observed within the IML where GAP-43 
immunoreactivity was found to be significantly reduced in APOEzA mice compared to 
APOE knockout and s3 mice (p<0.05). GAP-43 immunoreactivity decreased within 
all layers of APOE knockout and APOEz3 mice at 1 year compared to 3 months. 
However, the levels of GAP-43 immunoreactivity were not different in APOEz4 mice 
at 1 year compared to 3 months. There was no statistical difference in the levels of 
GAP-43 between APOE knockout, s3 and s4 mice at 1 year (Figure 6.2).
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Figure 6.1 Quantification of synaptophysin immunoreactivity within the inner, middle 
and outer molecular layers (IML, MML and OML) of the hippocampal dentate gyms 
of 3 month adult mice and 1 year old aged APOE knockout, e3 and s4 transgenic 
measured as relative optical density values. ANOVAR was carried out on the groups 
and the genotypes compared using a Student’s unpaired /-test with Bonferroni 
correction for multiple comparisons.
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Figure 6.2 Quantification of GAP-43 immunoreactivity within the inner, middle and 
outer molecular layers (IML, MML and OML) of the hippocampal dentate gyrus of 3 
month old adult mice and 1 year aged APOE knockout, s3 and e4 transgenic mice 
measured as relative optical density values. ANOVAR was carried out on the groups 
and the genotypes compared using a Student’s unpaired /-test with Bonferroni 
correction for multiple comparisons. *p<0.05
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6.4.1.3 IML width alterations in ageing
IML width acts as an indication of the degree of sprouting from the commissural 
associational neurons. This fibre system has been shown to sprout in conditions of 
chronic injury (see chapter IV and V). Statistically significant variance in the baseline 
optical density readings of GAP-43 immunostained sections was detected in 3 month 
old mice. This suggested that there may be baseline differences in sprouting between 
the genotypes which may be detected by measurement of IML width.
The IML at 3months of age was similar in APOE knockout and s3 mice. However, 
IML width was significantly narrower in APOEz4 mice compared to APOE knockout 
and s3 mice (p<0.05). At 1 year, IML width is still significantly narrower in APOEzA 
mice compared to APOE knockout (p<0.05) and s3 mice (p<0.01). This is because 
IML width increases in s3 mice between 3 months and 1 year of age but does not 
increase m APOEzA mice (Figure 6.3).
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Figure 6.3 Quantification of hippocampal IML width in GAP-43 immunostained 
sections from 3 month old adult and 1 year old aged APOE knockout, b3 and e4 
transgenic mice. ANOVAR was carried out on the groups and the genotypes 
compared using a Student’s unpaired /-test with Bonferroni correction for multiple 
comparisons. **p<0.01 and *p<0.05
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6.4.2 Apolipoprotein Response to Ageing
6.4.2.1 Apolipoprotein £
(a) Astrocytic immunoreactivity
Apolipoprotein E immunoreactivity was pale within the neuropil. Astrocytic staining 
was present throughout the hippocampus and throughout the whole brain. This 
staining was similar in both c3 and e4 mice. The degree of astrocytic staining did not 
alter with age. APOE knockout mice displayed no apoE immunoreactivity.
(b) Neuropil immunoreactivity
Optical density readings were collected from the neuropil of APOEz3 and e4 mice at 
3 months and 1 year of age. ANOVAR revealed no statistically significant variance in 
apoE neuropil immunostaining in the 3 month old APOEzl and e4 mice. ApoE 
immunoreactivity was similar in 1 year old APOEz3 mice compared to levels at 3 
months of age (Figure 6.4 and 6.5). ApoE immunoreactivity was significantly greater 
in APOEzA mice compared to e3 mice at 1 year old (p<0.05).
0.4.2.2 Apolipoprotein J
ApoJ immunoreactivity was present within the neuropil and also lightly stained 
neurons. The degree of staining was similar in APOE knockout, APOEz3 and s4 
transgenic mice. ANOVAR revealed no statistically significant variance in apoJ 
staining intensity in 3 month old mice in any layer. ApoJ immunoreactivity did not 
alter significantly between 3 months and 1 year of age in APOEz3 mice (Figure 6.6). 
There was trend for greater apoJ immunoreactivity in APOE knockout and 84 mice 
compared to APOEzA mice within all layers.
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Figure 6.4 Quantification of apoE immunoreactivity within the inner, middle and outer 
molecular layers (IML, MML and OML) of the hippocampal dentate gyrus of 3 
month old adult and 1 year old aged APOEz3 and s4 transgenic mice measured as 
relative optical density values. ANOVAR was carried out on each group and the 
genotypes compared using a Student’s unpaired /-test with Bonferroni correction for 
multiple comparisons. *p<0.05
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Figure 6 5 Increased apoE immunoreactivity at 1 year of age
Illustrative examples of apoE immunoreactivity in AP()Ez3 and 84 transgenic mice at 
age 3 months and 1 year. Neuropil apoE immunoreactivity is increased at 1 year o f 
age throughout most regions of the brain including the hippocampus. x50 
magnification
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Figure 6.6 Quantification of apoJ immunoreactivity within the inner, middle and outer 
molecular layers (IML, MML and OML) of the hippocampal dentate gyrus of 3 
month old adult and 1 year old aged APOE knockout, e3 and e4 transgenic mice 
measured as relative optical density values. ANOVAR was carried out on the groups 
and the genotypes compared using a Student’s unpaired /-test with Bonferroni 
correction for multiple comparisons.
179
6.4.3 Cytoskeletal Alterations in Ageing
6.4.3.1 Alterations in MAP-2 immunoreactivity
MAP-2 characteristically labelled the soma of neurons and associated dendritic 
networks most intensely. At 3 months of age, APOEzl mice and APOE knockout 
mice displayed a trend for slightly greater MAP-2 immuno staining compared to 
APOEzA mice but this did not reach statistical significance (Figure 6.7). At 1 year of 
age MAP-2 immuno staining was reduced in APOE knockout and s3 transgenic mice 
compared to 3 month old animals. MAP-2 immunoreactivity remained similar in 
APOEz4 mice between the age of 3 months and year. There was no significant 
difference in MAP-2 immunoreactivity between APOE knockout, e3 and e4 mice at 
this timepoint although s3 mice did show a trend for slightly greater MAP-2 
immunoreactivity compared to e4 mice. No difference in dendritic structure was 
evident at 3 months or 1 year of age in APOE knockout, c3 or e4 mice (Figure 6.8).
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Figure 6.7 Quantification of MAP-2 immunoreactivity within the inner, middle and 
outer (IML, MML and OML) of the hippocampal dentate gyrus of 3 month old 
adult and 1 year old aged APOE knockout, e3 and s4 mice measured as relative 
optical density values. ANOVAR was carried out on the groups and the genotypes 
compared using a Student’s unpaired /-test with Bonferroni correction for multiple 
comparisons.
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Figure 6.8 MAP-2 immunoreactivity in the dentate molecular layer o f aged APOE 
knockout, s3 and s4 transgenic mice. Dendritic structure is similar in all mice 
although less dendritic processes are visible in some knockout mice. x400 
magnification
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6.5 Discussion
6.5.1 Ageing and the human brain
In the last hundred years, with the improvement of medical care around the world, 
humans are living longer with the number of individuals who are octogenarians or 
above increasing sharply. Care of the elderly is an economical burden around the 
world and in association with this, much investment has been made in the 
investigation of age related diseases such as AD and factors involved in the ageing 
process. Ageing is a form of chronic brain injury. The characteristic loss of cells and 
synapses in the aged brain is well defined and ultimately leads to memory impairment, 
dementia and cognitive deficits. One of the regions of the brain most vulnerable to cell 
loss is the entorhinal cortex. The death of cells in this region triggers a cascade of 
degenerative events within the hippocampus. APOE genotype may affect the process 
of brain ageing as it does the progression of AD and outcome after head injury. The 
results of this study indicated that APOE genotype does not influence hippocampal 
plasticity in response to ageing.
6.5.2 APOE genotype influence on effects of ageing in APOE knockout, c3 and 
c4 mice
In the present study, using markers for synaptic, fibre and dendritic alterations, there 
was no evidence that APOE genotype influenced alterations in these markers at 1 year 
of age compared to 3 months. There was also no indication that deficiency of apoE 
produced synaptic, fibre and dendritic alterations at 1 year compared to 3 months. 
However, there was some subtle evidence, using width of IML as a measure of 
sprouting, that the e4 allele was associated with reduced sprouting in both 3 month 
and 1 year old APOEzA mice compared to knockout and s3 mice. There was also 
some evidence in 3 month old mice that the s4 allele was associated with reduced 
GAP-43 immunoreactivity indicative of reduced fibre density compared to APOE 
knockout and c3 mice. This may suggest that there are underlying structural 
differences although no gross dendritic abnormalities were immediately apparent using 
MAP-2 immunoreactivity.
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Several studies have investigated the effects of ageing in APOE knockout mice. 
Masliah et al (1995) found that APOE knockout mice displayed an age-dependent 15- 
40% loss of synaptophysin and MAP-2 immunoreactivity in the neocortex and 
hippocampus at 20 months of age (changes could result from extreme ageing) 
compared to wild-type C57BL/6J controls. The authors highlighted that dendritic 
changes were evident as early as 4 months of age, suggestive of a role for apoE in the 
modulation of cytoskeletal structure. In association with this, APOE knockout mice 
also displayed an age-dependent decline in cognitive capabilities (Masliah et al, 1997; 
Veinbergs et al, 1999). The studies by Masliah et al conflict with the findings of other 
groups. Studies of other APOE knockout mice have indicated that there is no 
evidence of exaggerated synaptic degeneration with age (Anderson et al, 1998; 
Cambon et al, 2000). Similarly, the present study indicated there was no evidence of 
synaptic, fibre or dendritic alterations. Although controversial, studies by Masliah et 
al have shown that the ageing effects in knockout mice may be ameliorated by 
administration of apoE protein. Intraventricular infusion of recombinant apoE E3 and 
E4 has been found to improve performance in learning tasks and this was correlated 
with the restoration of neuronal integrity in APOE knockout mice.
Ageing studies in transgenic mice expressing apoE neuronally have shown that 
neuronal integrity is not dramatically altered in APOEzZ and knockout mice with age 
but APOEzA mice display a significant age-dependent loss in synapses and MAP-2- 
positive dendrites (Buttini et al, 1999, 2000). The effect o f APOE genotype on ageing 
was assessed in another study which compared axonal structure in astrocytically and 
neuronally-expressing transgenic mice. Prominent axonopathy was found in mice 
expressing APOEzA neuronally however astrocytically expressing APOEzA mice 
remained relatively normal throughout life (Tesseur et al, 2000). These results parallel 
the findings of the present study, which also found no genotype difference in 
pathology between astrocyte expressing s3 and s4 mice. The contrast in the findings 
of the present study (also Tesseur et al) and the study by Buttinis group could reflect 
a detrimental effect of endogenous neuronal apoE expression in ageing. Behavioural 
phenotyping studies in the line of transgenic mice employed in the present study has 
revealed that APOEzA mice express profound working memory impairments with age,
184
even in the absence of Alzheimer’s-like pathology (Hartman et al, 2001). The authors 
also highlight that there was no significant difference in the level o f synaptic, neuronal 
or glial markers between the genotypes, also a similar finding to that of the present 
study. Ultrastructural studies of aged transgenic mice have shown that in APOEzA 
mice, the synapse per neuron is greatly reduced compared to APOEz2 and knockout 
mice (Cambon et al, 2000). This is also associated with an increase in synapse zone 
area in APOEzA mice. These findings could explain the unaltered synaptophysin 
immunoreactivity with age, in APOEzA mice, in our study.
The neuropathological changes that occur with age are very subtle and are certainly 
not of the magnitude observed in the lesioning studies. The techniques employed in 
this study may not be appropriate to detect these very small changes and techniques 
such as electrophysiology may be more sensitive for detecting loss of cell connections. 
The end survival point may also be a crucial factor. In the present study, the oldest 
mice were all approximately 1 year old and are classed as aged in mouse lifespan 
terms. In other studies, some investigators have allowed survival terms of up to 20 
months and this may allow manifestation of more exaggerated neuropathological 
abnormalities. Perhaps extending survival time in future studies may allow 
visualisation of more exaggerated changes with age. In previous chapters, it has been 
shown that the APOEzA allele is detrimental to the plasticity response following 
injury. Therefore, APOE genotype effects may only manifest themselves when the 
system is stressed in some way leading to greater changes in pathology. It will be 
interesting in the future to study plasticity in aged transgenic mice.
6.5.3 Evidence for an APOE genotype influence on ageing in the human brain
ApoE performs an important role in the maintenance of neuronal integrity under 
normal physiological conditions. Aside from the multitude of investigations 
highlighting that the APOEzA allele is associated with AD in humans, it is now 
apparent that APOE genotype may modulate the brains response to the normal ageing 
process. Studies in middle-aged humans have shown that individuals with an APOEzA 
genotype perform poorly in memory and learning tasks compared to individuals not 
possessing an zA genotype suggesting some vital synaptic connections may already be
185
lost (Flory et al, 2000). In a study of non-demented individuals, hippocampal atrophy 
was found to be significantly greater in individuals carrying an s4 allele compared with 
control groups (Crook et al, 1986; Bigler et al, 2000). In addition, the hippocampal 
and entorhinal cortex volume of s4 AD patients is significantly reduced compared to 
control groups (Lehtovirta et al, 1995). A cohort of 563 elderly patients without AD 
were analysed over a period of 7 years for cognitive and visuospatial skills. The 
APOEs4 allele was found to be associated with a more rapid decline in memory with 
time compared with control individuals (Mayeux et al, 2001). With the use of 
transgenic animal models the role of apoE in ageing can now be more fully addressed 
in mice expressing human APOE alleles.
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Chapter VII
An In Vitro Organotypic Hippocampal Slice Model to Study APOE 
Genotype Influence on Synaptic Plasticity and Analysis of Herpes 
Simplex Virus as a Vector for APOE Delivery
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7.1 Introduction
Organotypic hippocampal slices possess a network of connections and cells, which 
allow the tissue to function in a more physiologically similar manner, to that of the 
whole animal. The tissue, which is most commonly used for organotypic culture is 
derived from neonatal animals and therefore will display a certain degree of natural 
plasticity due to ongoing developmental changes (Bolz et al, 1990).
The hippocampus is dissected from the surrounding cortical tissue before culturing 
and this results in removal of the perforant pathway to the dentate gyrus of the 
hippocampus (Heimrich and Frotscher, 1990). This is somewhat analogous to the 
hippocampal denervation by entorhinal cortex lesion discussed in previous chapters. 
The in vitro slice method results in a period of degeneration and reinnervation at 
longer culture periods. The process of sprouting within the hippocampus has been 
identified in previous studies and is a well-characterised response to removal of 
cortical inputs (Frotscher and Gahwiler, 1988; Stoppini et al, 1993, 1997). In the 
study discussed within this chapter the plasticity response of hippocampal slices is 
assessed in wild type mice and APOE knockout, e3 and e4 transgenic mice. This 
method was established to allow more dynamic alterations to be studied. In vivo, 
regenerative alterations do not occur until about 90 days post-lesion whereas in vitro 
this occurs much earlier. This study tested the hypothesis that the plasticity response 
in APOEzA slices would be impaired. The Herpes Simplex virus as a vector for gene 
delivery o f APOE is also assessed.
7.2 Aims
(1) To validate an organotypic hippocampal slice culturing model and use this model 
to characterise plasticity in hippocampal slices derived from C57BL/6 mice, APOE 
knockout, s3 and c4 transgenic mice.
(2) To determine Herpes Simplex virus (HSV) expression in slices after exogenous 
administration.
188
7.3 Materials and Methods
7.3.1 Mice
7.3.1.1 C57BL/6
Breeding pairs of male and female mice were obtained from Harlan Olac and bred in 
an animal unit at the University of Glasgow. Only male pups were employed in the 
study and were used at approximately 7 days old.
7.3.1.2 Human APOE transgenic mice on a GFAP promoter
APOE transgenic mice were generated as previously described in chapter II.
7.3.2 Organotypic Hippocampal Slice Culture
7.3.2.1 Tissue harvest and culturing periods
Slices were derived from male neonatal mouse pups and cultured as explained in detail 
in Chapter II. Tail tips were collected from the transgenic mice for PCR analysis to 
determine APOE genotype. Slices were cultured as previously described (see Chapter 
II). Cultures were maintained for a period of 7 or 18 DIV (days in vitro) (n=5/6 
C57BL/6J and n=8 transgenic per time-point). Following the desired culture period 
the medium was removed and the slices submersion fixed in 4% paraformaldehyde for 
2 hours. The fixative was then removed, phosphate buffer added and the tissue stored 
at 4°C. Immunohistochemistry for apoE, synaptophysin, GAP-43, apoJ and MAP-2 
was carried out as outlined in chapter II.
7.3.2.2 Quantification of immunohistochemistry and statistical analysis
Relative optical density values (ROD) for immuno staining were measured using an 
image analyser connected to a microscope. Optical density readings were collected 
from the dentate molecular layers and from the CA1 pyramidal layer to ensure 
consistency of immunostaining. Ten optical density readings were collected across the 
expanse of the molecular layers. Five from the IML/MML and five from the 
MML/OML using a 1cm2 sampling box and an average of the ten readings taken. In 
C57BL/6J mice optical density readings were compared in the 7 day and 18 day slices 
using a Student’s unpaired /-test. In the tissue derived from the transgenic mouse 
lines, ANOVAR was carried out on the optical density readings and the genotypes
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compared using a Student’s unpaired t-test with Bonferroni correction for multiple 
comparisons. Readings were also collected from a region not directly affected by the 
culturing process as a reference area to ensure consistency of staining between slices.
7.3.3 Herpes Simplex Virus as a Vector for Gene Therapy
7.3.3.1 Addition of Herpes Simplex virus 1716 to hippocampal slice preparations
The virus employed in this study was produced by Prof Moira Brown and this work 
was carried out in collaboration with her laboratory. Briefly, the gene endocing 
ICP34.5 protein in HSV was deleted producing ICP34.5 null mutant virus that is 
avirulent. The virus contains a green fluorescent protein (GFP) reporter gene and 
therefore when replicated in cells fluorescence green allowing detection. Hippocampal 
slices were prepared from C57BL/6J wildtype mice and APOEz3 transgenic mice as 
previously described and transported to the Neurovirology Unit at the Southern 
General Hospital. All virus handling was carried out within a category 2 culture hood. 
Following virus use all instruments were submerged in detergent and the culture hood 
exposed to U.V. radiation for at least half an hour to exterminate any stray virus 
particles. 106 and 105 virus particles were diluted in culture medium and added directly 
onto the slices as a single dose of lOpl of the mixture pipetted directly onto the 
surface of the slices. The slices were then returned to an incubator and maintained for 
a period of 3, 7, 12 or 18 DIV with changing of the medium every 3 DIV. Control 
cases received no infection by HSV1716 virus. GFP labelled wild type virus was also 
employed.
7.3.3.2 Fluorescence microscopy
Following the appropriate survival period the slices were submersion fixed in 4% 
paraformaldehye for 2 hours. The slices were mounted onto glass slides and 
coverslipped, sumberged in hardening medium or the slices were removed unfixed, 
attached to the membrane and visualised without the addition of a coverslip.
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7.4 Results
7.4.1 Setting up the model and technical considerations
Initially mouse hippocampal slices were cultured using the method learned using rat 
tissue including the culture medium which consisted of 70.5% basal medium, 24% 
normal horse serum, 4% glucose, 0.5% glutamax and 1% streptomycin/penicillin (a 
method employed by Dr B Morris, University of Glasgow). However, the slices 
would only survive for short periods of time. The method therefore had to be adapted 
for long-term survival of the slices. Advice given to us by Dr Bruce Teter (UCLA) 
about culture medium consistency allowed adaptation of the system for long-term 
survival. Using this culture medium, slices could be maintained for over 20 days. The 
slices were taken at 300pm to maximise the number of slices that could be obtained 
from each brain, but also so that they remained structurally robust.
Immunohistochemistry was optimised for the antibodies used employing standard 
procedures. Analysis of immunohistochemistry was slightly different to that previously 
employed. Due to the thickness of the slices the trilaminar pattern was not as obvious 
as in the microtome sections. Therefore measurements were taken from approximate 
combined regions IML/MML and MML/OML and averaged to give a representative 
measurement of the entire molecular layer. Readings were also taken from the 
pyramidal layer, which remains relatively unaffected by dissection of the hippocampus 
to ensure consistency of staining between slices.
7.4.2 Slice viability
Cell viability of the slice was assessed by analysis of neuronal morphology in MAP-2 
immunostained slices. Neuronal morphology within the pyramidal layer and dendritic 
network structure is assessed. Healthy cells have a normal round morphology and are 
strongly MAP-2 immunoreactive (Figure 7.1).
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Figure 7 1 MAP-2 immunoreactivity in hippocampal slice cultures
Illustrative examples o f MAP-2 immunoreactivity post-ECL in hippocampal slices 
cultured for 18 days. Healthy slices display clear defined neuronal cell bodies with 
dendritic processes evident (a). Although the slices are very thick, the CA1 pyramidal 
layer can always be seen clearly in healthy slices. When slices are non-viable, neuronal 
cell bodies are no longer evident in the pyramidal layer and often stain very poorly 
with MAP-2. The illustration (b) shows the grainy appearance o f MAP-2 staining in a 
dead slice.
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7.4.3 Analysis of Plasticity in Hippocampal Slices Derived from 
C57BL/6J Mice
7.4.3.1 Alterations in synaptophysin immunoreactivity
Synaptophysin immunoreactivity within the molecular layers of the dentate gyrus of 
cultured slices is regular, punctate and similar to that observed in the paraffin 
embedded sections from in vivo studies. The granular layer and pyramidal cell layers 
are stained only lightly. Optical density readings were collected from the molecular 
layers of the dentate gyrus of slices cultured for 7 or 18 days. At day 7 in vitro 
synaptic loss occurs in the dentate molecular layers degenerate due to removal of the 
cortical input. At day 18 in vitro, synaptophysin immunoreactivity increased within 
the molecular layers and was significantly different to that of the 7 day slices when 
compared using a Student’s unpaired t-test (p<0.05) (Figure 7.2 and 7.3).
7.4.3.2 Alterations in GAP-43 immunoreactivity
GAP-43 immunoreactivity within the molecular layers of the dentate gyrus in cultured 
slices is regular, with the inner molecular layer being slightly more darkly stained 
compared to the middle and outer layers. Optical density readings were collected from 
the molecular layers of the dentate gyrus of slices cultured for 7 or 18 days. At day 7 
in culture, fibre loss occurs within the dentate gyrus due to removal of the cortical 
input. At day 18 in vitro, GAP-43 immunoreactivity increased within the molecular 
layers and was significantly different to that of the 7 day slices when compared using a 
Student’s unpaired /-test (p<0.05) (Figure 7.2 and 7.4).
7.4.4 Apolipoprotein Alterations in C57BL/6J Derived Hippocampal 
Slices
Neuropil apolipoprotein E immunoreactivity within the hippocampus was present as a 
uniform punctate stain with no evidence of neuronal staining. In 7 day slices, apoE 
immunoreactivity within the neuropil was darker within the molecular layers of the 
dentate gyrus than in any other region. Some astrocytic apoE immunoreactivity was 
also evident at this time-point. At day 18 in vitro, apoE immunoreactivity was 
reduced within the molecular layers and this was significantly different to 
immunoreactivity in the 7 day slices when compared using a Student’s unpaired Mest
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(p<0.01). Only minimal astrocytic immunoreactivity was evident at this timepoint 
(Figure 7.2 and 7.5).
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Figure 7.3 Increased synaptophysin immunoreactivity by day 18 in vitro
Illustrative examples of synaptophysin immunoreactivity in the dentate molecular 
layers o f the hippocampus of hippocampal slices derived from C57BL/6 mice cultured 
for 7 and 18 days in vitro. The arrows highlight the molecular layers, x 400 
magnification. As can be seen from the illustrations the stratum lacunosum moleculare 
(slm) also alters post-culture.
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Figure 7.4 Increased GAP-43 immunoreactivity by day 18 in vitro
Illustrative examples o f GAP-43 immunoreactivity in the dentate molecular layers o f 
the hippocampus in hippocampal slices derived from C57BL/6 mice cultured for 7 and 
18 days in vitro. The arrows highlight the molecular layers, x 400 magnification. As 
can be seen from the illustrations, the stratum lacunosum moleculare (slm) also alters 
post-culture and immunoreactivity is increased there also by day 18 in vitro.
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Figure 7.5 Increased apoE immunoreactivity by day 7 post-ECL
Illustrative example o f  apoE immunoreactivity in the hippocampal molecular layers in 
hippocampal slices derived from C57BL/6 mice and cultured for 7 or 18 days. ApoE 
immunoreactivity is increased within the neuropil and within astrocytes by day 7 in 
vitro. By day 18 apoE immunoreactivity has declined. The arrows highlight the 
molecular layers, x 400 magnification. The red arrows indicate astrocytic 
immunoreactivity.
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7.4.5 Analysis of Plasticity in Hippocampal Slices Derived from 
APOE Knockout, s3 and s4 Transgenic Mice
7.4.5.1 Alterations in synaptophysin immunoreactivity
Synaptophysin immunoreactivity in slices derived from transgenic mice displayed a 
similar pattern as previously outlined for C57BL/6J mice and was similar in pattern 
between APOE knockout, s3 and s4 slices. In 7 day slices, synaptophysin 
immunoreactivity was compared in knockout, APOEs3 and c4 derived hippocampal 
slices. Synaptophysin immunoreactivity was significantly greater in e4 slices compared 
to s3 and knockout slices (p<0.01). Synaptophysin immunoreactivity in e3 slices was 
not significantly different to that in knockout slices. By day 18 in vitro, synaptophysin 
immunoreactivity increased within the dentate molecular layers of e3 derived slices 
and APOE knockout slices however in contrast immunoreactivity in s4 slices was not 
significantly different between 7 DIV and 18 DIV. Synaptophysin immunoreactivity 
was significantly greater in APOEz3 mice at 18 DIV compared to APOEs4 slices 
(p<0.05) and APOE knockout slices (p<0.01) (Figure 7.6 and 7.8).
7.4.5.2 Alterations in GAP-43 immunoreactivity
GAP-43 immunoreactivity in APOE transgenic derived slices displayed a similar 
pattern of staining as observed in slices derived from C57BL/6J mice and was grossly 
similar in pattern between APOE knockout, e3 and c4 slices. GAP-43 
immunoreactivity was compared in day 7 slices and it was found that there was no 
statistically significant difference in intensity of immunostaining between APOE 
knockout, s3 and c4 slices. By day 18 in vitro, GAP-43 immunoreactivity was 
increased within the molecular layers of the dentate gyrus in all genotypes. However, 
GAP-43 immunoreactivity is greatly increased in APOEsl slices and was significantly 
greater compared to APOE knockout (p<0.01) and APOEzA slices (p<0.01) at this 
time-point (Figure 7.7 and 7.9).
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Figure 7 8 Synaptophysin immunoreactivity in hippocampal slices from 
transgenic mice
Illustrative examples o f synaptophysin immunoreactivity in the molecular layers o f 
hippocampal slices, derived from APOE knockout (KO), s3 and s4 transgenic mice. 
The arrows highlight the molecular layer region, x 400 magnification
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Figure 7.9 GAP-43 immunoreactivity in hippocampal slices from APOE 
transgenic mice Illustrative examples o f GAP-43 immunoreactivity in the molecular 
layers o f hippocampal slices derived from APOE knockout (KO), 83 and £4 transgenic 
mice. The arrows highlight the molecular layer region. The stratum lacunosum 
moleculare GAP-43 immunoreactivity also increases by day 18 in vitro, x 400 
magnification
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7.4.6 Apolipoprotein Alterations in APOE  Transgenic Derived 
Hippocampal Slices
7.4.6.1 Apolipoprotein E
Baseline apoE levels in this line of transgenic mice have been assessed and APOEE3 
and e4 mice display comparatively similar levels of apoE (see Chapter V). APOE 
knockout slices do not display any apoE immunoreactivity at any time. Neuropil apoE 
immunoreactivity was measured using relative optical density measurements and 
compared between APOEz3 and e4 slices using a Student’s unpaired /-test. In 7 day 
slices, apoE immunoreactivity was significantly greater in APOEE3 slices compared to 
s4 slices (p<0.0001). The entire hippocampus displayed dense astrocytic apoE 
immunoreactivity and was particularly dense in the dentate molecular layers, but was 
similar in both APOEz3 and e4 slices. In day 18 slices, apoE neuropil apoE 
immunoreactivity declined in both APOEE3 and e4 slices and was similar in each 
genotype. Astrocytic apoE immunoreactivity also declined within the molecular layers 
at this timepoint (Figure 7.10 and 7.12).
7.4.6.2 Apolipoprotein J
ApoJ immunoreactivity was present within the neuropil and labelled some neurons 
lightly. In day 7 slices, apoJ immunoreactivity was also evident within the dentate 
molecular layers. At this time-point there was no statistically significant difference in 
apoJ immunoreactivity between the three genotypes. In 18 day cultures, apoJ 
immunoreactivity declined in all slices but was not significantly different between the 
three genotypes (Figure 7.11). No astrocytic apoJ immunoreactivity was evident at 
this time. (ApoJ immunoreactivity not illustrated)
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Figure 7 12 ApoE immunoreactivity is increased by day 7 in vitro in s3  and s4 
mice.
Illustrative examples o f apoE immunoreactivity in the molecular layers o f 
hippocampal slices from APOEz3 and s4 transgenic mice cultured for 7 or 18 days. 
ApoE is increased in the neuropil and also within astrocytes within the molecular 
layers (see inlay) by day 7 in vitro. APOE knockout slices do not display any apoE 
immunoreactivity. X200 magnification
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7.4.7 Uptake and Replication of Herpes Simplex Virus 1716 in 
Hippocampal Slices
7.4.7.1 Expression of HSV 1716 in C57BL/6J derived hippocampal slices
Slices were allowed to survive for periods of 3, 7, 12 and 18 DIV. Following this they 
were fixed and mounted for viewing by fluorescence microscopy. Control slices 
displayed no GFP expression at any timepoint. GFP expression was present in all 
slices at every timepoint studied. The expression was localised to the dentate gyrus 
and was cellular in nature (Figure 7.13). Some staining was also evident within the 
granule cell layer. The occasional GFP expressing cell could be visualised within the 
CA1 pyramidal cell layer. Expression was least intense in 3 day slices and was 
increased in day 7, 12 and 18 slices however expression levels were similar at these 
time-points.
1A.1.2 Expression of HSV 1716 in APOEeS transgenic mice derived 
hippocampal slices
Slices were allowed to survive for periods of 3, 7, 12 and 18 DIV. APOEe3 
transgenic mice were chosen for these preliminary expression studies to eliminate any 
unforseen adverse effects which may be associated with being s4 i.e. viral uptake. 
Control slices displayed no GFP expression at any timepoint. Slices from transgenic 
mice displayed similar expression to that observed in C57BL/6J wildtype mice. The 
expression was localised to the dentate gyrus and was cellular in nature (Figure 7.14). 
Dense expression was present within the molecular layers of the dentate gyrus 
although some staining was also evident within the granule cell layer. The occasional 
GFP expressing cell could be visualised within the CA1 pyramidal cell layer. At day 7, 
12 and 18 slices expression levels were similar in all slices. Astrocytic proliferation 
occurs post-culture and this would suggest that the virus expression is located there 
(Appendix A3.3).
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Figure 7.13 Expression of HSV 1716 GFP in hippocampal slice cultures from a 
C57BL/6J mouse
Illustrative example o f HSV 1716 expression in the molecular layers o f the dentate 
gyrus after 7 days (a, b) and 18 day (c, d) in vitro, (a, c) x50 (b, d) x400
magnification
Figure 7.14 Expression of HSV 1716 in hippocampal slices from an AP()Ez3 
transgenic mouse
Illustrative example o f HSV 1716 expression in a hippocampal slice cultured for 18 
days in vitro. Expression is still intense within the hippocampal dentate molecular 
layers at this timepoint. (a) xlOO magnification and (b) x 400 magnification
210
7.5 Discussion
In this study, a model of organotypic hippocampal slice culture was developed in the 
laboratory at the Wellcome Surgical Institute. This model was developed because it 
allows simple manipulation of environmental conditions. Exogenous compounds and 
treatments may be applied with relative simplicity compared to trials in vivo. In this 
study, the model was validated in C57BL/6J slices and at 18 days sprouting was 
detected. This model was then used to examine APOE genotype differences in 
sprouting and it was determined that neuronal repair was impaired in hippocampal 
slices derived from APOEzA mice. Lastly, the model was used to examine the utility 
o f HSV as a delivery vector for apoE. Expression of HSV was found up to 18 days in 
vitro.
7.5.1 Plasticity in hippocampal slices derived from C57BL/6J mice
As previously mentioned, the process of culturing slices causes a cascade of events 
within the hippocampus, which mimic the events that occur after entorhinal cortex 
lesion. This entails a period of degeneration and with longer survival periods, 
subsequent reinnervation (Stoppini et al, 1991; Gahwilwer et al, 1997). It was 
necessary to determine if we could detect these events in slices derived from 
C57BL/6J wild-type mice using the markers previously employed in the in vivo 
studies. Using the time periods suggested to us by Dr Teter it was determined that by 
day 18 in vitro slices displayed sprouting and reactive synaptogenesis. This study is in 
accordance with what other investigators have determined in slices derived from 
rodents (Frotscher and Gahwiler, 1988; Stoppini et al, 1993, 1997). Additional to 
this, it was also found that apoE was increased within the neuropil by day 7 in vitro, 
where levels were approximately 30 % greater than at 18 days in vitro (Teter et al, 
1999). This model was chosen on the basis that it provided a more physiologically 
relevant system to study apoE, rather than the commonly chosen single cell 
preparations. Tissue culturing of this kind allows the ease of manipulation that single 
cell cultures afford. However, cells within organotypic cultures exist within an 
environment of networked cells that more closely mimic the environment in the whole 
animal.
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7.5.2 APOE genotype influence on plasticity in slices derived from transgenic 
mice
The data from the in vivo studies in this thesis indicate that APOE genotype influences 
plasticity mechanisms. Several in vitro studies, using single cell culture, have shown a 
role for apoE in neurite outgrowth and have highlighted also the impaired capacity of 
apoE E4 in producing this neurite outgrowth. Using more advanced culture 
techniques such as hippocampal slice culture it is possible to assess APOE genotype 
influence on plasticity in a more physiologically relevant system. Hippocampal slices 
derived from human APOEz4 transgenics with the human promoter sequences, have 
been shown to display impaired sprouting capabilities (Teter et al, 1999). In that 
study by Teter et al it was determined that slices from APOE knockout mice did not 
exhibit any Timm’s-stained sprouting in the dorsal hippocampus. The ability of the 
APOEz?> and s4 allele to rescue sprouting was analysed and it was found that 
expression of the e3 allele fully restored dorsal hippocampal sprouting. The e4 allele 
also increased sprouting but to only 58% of that caused by APOEz3. The medium 
from APOEz3 transgenic mice was collected and administered to slices derived from 
APOE knockout mice. Sprouting was increased by 20% in these knockout slices 
highlighting the plasticity promoting effects. In the present study, evidence of 
sprouting and reactive synaptogenesis was found in APOE knockout, s3 and s4 slices. 
Plasticity was impaired in APOEzA slices where synaptophysin and GAP-43 
immunoreactivity was significantly lower at day 18 in vitro compared to that in APOE 
knockout and APOEz3 derived slices. APOEz3 mice displayed the greatest capacity 
for plasticity. However, interestingly in 7 day cultured slices, apoE increased within 
the neuropil but to a greater extent in APOEz3 slices than in APOEs4 slices. At day 
18 in vitro, apoE levels were not significantly different between the genotypes. This 
greater increase in c3 slices may indicate why there is such a degree of plasticity 
within the APOEz? slices. The slices derived from APOE knockout mice also display 
repair processes at day 18 in vitro, a finding paralleled in the in vivo study (see 
Chapter V). The plasticity observed in APOE knockout mice may be due to some 
other contributory factor, such as apoJ. At day 7 in vitro, apoJ immunoreactivity is 
increased within the neuropil in all slices and to a greater extent in APOE knockout 
slices although not significantly so. At day 18, apoJ immunoreactivity had decreased
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and was similar in APOE knockout, e3 and e4 slices. The present study indicated the 
utility of organotypic hippocampal slice culture as a system to study the role of apoE 
and APOE genotype differences in neuronal repair.
7.5.3 Adenoviral vector therapy in the treatment of atherosclerosis
The studies presented in this thesis build on clinical work to strongly indicate the 
APOEz4 allele is associated with a poor recovery after injury via a poor reparative 
capacity. It would therefore be beneficial to be able to increase the levels of ‘good’ 
forms of apoE (E2, E3) in an attempt to ameliorate effects of the APOE e4 allele. 
There is evidence to suggest that increasing exogenous levels of apoE may improve 
outcome after brain injury or improve the effects of ageing (Masliah et al, 1997, 
Horsburgh et al, 1999). However these studies are limited because o f acute short­
term administration and problems with the crossing of the blood-brain barrier 
(Laskowitz et al, 2000). Obviously intraventricular infusion of apoE is not a valid 
option in therapy for humans. This has lead to the search for more effective 
techniques of treatment such as gene therapy. This is not a new advance in the field of 
apoE research. For a number of years several groups have been investigating the 
merits of using adenoviral vector delivery of apoE to APOE knockouts to reduce 
atherosclerosis (Kashyap et al, 1995; Stevenson et al, 1995; Cioffi et al, 1999, Hasty 
et al, 1999; Desurmont et al, 2000). The outcome of these animal studies proved that 
using adenoviral vectors to deliver apoE, the atherosclerotic plaque formations, which 
occurred in the arterial walls of APOE knockout mice, could be completely regressed. 
This therapy also reversed the hypercholesterolaemic phenotype evident in these mice. 
However, a finding that has hampered the development of any adenoviral treatment 
into human therapies is that adenovirus actually causes massive complications in the 
brain. Investigators in the States, researching adenovirus mediated therapy in humans, 
found that there was a high mortality rate. They did not report these findings and 
unfortunately several other patients died in the process. All adenovirus therapies have 
now been withdrawn from clinical trials. In this study our aim was to carry out a pilot 
study assessing viral vector expression in hippocampal slices, but using a Herpes 
Simplex Virus.
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7.5.4 Herpes Simplex virus as a vector for gene delivery
The herpes simplex virus (HSV) exists naturally within the human body and exists in 
many forms. The most common form being that which travels in the trigeminal nerve 
and causes the common cold sore. Under normal conditions the virus may invade and 
replicate within any cell in body. The virus employed in this study was engineered in 
the laboratories of Prof Moira Brown, University of Glasgow. The herpes simplex 
virus (HSV) protein ICP34.5 is a specific determinant of virulence. When this protein 
is removed (null mutant), the virus is avirulent and may only replicate in replication 
competent cells (Dolan et al, 1972). In this capacity the virus has already been 
developed into a therapy for the treatment of malignant melanoma. The virus was first 
tested, in vitro, for its ability to replicate in cells derived from human glioblastomas 
cells (Brown et al, 1994) and then in a rodent model of intracranial murine melanoma. 
Stereotaxic injection of the HSV 1716 mutant resulted in complete tumour regression 
and a significantly increased survival time of each animal (McLean et al, 1991; 
Randazzo et al, 1995). Histopathological analysis of the brains of mice administered 
the virus display mild meningoencephalitis at early timepoints, which is associated 
with virus antigen expression. At day 28 post-injection, no virus antigen could be 
detected and therefore proved to be self-limiting in terms of expression. No other 
adverse neuropathological alterations were noted (McKie et al, 1998, Howard et al, 
1998). The success of this work allowed the virus to be approved for Phase 1 toxicity 
trials and a group of patients, with recurrent glioblastoma, have already received 
direct intratumoural injection of the ICP34.5 null mutant 1716 in patients (Rampling 
et al, 1998). The patients treated thus far have not shown any adverse side effects 
even though they are immunosuppressed. Although these were merely toxicity tests, it 
is worth mentioning that these patients showed tumour regression and prolonged 
survival (unpublished data). Although lacking the ICP34.5 gene, the HSV 1716 may 
establish cell latency in vivo (Robertson et al, 1992) and may therefore act as an 
efficient delivery system for genes into the CNS. It is with this in mind that we 
embarked on the pilot studies of HSV treatment in hippocampal slices. The aim is to 
develop a gene based apoE therapy where perhaps an individuals’ APOE genotype 
may be manipulated by administration of a beneficial APOE genotype mediated by 
HSV delivery. Therapies such as this would not only be beneficial following head
214
injury and in AD but also a host of other human diseases, with which the APOEe4 
genotype is adversely associated. We found that the HSV 1716 mutant was taken up 
and expressed by hippocampal slices following direct application to its surface. 
Expression was evident by day 3 post-culture and persisted until the longest culture 
period of 18 days. As yet it is unclear what cell types were expressing the virus 
however, much of the GFP expression was confined to the hippocampal dentate 
gyrus. It is likely that the majority of the expression is astrocytic, because astrocyte 
proliferation occurs within the molecular layers post-culture. However, cells o f the 
dentate granule layer also appeared to express GFP. Whether these are neurons is 
unclear, however, this virus strain can establish cell latency in vivo as previously 
stated. It may also be possible that these cells are neuronal progenitors as 
neurogenesis has been witnessed in the hippocampus. This study is by no means a 
complete work as the virus is now being tested for expression and toxicity after 
intracerebral injection in vivo. APOE gene sequences and promoter sequences must 
also be attached to the virus, a process that will obviously take a considerable length 
of time. Nevertheless, we are one step closer in the engineering of an efficient gene- 
based therapy.
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Chapter VIII
APOE Genotype Influence on Apolipoprotein E Interaction with
Microtubules
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8.1 Introduction
Eukaryotic cells have an internal structural support system called the cyto skeleton 
which not only functions in cell structure maintenance but also intracellular transport 
and neurite outgrowth (Alvarez et al, 2000). The cytoskeleton is composed of three 
classes of filaments: microfilaments, intermediate filaments and microtubules (Barr 
and Keiman, 1993). Microtubules will be the main focus of this chapter. Microtubules 
are hollow cylindrical structures composed of two 55 kDa subunit proteins, a  and p 
tubulin and are approximately 25nm in diameter (Figure 8.1).
Protofilaments
Tubulin /  “  subunit
Heterodimer 1  (Jsububit
25 nm
Figure 8.1 Diagram illustrating microtubule structure.
It was suggested, at the outset of this thesis, that apoE binding to microtubules 
defended the structure from phosphorylative enzymes and the process also aided in 
neuronal sprouting after injury (Roses et al, 1995). However, studies in this thesis and 
other studies have shown that neuronal plasticity is severely impaired in humans and 
mice carrying APOEg4 alleles. In Chapter IV of this thesis it was shown that 
dendritic structure (by MAP-2 immunostaining) is severely disrupted in APOEg4 mice 
after injury. This chapter tested the hypothesis that different apoE isoforms interact 
differently with microtubules and this may underlie the observed difference in 
plasticity after injury.
8.2 Aims Microtubular binding of apoE E3 and E4 protein was analysed and apoE 
isoform specific differences were determined.
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8.3 Materials and Methods
8.3.1 Immunohistochemistry on paraffin sections
The microtubules to be used in this study are composed of pure tubulin. Thus tubulin 
immunohistochemistry was carried out on the tissue sections obtained from transgenic 
mice (both human and GFAP promoter) to determine firstly, whether there were 
APOE genotype differences in alterations in tubulin after entorhinal cortex lesion. 
Sections from 0 day control and 90 day survival mice were used. Relative optical 
density values of immunohistochemistry were collected using an MCID analysis 
system. Six readings were collected from each molecular layer using a 1cm2 sampling 
box and the readings averaged. The percentage difference between the ipsilateral and 
contralateral hippocampal values was taken and the APOEs3 and s4 genotypes 
compared using a Student’s unpaired Mest. The data is represented graphically as the 
mean +/- S.E.M.
8.3.2 Microtubule Associated Spin-Down Assay
8.3.2.1 Microtubule assembly
Tubulin protein was diluted in 2.5pl of microtubule cushion buffer and incubated at 
35°C for exactly 20 minutes. Simultaneously, 180pl of tubulin dilution buffer and 
40pM of taxol were mixed together and incubated at 35°C. 180pl of this solution was 
then added to the polymerised tubulin. The solution now contains a population of 
microtubules at a concentration of lxlO12 microtubules/ml and 5-10pm in length.
8.3.2.2 Microtubule binding activity
A preliminary experiment to determine if apolipoprotein E shows microtubule binding 
activity was carried out as outlined in Chapter II. Microtubule preparations were 
incubated with apoE E3 or E4 (derived from human plasma)(8 
reactions/genotype/concentration) at a concentration of 5 jug/ml or 20pg/ml and 
centrifuged at 48,000 rpm. The supernatant and pellet fractions were then separated 
by electrophoresis, transferred and immunoblotted for apoE (see chapter II). The 
membranes were stripped and reprobed with the tubulin antibody to check for the 
presence of microtubule protein in the pellet fraction. A molecular weight marker was 
run simultaneously.
218
8.3.2.3 Quantification o f  microtubular binding and statistical analysis
For analysis purposes it was initially determined, on gross examination of blots, 
whether apoE was present in the supernatant or pellet fraction. Any protein that is 
microtubule bound should be present within the pellet fraction. Any unbound protein 
remains within the supernatant fraction. Protein bands were analysed as relative 
optical density values using a 1cm2 sampling box. Optical density values from the 
pellet and supernatant fractions were then compared between apoE E3 and apoE E4 
containing microtubule preparations using a Student’s unpaired /-test. Data is 
represented graphically as the mean values +/- S.E.M
8.3.3 ApoE Binding in Fluorescent Microtubule Preparations
8.3.3.1 Microtubule assembly
It was determined from an initial study that the final labelling stoichiometry of the 
microtubules should be 0.33 labels per tubulin heterodimer. Microtubules were 
assembled as outlined in Chapter II. This solution contains a population of taxol 
stabilised microtubules at a concentration of 7xl0,o/ml. The micro tubules can be 
visualised microscopically at this stage by diluting 1 pi of the microtubule preparation 
in lOpl of taxo 1/microtubule buffer containing 20pl of antifade solution. This solution 
is then smeared onto a slide, coverslipped and visualised using fluorescence 
microscopy.
8.3.3.2 Addition oflipidated human apoE E3 and E4 to microtubule preparations 
Microtubule populations were split so the apoE isoforms were being tested in a 
homogenous population of microtubules. The microtubules were incubated with apoE 
E3 and E4 bound to HDL, at a concentration of 5pg/ml or 20pg/ml for 20 mins at 
room temperature to allow binding to occur. An apoE polyclonal antibody 
(Chemicon) was added to the microtubule/HDL/apoE mixture at a concentration of 
1:100 and incubated for 30 mins. Goat secondary antibody was then applied for 30 
mins (1:100) and the signal amplified using fluorescein avidin D (30 mins). lp l of this 
final mixture was dissolved in lOpl of taxol/microtubule and lOpl of antifade and
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smeared onto a microscope slide. The microtubules appear red (rhodamine) and the 
apoE appears green (fluorescein).
8.3.3.3 Confocal imaging o f fluorescent microtubules
Images were visualised using confocal microscopy and the binding of apoE described 
qualitatively. Z-stack projections were collected from representative microtubules for 
illustrative purposes.
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8.4 Results
8.4.1 Cytoskeletal Alterations Post-Lesion
8.4.1.1 Alterations in (3-tubulin following ECL in APOEz3 and s4 transgenic 
mice (human promoter)
p-tubulin immunostaining was punctate and intense throughout the entire molecular 
layer. In 0 day control mice p-tubulin immunoreactivity was similar in the ipsilateral 
and contralateral hippocampus and was similar in both APOEz3 and z4 mice. At day 
90 post-ECL, tubulin immunoreactivity was greater in APOEzi mice compared to e4 
mice, where immunoreactivity was up to 10% below levels in 0 day controls. This did 
not reach statistical significance (Figure 8.2).
8.4.1.2 Alterations in p-tubulin following ECL in APOEz3 and s4 transgenic 
mice (GFAP promoter)
In 0 day control, mice tubulin immunoreactivity was punctate and densely stained the 
molecular layers of the dentate gyrus, but was similar in APOEz3 and s4 mice. At day 
90 post-ECL, APOEz3 mice displayed a trend for greater recovery of tubulin 
immunoreactivity at this time-point compared to APOEzA mice, however this did not 
reach statistical significance (Figure 8.3).
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Figure 8.2 APOE  expressing mice driven by the human promoter
Quantification of p-tubulin immunoreactivity in the inner, middle and outer molecular 
layers (IML, MML and OML) of the hippocampal dentate gyrus measured as relative 
optical density values at 0 and 90 days post-lesion. Percentage difference between the 
ipsilateral and contralateral hippocampus immunoreactivity was compared in s3 and 
s4 transgenic mice using a Student’s unpaired 7-test.
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Figure 8.3 APOE  expressing mice driven by a GFAP promoter
Quantification of (3-tubulin immunoreactivity in the inner, middle and outer molecular 
layers (IML, MML and OML) of the hippocampal dentate gyrus measured as relative 
optical density values at 0 and 90 days post-lesion. Percentage difference between the 
ipsilateral and contralateral hippocampus immunoreactivity was compared in s3 and 
e4 transgenic mice using a Student’s unpaired t-test.
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8.4.2 ApoE Derived from Human Plasma
8.4.2.1 Enzyme iinked-immunosorbent assay (ELISA) determination of apoE 
concentration
An ELISA was carried out on the human plasma samples to determine the 
concentration of apoE in each sample. The stock solutions were then diluted to a 
concentration of 5pg/ml and checked by ELISA to ensure that the apoE concentration 
was identical for each isoform. This was also checked by dot blotting (Figure 8.4). 
These concentrations were chosen because apoE is at a concentration o f 5p.g/ml 
within the CSF ApoE is increased within the brain following injury and therefore a 
higher concentration (20pg/ml) o f apoE was chosen to see if this altered the manner 
in which each isoform bound to the microtubules.
e3 s4
Figure 8.4 Dot blot showing similar apoE levels in a defined quantity o f HDL isolated 
from human plasma
8.4.3 APOE Genotype Influence on Microtubule Binding 
(microtubule spin-down assay)
8.4.3.1 Microtubule binding of apoE isoforms at a concentration of 5pg/ml
Any protein that is microtubule bound segregates into the pellet fraction and any 
unbound protein remains within the supernatant fraction. Tubulin protein was 
identical in E3 and E4 reactions and was only present within the pellet fraction 
(Appendix A3.4). No tubulin protein was present within the supernatant fraction. At 
5pg/ml, significantly greater amounts o f apoE E4 were present within the pellet 
fraction compared to apoE E3 (p<0 0001). In the supernatant fraction however, apoE 
E3 was found to significantly greater compared to apoE E4 (p<0.01). Combining 
protein band levels showed there was no statistically significant difference in protein 
levels between apoE E3 and E4 reactions (Figure 8.5) (also see appendix A3.5).
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8.4.3.2 Microtubule binding of apoE isoforms at a concentration of 20pg/ml
At an apoE concentration of 20pg/ml, significantly greater amounts of apoE E4 were 
present within the pellet fraction compared to apoE E3 (p<0.05). In the supernatant 
fraction however, apoE3 was found to be significantly greater compared to apoE E4 
(p<0.05). Combining protein band levels showed there was no statistically significant 
difference in protein levels between apoE E3 and E4 reactions (Figure 8.6) (also see 
appendix A3.5).
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Figure 8.5 Semi-quantification of western blotting bands showing microtubule binding 
of apoE E3 and E4 at a concentration of 5pg/ml. ***p<0.0001 and **p<0.01
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8.4.4 Fluorescent microtubule assay
8.4.4.1 Characterisation of microtubule structure
Micro tubules under normal conditions appear almost ‘star-like’ in shape where the 
tubulin, once polymerised, forms an organising centre with processes radiating from 
the centre point and are all approximately 5-7pm in diameter. Microtubule structure 
was then assessed following addition of apoE E3 and E4 protein. Microtubules 
exposed to apoE E3 protein were found to have a regular shape with an identifiable 
organising centre with many processes radiating from the centre. There was also a 
tendancy for microtubules exposed to apoE E3 to form aggregates where multiple 
microtubule structures formed clusters (Figure 8.7 and 8.8). Microtubules exposed to 
apoE E4 were very irregularly shaped. These microtubules tended to be long and 
‘spindle’ shaped with fewer processes radiating from the organising centre. 
Microtubules treated with apoE E4 were also less often found in aggregates and on 
the occasion they did form clusters, these too were irregularly shaped.
8.4.4.2 Microtubule binding of apoE isoforms
The microtubules were examined initially to determine localisation of binding. There 
were no gross differences in the location to which each isoform bound. ApoE E3 and 
E4 were both found to bind along the full length of the microtubule processes (Figure 
8.9). At both apoE concentrations, it appeared that there was significantly greater 
apoE immunoreactivity on microtubules incubated with apoE E4 compared to those 
incubated with apoE E3, although this was most apparent at the 20pg/ml 
concentration (Figure 8.7 and 8.8).
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apoE E3 apoE E4
Figure 8 7 Confocal images of microtubule bound apoE
ApoE E3 and E4 binding to microtubules at an apoE concentration o f 5pg/ml. The 
illustrations show (a, d) microtubules (red), (b, e) apoE protein (green) and (c, f) a 
combined image.
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apoE E3 apoE E4
Figure 8.8 ApoE E3 and E4 binding to microtubules at an apoE concentration o f 
20[ig/ml. The illustration show (a, d) microtubules (red), (b, e) apoE protein (green) 
and (c, f) a combined image.
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2 p m
Figure 8.9 High power magnification o f microtubule processes with (a) apoE E3 
and (b) apoE E4 bound.
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8.5 Discussion
Microtubules play a key role in a cell’s ability to alter shape and how efficiently they 
perform this task may depend upon how several other proteins interact. In previous 
chapters of this thesis, it has been shown that neuronal repair mechanisms are 
impaired in transgenic mice expressing human APOEzA alleles. These studies parallel 
human studies which have shown impaired repair responses after head injury 
(Teasdale et al, 1997) and in AD (Arendt et al, 1999) in individuals possessing 
APOEzA alleles. One mechanism of how apoE may modulate plasticity is via 
differential interactions with the neuronal cytoskeleton. In this chapter, microtubule 
binding of apoE E3 and E4 isoforms was analysed. The present study is the first to 
study direct apoE interactions with the major microtubule protein, tubulin. It was 
found that not only did apoE E4 bind to microtubules to a greater extent than apoE 
E3, but that microtubules incubated with apoE E4 displayed an irregular structure. 
The data suggests that apoE E4 may have a detrimental effect on microtubule 
metabolism.
8.5.1 The role of the microtubule in plasticity
Microtubules are important in determining the shape of cells. Microtubules are present 
in the cytoplasm of cells and can also be found at the poles of mitotic spindles. 
Microtubules radiate from centrosomes. These centrosomes are the sites of initiation 
of microtubule growth and are called microtubule organising centres (MTOC). 
Microtubules have an intrinsic polarity where one end is called the plus end and the 
other, the minus end. Both ends are capable of assembly and disassembly but the plus 
end extends more rapidly. The minus end is nearest the MTOC. Microtubules extend 
under conditions where a cell requires them to polymerise for cell membrane 
extesnsion (Caroni et al, 1997; Alvarez et al, 2000) This process occurs most 
prominently in the growth cone of extending neurites, in an attempt to extend and 
support the new cell process. The microtubules in the present study are stabilised with 
taxol and this compound promotes polymerization of tubulin monomers into 
microtubules.
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8.5.2 Abnormalities in dendritic process structure in APOEz4 transgenic mice
ApoE is believed to play a role in modulation of the neuronal cytoskeleton. APOE 
genotype may influence the behaviour of the neuronal cytoskeleton. In Chapter IV, it 
was shown that there was impaired dendritic reorganisation post-ECL where at day 
90, APOE e4 mice (human promoter) displayed a deficit in MAP-2 immunoreactivity 
compared with APOE e3 mice. In addition, there was also a marked difference in 
dendritic structure between APOE s3 and s4 mice. The dendritic networks in 
APOEzA mice were highly disorganised and irregular compared to s3. This structural 
abnormality may arise as a result of differential interaction of each apoE isoform with 
certain cytoskeletal proteins. In the transgenic mice expressing human APOE alleles 
under the GFAP promoter (Chapter V), no such isoform effect on dendritic structure 
was detected. The findings could reflect the fact that apoE is only expressed in 
astrocytes in these mice. When expressed endogenously in neurons, apoE does not 
have to overcome the problems of escaping the endocytic pathway to interact with 
intracellular elements. At present, it is unclear whether apoE which enters a neuron 
via receptor mediated mechanisms is even capable of escaping endosomes. This could 
have vital implications as to how apoE interacts with the cytoskeleton, if at all. These 
isoform specific differences on the cytoskeleton may only arise when apoE is free to 
interact i.e. when present endogenously within the neurons. Tubulin staining in both 
transgenic lines suggests there is also a deficit in tubulin immunoreactivity at day 90 
post-ECL in APOEzA mice, where an impairment in the reparative capacity is evident.
8.5.3 In vitro evidence for a role of apoE in microtubule metabolism
Using cell culture techniques, the outgrowth promoting effects of apoE have been 
demonstrated. Initially, it was shown that apoE promoted neurite extension in the 
presence of an exogenous lipid source (VLDL) in dorsal root ganglia (Handelmann et 
al, 1992). Further studies revealed that this outgrowth promoting effect was APOE 
genotype dependent. ApoE E3/ VLDL complex promoted neurite extension in dorsal 
root ganglia, whereas apoE E4 did not (Nathan et al, 1994). The type of lipoprotein 
bound to apoE may also be important in the promotion of plasticity. In the CNS, 
apoE is mainly associated with HDL and this is the most physiologically relevant to 
employ in studies of this sort. Neuro-2A cells incubated with apoE E3/HDL complex
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display extensive outgrowth, but when incubated with apoE E4 outgrowth is 
attenuated (Bellosta et al, 1995). This effect is also evident when neuro-2A cells are 
grown on a monolayer of astrocytes secreting either apoE E3 or E4 (Fagan et al, 
1996). These differential effects on outgrowth may be due to the way in which the 
cytoskeleton behaves in response to apoE E3 and E4.
Analysis of cytoskeletal structure in cells incubated with apoE E3 and E4 has shown 
that cells treated with apoE E4 display depolymerisation of microtubules (Nathan et 
al, 1995). Another study showed that apoE E3 and E4 accelerated microtubule 
assembly equally, however that study did not allow analysis of microtubule structure 
(Scott et al, 1996). In the present study, it was found that microtubules incubated 
with apoE E3 are regularly shaped, with many processes radiating from the organising 
centre. In contrast, microtubules incubated with apoE E4 are highly irregular. They 
appear extremely spindle-like in morphology with a reduced number of processes 
radiating from the organising centre. Those incubated with apoE E3 also tended to 
form networks and regularly existed as clusters. This was not true of those incubated 
with apoE E4 and when these did form networks they were highly irregular in shape. 
Although the apoE protein was added to the microtubules after the majority of 
assembly had taken place, they are bathed in taxol buffer, which means the 
microtubules continue to polymerise because there is always some monomeric tubulin 
available. Therefore when the apoE was added, it became involved in the assembly 
process. This allowed insights into apoE isoform effect on microtubule structure. In 
future experiments of this type, it would be interesting to have the apoE isoforms 
present from the beginning of the polymerisation process. In general, it would seem 
that the apoE E4 isoform has a detrimental effect on microtubule structure.
8.5.4 ApoE isoforms and binding to cytoskeletal proteins
One mechanism of how apoE may modulate microtubule structure, is by the manner 
in which it binds to microtubules and microtubule-associated proteins. The binding of 
apoE iso forms to microtubule-associated proteins has previously been investigated 
(Huang et al, 1996). ApoE E3 has been shown to bind with high-avidity to the 
microtubule-associated protein tau. ApoE E4 does not bind as avidly. The fact that 
apoE E3 binds efficiently means it can protect microtubule structure from
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hyperphosphorylation. Hyperphosphorylation of tau results in the protein binding to 
itself, which causes the formation of neurofibrillary tangles. Higher avidity binding of 
apoE E3 has also been shown in association with the MAP-2c protein. In this chapter 
the binding of apoE to the major microtubule protein, tubulin was studied. Using non­
denaturing polyacrylamide gel electrophoresis, it was found that at both apoE 
concentrations, apoE E4 protein was present predominantly within the pellet fraction 
(microtubule bound) whereas greater levels of apoE E3 were present within the 
supernatant fraction (unbound). This suggested that more apoE E4 was bound to 
microtubules than apoE E3. Images of microtubules with apoE bound, analysed by 
confocal microscopy revealed similar results, where it appeared that greater apoE 
immunoreactivity was present on the microtubules treated with apoE E4 than those 
treated with apoE E3. This type of study would further benefit from a time course 
study to analyse interaction and dissociation with time. In this study, apoE E4 protein 
was found to bind microtubules to a greater extent than apoE E3 protein. A previous 
study looking at binding of apoE isoforms to various cytoskeletal proteins found that 
there was no difference in the binding avidity of apoE E3 and apoE E4 at an apoE 
concentration of 5pg/ml (Fleming et al, 1996). This study did not examine apoE at 
higher concentrations and it also failed to combine the apoE with a lipoprotein source. 
In the present study the apoE was isolated from plasma but it was associated with the 
endogenous HDL lipoprotein. This makes this assay more physiologically relevant as 
apoE is always lipoprotein bound within the CNS. The presence of lipoprotein may 
have vital implications to the way in which an apolipoprotein interacts with 
cytoskeletal components.
8.5.5 Technical considerations and concluding remarks
This study was the first step to understand the interactions of apoE with microtubules. 
Ideally, this experiment would have benefited from using apoE/HDL isolated from 
CSF. However, at the time of these studies it was impossible to concentrate apoE- 
HDL from CSF. Furthermore a large volume of CSF would be required and this was 
not available. The use of apoE from plasma provided the best physiologically relevant 
information. This study also benefited from the fact that apoE is combined with the 
endogenous lipoprotein source. In the CNS, apoE is bound to HDL and although
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slightly different between the CNS and plasma, it again was more physiologically 
relevant than using recombinant apoE and a false lipoprotein source.
The concentrations of apoE were chosen on the basis that apoE in the CNS exists at a 
concentration of approximately 5pg/ml. A higher concentration was also chosen on 
the basis that apoE is increased after injury and it was important to establish the effect 
of elevated apoE on microtubule interactions. In these studies it was found that 
greater levels of apoE E4 were bound to microtubules. This result was surprising in 
view of other studies that indicate apoE E3 binds with greater avidity to MAP and 
tau. The explanation as to why apoE E4 should bind tubulin to a greater extent is 
unclear. However, it may be that apoE E4 binds more strongly and once associated 
with microtubules is not easily dissociated whereas apoE E3 binds, transports and 
dissociates readily and would be available for further interaction. If for instance, the 
apoE E4 cannot become dissociated, it is not free for subsequent interactions. This 
has not yet been studied and further investigation may be required to confirm this. 
This study also highlighted that microtubule structure was highly irregular when 
incubated with apoE E4 and may explain the dendritic abnormalities observed in the 
in vivo studies.
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Chapter IX General Discussion
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9.1 Evidence for a role of apoE in regeneration
Studies in the PNS and in populations of neurons in culture have shown that apoE is 
involved in regeneration. ApoE is upregulated in transected peripheral nerves and this 
increase has been shown to coincide with regeneration (Ignatius et al, 1987). Similarly 
apoE promotes neurite outgrowth from Neuro-2A cells incubated with apoE (Pitas et al, 
1998). A model of entorhinal cortex lesion and an in vitro organotypic hippocampal 
slice culture method was established in this thesis to assess apoE function in 
compensatory sprouting in the hippocampus post-injury. The brain maintains an 
incredible capacity to repair itself. This manifests itself as an ability to compensate for 
loss of function but also the ability to compensate at the cellular level. ApoE is believed 
to play an important role in this regeneration process by providing lipid and cholesterol 
material for the reconstruction of cellular elements. Data in this thesis supports this 
contention with the finding that apoE is upregulated following injury at periods which 
parallel regeneration and clearance of lipid material from the local environment post- 
ECL. The actions of apoE on other cellular elements may also contribute to its ability to 
stimulate sprouting mechanisms and these will be discussed later.
9.2 Overwhelming evidence for an adverse effect of the APOEzA allele 
on long-term neuronal plasticity: impaired clinical recovery
Numerous human studies have highlighted an adverse effect of the APOEzA allele on the 
brains response to disease and trauma, primarily mediated by its effects on brain 
plasticity. This includes impaired neuronal remodelling in s4 individuals suffering from 
AD, attenuated recovery from stroke, cardiopulmonary bypass and intracerebral 
haemorrhage and adverse effects on the progression and severity of neurodegenerative 
disorders such as Multiple Sclerosis, Parkinsons disease and Motor Neuron disease. This 
is only to mention a few instances with which the APOEzA allele is adversely associated. 
The e4 allele has also been shown to associated with a poor outcome following 
traumatic brain injury. The most compelling evidence supporting this hypothesis, was 
the recent finding by Teasdale et al (2000) showing a poorer long-term outcome 
following head injury in APOEzA individuals, compared to non-s4 individuals. This is 
particularly significant considering the subjects were under the age of 15 years. This 
reinforces the fact that the adverse effect is not due primarily to age-related mechanisms
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(i.e. increased amyloid deposition), but a mechanism mediating brain plasticity. In 
addition, animal studies have confirmed there is a genotype effect not only in acute brain 
injury but that there is also a pronounced effect on the brains long-term response to 
injury (Buttini et al, 2000; White et al, 2001). Studies in this thesis have shown for the 
first time that APOE genotype modulates the long-term recovery of the brain following 
injury and have provided strong evidence for an adverse effect of the APOEzA allele in 
brain plasticity. This thesis has also attempted to establish some o f the mechanisms that 
underlie the genotype specific effects on brain plasticity after injury, some of which are 
discussed in the following sections.
9.3 Influence of the localisation of apoE within the brain on recovery 
after injury
9.3.1 Neuronal apoE expression versus glial apoE expression
Human neurons and glia express apoE endogenously. This thesis has shown that the 
compartmentalisation of apoE within the nervous system could have vital implications 
for how it modulates neuronal plasticity. The transgenics studied in Chapter IV, express 
apoE within neurons and glia, due to expression being regulated by the endogenous 
human promoter sequence. Transgenic mice such as these, are believed to have a pattern 
of apoE expression similar to that in the human brain. The transgenic mice employed in 
Chapter V express apoE within astrocytes only, because expression is regulated by a 
GFAP promoter sequence. In both studies, the APOEzA mice exhibited a poor recovery 
from the injury, when compared with APOEz3 and knockout mice. However, comparing 
the degree of recovery within the two different transgenic lines it is evident that, in 
general, the line that expresses neuronal apoE display a greater capacity for 
regeneration, by day 90 post-ECL. Synaptophysin and GAP-43 immunoreactivity 
recovers close to, or above baseline levels in this line and although transgenics 
expressing glial apoE display some ability to recover from the injury, there remains a 
significant deficit in synaptophysin and GAP-43 levels at day 90 post-ECL. This 
difference between the different lines may indicate the importance of endogenous
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Figure 9.1 Diagram illustrating apoE trafficking. Neuronally expressing transgenics express 
apoE endogenously in neurons and therefore it is immediately available for the response to 
injury/ stress. These transgenic mice also express astrocytic apoE and this is readily 
available to scavenge lipid from the environment. In contrast, ‘GFAP’ mice only benefit 
from astrocytic expression. The processes o f lipid clearance may remain intact but the lack 
o f endogenous neuronal expression could have profound effects on the response to injury 
and the interaction with the cytoskeleton.
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neuronal expression to repair in response to injury. It could also reflect a delayed 
response in the mice expressing astrocytic apoE. ApoE (and its lipid components) is 
transported from distant sites i.e. astrocytes to neuropil/neurons in response to injury and 
thus the effectiveness of apoE to promote neuronal repair is slower than in endogenously 
neuronal expressing transgenic mice (see Figure 9.1). The function of apoE may be seen 
as twofold. These are (1) scavenging of lipid from the environment and (2) intracellular 
effects. Astrocytic apoE has been shown to be involved in the lipid scavenging process. 
In this respect it is likely that the two types of transgenic mouse do not differ 
significantly as they both express apoE astrocytically and it is shown in this thesis that 
lipid degeneration products are cleared efficiently post-injury in both mouse lines.
In the human transgenics, neurons also endogenously express apoE and it is therefore 
readily available for emergency use intracellularly after injury (to interact with cellular 
elements), something which is not possible for the GFAP transgenics or indeed wild- 
type mice. In addition, neurons are capable of synthesising cholesterol and phospholipid 
and therefore all the tools required for membrane biosynthesis are immediately available 
without having to be transported from great distances away and then being endocytosed. 
There is also evidence to suggest that endocytosed apoE may not be capable of 
interacting with the cytoskeleton because it does not escape from the endocytic 
trafficking pathway (DeMattos et al, 2000). This could also have important implications 
for recovery in GFAP transgenic mice. In this study, it is also evident that localisation of 
expression of apoE, influences the pattern of apoE and apoJ expression post-ECL. In 
wild-type C57BL/6J and GFAP transgenic mice, there is increased expression at day 7 
post-ECL, but also at day 90 there is increased expression within the OML. This late 
expression is absent from the response in the human transgenic mice. This could reflect 
a last ‘ditch’ attempt by the ‘GFAP’ expressors to compensate for the deficit in synapse 
and fibre density with a late surge of astrocytic apoE release. This is consistent with the 
demonstration that upregulation of apoE occurs in a region of the molecular layer, which 
has sustained the most severe damage.
The location of apoE in the brain appears also to be crucial in its response to the ageing 
process. In previous studies it has been shown that when expressed neuronally, apoE4 
has an adverse effect on neurodegeneration in the ageing CNS (Buttini et al, 1999;
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Tesseur et al, 1999) and when expressed astrocytically it is not detrimental. This is in 
agreement with the ageing study in this thesis, which did not observe any genotype 
effects on ageing in ‘GFAP’ transgenic mice. The response in the brain to injury and 
ageing appears to be almost the complete opposite in terms o f outcome, where neuronal 
apoE expression may be more beneficial in recovery from brain injury, and astrocytic 
apoE more beneficial in ageing. This also highlights that how apoE functions in ageing 
and after injury may be two completely different mechanisms.
242
9.4 Mechanisms of Isoform Effect on Plasticity
There are several mechanisms by which apoE iso forms may differentially influence 
plasticity and these will be discussed in the following sections.
9.4.1 Isoform-specific differences in receptor interactions
Although no fundamental differences in LRP receptor expression between the genotypes 
could be detected in this thesis, this obviously does not account for functional 
differences in the way each isoform interacts with the receptor. In the brain, the LRP 
receptor is expressed on neurons and astrocytes, where it is located on cell bodies and 
also on processes (Stockinger et al, 1998). The presence of LRP on processes is 
especially important in the models employed in this thesis. This is because apoE is 
upregulated in regions where there are no neuronal cell bodies, only dendritic processes, 
where its lipid uptake mediating effects are most required for repair. Several studies 
have indicated that apoE E3 promotes neurite extension in cultured cells but apoE E4 
does not, an effect that is mediated by the LRP receptor (Holtzman et al, 1995; Poirier et 
al, 1995; Bellosta et al, 1995; Pitas et al, 1997). The outgrowth promoting effects of 
apoE E3, may be abolished by blocking the receptor (Holtzman et al, 1995; Fagan et al, 
1996). The single amino acid change in the protein, which results in the E4 isoform, is in 
the receptor-binding domain (Mahley et al, 1988; Rebeck et al, 1993). However, binding 
studies have revealed that E3 and E4 do not differ greatly in their affinity for the LRP 
receptor (Weisgraber et al, 1982), whereas E2 shows a reduced capacity for binding 
(Beffert et al, 1998). However, it is not the receptor itself that is responsible for a 
genotype effect but an associated protein. Heparin sulphate proteoglycan (HSPG) is 
closely associated with the receptor and functions in the initial capture of lipid from the 
environment (Mahley and Ji, 1999). Treatment of cells with heparinase abolishes uptake 
of apoE and attenuates the outgrowth promoting effects of apoE E3 (Bellosta et al, 1995; 
Ji et al, 1998). HSPG sequesters apoE-enriched lipoprotein particles before being 
endocytosed via the LRP receptor (Mahley et al, 1994). Incubation of Neuro-2A cells 
with apoE E3 and E4-VLDL resulted in a similar increase in the cholesterol content of 
the cells, suggesting a similar ability to internalise lipoprotein particles (Nathan et al, 
1995). In contrast, cells were found to contain a greater accumulation of apoE E3 than
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E4. The authors suggested that this may be due to an isoform difference in accumulation 
or retention but the effect is primarily mediated by the HSPG (Ji et al, 1998). This 
differential effect at the receptor surface may also have implications on how the apoE is 
trafficked throughout the rest of the cell.
9.4.2 Endocytosis and intracellular trafficking
The differential accumulation and retention of apoE3 and E4 in cells may be due to a 
variation in storage once inside the cell. One hypothesis is, that apoE3 is directed to an 
intracellular pool (Ji et al, 1998). It is also believed that once endocytosed, apoE4 is 
unable to escape the endosomal packaging and is rapidly trafficked through the cell 
without interacting with intracellular elements (i.e. membrane) and may even be rapidly 
resecreted (Rensen et al, 2000). Experiments by Lovestone et al (1996), have shown that 
apoE3 is retained throughout cells and is present within the cytoplasm however, apoE4 
was present within vesicles, presumably of the endocytic class. A study by Demattos et 
al (1999) showed that when apoE was bound to a nuclear localisation signal (NLS), 
apoE was able to enter the nucleus when it reached the cytosol. In contrast, when an 
exogenous apoE source (+NLS) was endocytosed into cells, it failed to escape the 
endocytic pathway. In addition, direct expression of apoE within the cytosol was found 
to be extremely toxic to the cell however this effect was possibly due to free apoE.
Proteins such as Rab-4, Rab-5A and rabaptin have recently been identified as proteins 
involved in endocytosis (Neve et al, 1998). Rab-4 is a marker of endosome recycling, 
whereas Rab-5A and rabaptin are proteins, which function in membrane fusion in the 
endocytosis process. Studies using Rab-5a in particular, have shown that apoE is 
endocytosed but that there may be an isoform difference in the way the isoforms are 
trafficked following this. After 1 hour of uptake, it was found that apoE3 no longer co­
localised with vesicle-associated proteins, whereas apoE4 was found to be 87% co­
localised. This was even apparent using a marker of late-endosomes (Cathepsin D) 
(DeKroon et al, 2001). It is also important to note that Cathepsin D also has secretase 
activity, which could have implications for amyloid deposition in AD. Endocytic 
pathway abnormalities have been found to be associated with sporadic AD. In one study, 
it was found that endocytic pathway abnormalities occur, before amyloid deposition is 
apparent, and the authors suggest that this is the earliest upstream event in the
244
pathogenesis of AD (Cataldo et al, 2001). Specifically, early endosomes have been 
found to be enlarged in the brains of AD patients (Cataldo et al, 1997). Further to this, 
studies in fetuses and children with Down’s syndrome, have shown that these endosomal 
abnormalities are even evident at this early stage, long before any other pathological 
hallmarks of AD have been identified. The APOEzA allele was found to promote early 
enlargement of endosomes, when compared with individuals not possessing an APOEzA 
genotype. Endosomes appeared as normal when tissue from familial AD cases as a result 
presenilin mutations.
9.4.3 Evidence for an APOE genotype influence on cytoskeletal interactions
Once inside the cell, the lipid from the complex may be cleaved and reutilised in a 
number of ways. Little is known however, of what becomes of apoE. ApoE may remain 
within the endocytic system and pass straight through the cell. One hypothesis is that 
apoE is able to interact with cytoskeletal proteins inside the cell and it is via this 
mechanism that apoE functions in neuronal process extension. Microtubules have been 
shown to function in several important processes within neurons, including neurite 
extension and retraction (Mitchison et al, 1988). Analysis o f the ability of apoE E3 and 
E4 to promote neurite extension was assessed in Neuro-2A cells and it was found that 
cells incubated with apoE E3, produced long neurites but those incubated with apoE E4 
did not. The authors hypothesised that this may be due in part, to microtubule status 
within the cells. It was found that, in the apoE E4 treated cells, microtubules were poorly 
formed and there was a greater amount of monomeric tubulin as opposed to polymeric 
tubulin, compared with that of apoE E3 treated cells (Nathan et al, 1995). Firther 
analysis revealed that apoE E3 bound to the cellular microtubules with a greater affinity 
than apoE E4. In similar studies, it has been shown that apoE E3 binds more readry to 
the microtubule associated proteins tau and MAP-2 (Strittmatter et al, 1994; Huang et al, 
1994). Conflicting evidence comes from Scott et al, (1998), who have shown that 
microtubule polymerisation is equally stimulated in the presence of apoE E3 and E4. 
The interaction of apoE with the cytoskeleton may not only be crucial for neirite 
extension but also stabilization. It is suggested that apoE may bind to the microtutule- 
binding domain of tau and MAP-2c and protect their structure from 
hyperphosphorylation (Roses et al, 1996). The hyperphosphorylation of tau results ii the
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formation of paired helical filaments (neurofibrillary tangles). Lovestone et al (1996) 
have shown that the cellular distribution of apoE is dependent on the presence of tau, 
although it was also noted that neither apoE3 nor E4 altered the phosphorylation state, a 
finding confirmed in a subsequent study (Flaherty et al, 1999). In contrast, expression of 
apoE4 in neurons of transgenic mice results in hyperphosphorylation of tau (Tesseur et 
al, 2000). In this thesis it is suggested that cytoskeletal structure alterations after injury 
are APOE genotype dependent when apoE is expressed in neurons but not when 
expressed in astrocytes alone (as assessed in MAP-2 immunstained sections). This not 
only suggests that apoE is capable of modifying cytoskeletal proteins and that it is 
isoform dependent, but also highlights how the primary localisation of expression may 
be crucial to this process. This does not exclude the possibility that there may be 
ultrastructural differences in cytoskeletal structure in GFAP transgenics that could not be 
detected using the techniques employed. It has been shown that cells incubated with the 
apoE E4 isoform display a significantly greater degree of microtubule polymerisation 
(Nathan et al, 1995) when compared with apoE E3. ApoE promotes microtubule 
assembly and the rate of assembly has been found to be similar when incubated with 
apoE E3 and E4. However, one mechanism of how apoE may modulate the behaviour of 
cytoskeletal proteins is by differential binding to various cytoskeletal proteins. The 
binding of apoE isoforms to cytoskeletal proteins has previously been examined. These 
studies have found that, in general, the apoE E3 iso form binds with higher avidity to 
MAPs and tau when compared with apoE E4 (Huang et al, 1994; Flaherty et al, 1999). 
In Chapter VIII it was shown that apoE E4 protein was more greatly associated with 
microtubules than apoE E3. This finding differs from a previous study that found apoE 
E3 and E4 bound tubulin equally well (Fleming et al, 1996). However the apoE used in 
that study lacked an endogenous lipid source. In the present study, apoE was bound to 
HDL, which is more physiologically relevant considering apoE is always HDL bound in 
the CNS. The presence and type of lipoprotein to which the apolipoprotein is bound may 
have severe implications for the way in which the apolipoprotein interacts with the 
cytoskeleton and other proteins. This has been shown previously where the lipidation 
state of apoE affects the avidity with which it binds amyloid. In chapter VIII it was also 
shown that microtubules incubated with apoE E4 displayed an irregular structure. 
Processes were long and spindle-like and the number of processes radiating from the 
organising centre was reduced compared with microtubules incubated with apoE E3.
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This suggests that apoE E4 has a detrimental effect on microtubule structure in vitro, and 
supports the finding of disarrayed dendritic processes in vivo.
9.4.4 Intracellular signalling pathways -  from receptor to cytoskeleton
From the most recent data, it has become apparent that apoE binding to the LRP receptor 
may modulate plasticity via a cascade of intracellular signalling events (Herz et al, 
2001). On binding to the NPxY cytoplasmic domain of the LRP receptor (Trommsdorf 
et al, 1998), FE65 and DAB1 (scaffold proteins) cause the assembly of a protein called 
Mena. Mena is a member of a family called Ena-Vasp proteins, which are enabled- 
vasodilator stimulated phosphoproteins. These proteins interact directly with the actin 
cytoskeleton but may also interact with other components such as tubulin and 
microtubule associated proteins. This process is thought to occur in the generation of 
neuritic processes. It has not been established as o f yet however, whether there is an 
apoE isoform effect on the ability to stimulate this process. If  for instance, apoE4 
interacts differently at the receptor surface, this could result in differing intracellular 
signalling events. As can be seen from the diagram (Figure 9.2), the binding of apoE 
also influences the processing of APP through this pathway although the significance of 
this is unclear. However, FE65 binding to cytoplasmic tails does result in attenuation of 
the endocytosis signal, thus leaving APP extracellularly for a-secretase cleavage (Herz 
et al, 2000). Another pathway that has been implicated in reorganisation of the 
cytoskeleton is that mediated by the ApoER2 receptor. Via the reelin signalling pathway 
and other members of the scaffold family o f proteins, apoE may cause cytoskeletal 
reorganisation, primarily through modifications of tau by MAP kinases. This has been 
shown to cause hyperphosphorylation of tau which leads to the production of 
neurofibrillary tangles in AD (Herz, 2001). Little is known at present of the precise 
function of apoER2 in the brain.
The LRP receptor has multiple ligands (up to 30 known) and each of these effect 
different actions intracellularly. One of these, a2  macroglobulin, binds to neuronal LRP 
receptors and induces calcium ion influx via NMDA receptors. The link between the 
LRP and NMDA receptor occurs via another scaffold protein, PSD-95. Entry of calcium 
due to LRP mediated activation of NMDA receptor channels may alter downstream 
signalling events and may modulate local synaptic plasticity alterations (Herz and
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Strickland, 2001). O f interest in this thesis is also the finding that the LRP receptor binds 
an array o f  viruses and toxins. On binding, viruses may be internalised via the LRP 
receptor and thus this may be how HSV enters cells in the hippocampal slices in this 
thesis.
ApoE
LRP
APP
Extracellular domain
Intracellular domain
E65
NPxY motifs
Mena
Reorganisation of 
the cytoskeleton
Figure 9.2 Intracellular signalling. The diagram illustrates the interactions o f receptor 
neuronal adaptor proteins and cytoplasmic structural proteins. When apoE binds to the 
LRP receptor a cascade o f intracellular events occur. The binding o f DAB1 and FE65 
molecules to the cytoplasmic tail o f the receptor (NPxY) promotes the assembly o f  
Mena and other proteins in the Ena-Vasp family. This in turn may act on the 
reorganization o f the cytoskeleton (Derived from Herz et al, 2000).
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9.4.5 APOE genotype, estrogen and sprouting
Estrogen has long since been known to be a strong influence on brain plasticity. Studies 
by Woolley and McEwan have shown that synaptic density increases in certain brain 
regions of the rat at stages of the estrus cycle when estrogen is most elevated. It was first 
discovered by Stone et al (1997), that in stages of the eostrus cycle, when estrogen was 
high, the brains of female rats expressed significantly greater levels of apoE mRNA 
within astrocytes and microglia. This was the first indication that estrogen may be 
neuroprotective, an effect that was mediated by increased apoE expression, due to 
actions via the a  estrogen receptor pathway (Srivastiva et al, 1997). At present these 
pathways remain largely ambiguous. Estrogen has been shown to enhance compensatory 
sprouting, in response to entorhinal cortex lesion (Geddes et al, 1985) and that apoE is 
increased in the response (Stone et al, 2000). Using animal models, it has been 
confirmed that estrogen replacement in wild-type mice following ovariectomy, restores 
the sprouting response. In addition, estrogen replacement does not promote sprouting in 
APOE knockout mice (Stone et al, 1998; Teter et al, 1999). It remains undetermined if 
APOE isoforms can differentially modulate sprouting via estrogen mediated mechanisms 
and this is currently under investigation in our laboratory although there is some data 
from human studies suggesting that APOE genotype may influence this to a certain 
extent. It is suggested that estrogen is protective against AD and this is supported by 
statistics showing that AD is more prevalent in the human male population. Several 
papers have been published outlining the beneficial effects of hormone replacement 
therapy in human females in reducing the risk of developing AD (Tang et al, 1996; 
Yaffe et al, 1998; Slooter et al, 1999) and that the efficacy of these drugs may be 
genotype dependent. Cognitive decline is reduced in non-e4 females with estrogen 
therapy but is not reduced in e4 females.
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9.5 C o n c lu d in g  re m a rk s
This thesis has sought to establish an in vivo and in vitro animal model to assess brain 
plasticity and, using these models, the influence of APOE genotype on long-term 
plasticity changes following injury has been elucidated. It is evident, not only from the 
data contained in this thesis, but also a wide range o f sources that the c4 allele of the 
APOE gene is generally deleterious to brain plasticity. This does not only have 
implications for AD and head injury but also a great number of human diseases, with 
which APOE genotype influence has been linked. This thesis has also attempted to 
assess at least some of the mechanisms by which APOE isoforms may mediate their 
differential effects on plasticity. These mechanisms and others are represented 
schematically (Figure 9.3). This thesis is by no means a complete work but it has 
provided a basis for the direction of future studies. Now the important role of apoE in 
plasticity has been established it is important to investigate all pathways with which it 
may mediate its effects. This includes further analysis of cytoskeletal interactions (via 
various mechanisms) and elucidation of the role of estrogen in plasticity. Regardless of 
the mechanism by which the APOEzA allele imposes its deleterious effects, it is hoped in 
the future that an efficient therapy may be developed. Presently, the greatest hope for an 
apoE therapy in the treatment of CNS disease and injury lies with gene therapy. A study 
in this thesis has begun to evaluate the merits of gene therapy and it is hoped this work 
will be further developed in the future.
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Figure 9.3 Schematic diagram illustrating pathways by which APOE genotype may 
influence the brains response to injury and disease.
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Appendix 1 Staining protocols and perfusion
A l.l Haematoxylin and Eosin histological staining on paraffin sections
1. Dewax in histoclear (lOmins)
2. Absolute alcohol (2mins)
3. Methylated spirit (lmin)
4. Wash in water (couple of mins)
5. Hematoxylin (l-10mins depending on section thickness and desired staining 
intensity)
6 . Differentiate in methanol containing 1% HC1
7. Wash in water
8 . Scot’s tap water substitute (lmin)
9. Wash in water
10. Aqueous eosin (3mins)
11. Wash sections thoroughly in water (10-20mins)
12. Dehydrate through a graded series of alcohols (70%, 90% 100%x2)
13. Clear in histoclear (5mins)
14. Mount coverslips with histomount
A1.2 Fink Heimer Silver staining
A. Potassium permanganate (KMNO4 ):- 0.1% in dH20
B. Decolourizing s o lu t io n Mix equal volumes of 1% hydroquinone and 1% oxalic 
acid. This solution should be prepared immediately before use. This compound is 
quite unstable.
C. Uranyl n i t r a te U0 2 (N0 3 ) 2  H2 O 0.5% in dH2 < 3
D. Silver n i t r a te AgNC>3 2.5% in dH2 0
E. Sodium h yd ro x id eNaOH 2.5% in cffi^O
F. Ammonical silver nitrate s o lu t io n 20ml silver nitrate solution, 1ml concentrated 
ammonia (28%), 1 .8 ml sodium hydroxide
G. Nauta-Gygax r e d u c e r 27ml 10% formalin, 27ml 1% citric acid, 90ml 90% 
alcohol, 910ml H2 O
H. Fixing s o lu t io n sodium thiosulphate (Na2 S2 0 3 .5 H2 0 ) 0.5% in dH2 0
I
Staining protocol (Staining Procedures Fourth Edition, Williams and Wilkins)
1. Rinse sections in water
2. Solution A (5-1 Omins)
3. Rinse in water
4. Decolourize in solution B
5. Rinse thoroughly
6 . Solution C(10ml), Solution D(10ml), H2O(30ml) for 30-60mins
7. SolutionC(15ml), Solution D(35ml) for 30-40mins
8 . Rinse thoroughly in water
9. Solution F (l-5mins)
10. Directly to reducer (Solution G) change after 30 secs, total period of l-2mins
11. Solution H 1 min
12. Rinse, dehydrate, clear and coverslip.
Background can be of variable tones of orange/yellow depending on the degree of 
fixation however the degeneration products always appear strikingly as black 
punctate neuropil staining.
A1.3 Transcardiac Perfusion of Mouse
Mice were halothane anaesthetised and fixed into a face mask and anaesthesia 
maintained throughout the procedure. The chest cavity was exposed by 2 incisions 
into the chest wall and the diaphragm removed to completely expose the heart. A 
perfusion needle was inserted into the left ventricle and clamped into place. 
Heparinised saline (10ml) was then administered using a constant infusion pump 
(3.33ml/min) and the right atria immediately snipped using scissors. 20mls of 4% 
paraformaldehyde was then delivered using the constant infusion pump. The head 
was then removed and placed in fixative overnight.
II
Appendix II Solutions and Sources
ABC Vector
Anti-mouse IgG HRP Promega
Anti-goat/sheep HRP Scottish health board
Ammonium persulphate Promega
Bovine serum albumin (fracion V) Sigma
DAB Vector
ECL Amersham
Geys balanced salt solution GIBCO
Glutamax I GIBCO
Hydrogen peroxide Sigma
Hydroquinone Sigma
Ibotenic acid Sigma
Kaleidoscope molecular weight marker Bio-Rad
Membrane inserts (0.4 pm pore size) Becton Dickinson
Microtubule associated protein spin-down assay Cytoskeleton Inc
Microtubule fluorescence motility kit Cytoskeleton Inc
Minimal essential medium GIBCO
Normal horse/goat serum Vector
Oxalic acid Sigma
PBS Oxoid
Protogel National Diagnostics
PVDF membrane Amersham
SDS Sigma
SG Vector
Silver nitrate Sigma
Streptomycin/ penicillin GIBCO
TCM serum replacement ICN Biomedicals
TEMED Amersham
Tris Sigma
Uranyl nitrate TAAB
III
A1.4 4% Paraformaldehyde
2 litres:- 1. Heat 1800ml o f 50mM PB to 65°C
2. Add 80g of paraformaldehyde to the heated PB in fumehood
3. Make up to 2L with 200ml o f PB
4. Filter
5. Store in fridge (use for upto 2 weeks)
A 1.5 Ibotenic acid
Purchased from Sigma in lmg powder form. This should be diluted at lOmg/ml in 
PBS (lOOpl), aliquoted and stored at 4°C. This compound precipitates once defrosted 
and therefore should be thawed immediately before commencement of surgery.
A1.6 PCR Analysis
Proteinase K digest mix:- 178pi water, 20pl buffer (Amplitaq Gold PCR 15mM 
MgCl), 2pl proteinase K (lOmg/ml) (final proteinase K concentration 1 OOpg/ml) 
Master Mix
Analar water 
Amplitaq buffer 
dNTPs(2mM) 
Primer L3(10mm) 
Primer R3+( 10mm)
9.025pl 
1.5pl 
1.5pl 
0.3pl 
0.3 pi
DMSO (Di Methyl Sulphoxide)1.5pl 
Amplitaq Gold polymerase 0.075pl
Total 14.2pl
To this master mix 0.8 pi of target DNA must be added.
IV
A1.7 Immunohistochemistry
5OmMPhosphate buffer{PB) To make 2L: 95ml (A) Sodium dihydrogen ortho
posphate (NaH2 P0 4 2 H2 0 )(2 4 g/L)
405ml (B)Disodium hydrogen orthophosphate 
(Na2HP04)(28.5g/L)
To make phosphate buffered add 9g NaCl/L to the above mixture
PBS: 50ml o f liquid PBS to 1L of distilled water
Bovine Serum Albumin (BSA) 10% BSA Fraction V (Sigma) in PBS
ABC complex: 1 drop of reagent A + 1 drop of reagent B in 5mls PBS
DAB: 2 drops buffer solution + 4 drops of DAB solution + 2 drops of hydrogen
peroxide solution in 5mis distilled water
A1.8 Western Blotting
1. Homogenisation B u f fe r 25mM Tris-HCl (pH6 ), 3mM MgCb, lOOmM NaCl
3.0275g + 0.6099g + 5.844g
Made up in 1L of distilled water
2. Samples', each tissue sample was weighed and the weight matched in volume of 
homogenisation buffer. Homogenates were then produced using a hand held 
homogeniser. The samples were then centrifuged for 15mins and the supernatant 
removed. Following protein content determination defined amounts of supernatant 
were diluted in water (X5 volume) and Laemmli buffer added to the final samples 
such that 40pl of sample contained lOjug of protein.
3. S D S 10%: Dissolve lOg of sodium dodecyl sulphate in 100ml of water. Solution 
should be coulourless. If necessary heat to dissolve.
Ammonium persulphate 10%: Dissolve O.lg APS in 1ml water immediately before 
to use.
V
Buffer 1: 18.15g Tris (1.5M), pH8 . 8  with HC1, 4ml 10% SDS, 100ml total volume 
with water
Buffer 2 : 6 g Tris (0.5M), pH6 . 8  with HC1, 4ml 10% SDS, 100ml total volume with 
water.
Running Buffer. 72g glycine, 15g Tris, 50ml 10% SDS (made up to 5L with 
distilled water and precooled to 4°C.
Blotting Buffer: 72g glycine, 15g Tris, 1L methanol (made up to 5L with water) 
2XTBS: 116.9g NaCl, 40ml 2M Tris (9.68g Tris in 40ml)/HCl pH7.5 made up to 
2L with distilled water.
TTBS: 1XTBS + 250pl Tween 20
Laemlli Buffer: 0.1M Tris HC1 pH 8 , 0.1% bromophenol blue, 5M urea, 5%DDT, 
5%SDS. Separate into aliquots and store at -20°C.
Table 10 Gel Preparations
Resolving Gel 12.5% X2 10% X2
h 2o 8 .6 ml 17.2ml 13.2ml 26.4ml
Buffer 1 1 2 ml 24ml 1 2 ml 24ml
Protogel 23ml 26ml 18.4ml 36.8ml
Glycerol 50% 4ml 8 ml 4ml 8 ml
APS 10% 320pl 640pl 320pl 640pl
Temed 50pl lOOpl 50pl lOOpl
Stacking Gel XI X2
h 2o 8.55ml 17.1ml
Buffer 2 3.75ml 7.5ml
Protogel 2.7ml 5.4ml
APS 10% 150pl 300pl
Temed 2 0 pl 40pl
Temed should be added to the mixture last as this stimulates polymerisation.
VI
A1.9 Organotypic Hippocampal Slice Culture
M e d iu m 96% essential medium (containing Hanks salt solution)
0.5% glutamax I supplement 
50U/ml streptomycin/penicillin 
1 % glucose
2% TCM (serum replacement)
Medium should be prepared under sterile conditions in a culture hood. The medium 
should be stored at 4°C and should be heated to 37°C before addition to cultures. 
Prepared medium should not be used after 7 days.
Geys balanced salt solution (for slides):- This should be chilled before used but 
stored at 4°C.
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Appendix III
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Figure A3.1 Western blotting bands from the hippocampus o f C57 BL/6J mice at day 0, 7 
and 28 post-ECL. The blots were incubated with antibodies to synaptophysin, GAP-43 
and apoE. i- ipsilateral, c- contralateral
VIII
Figure A3 2 Silver staining in a 3 day control section
Illustrative example o f  the presence o f silver labelled degeneration products in the 
molecular layers o f the dentate gyrus. This section was run in parallel with sections 
from chapter VI to ensure the accuracy o f staining since no 3 day timepoint was 
included in that study.
IX
Granule cell layer
F igure A3.3 Astrocyte proliferation in the molecular layers of the hippocampal 
dentate gyrus post-culture
Illustrative example o f astrocyte proliferation post-culture in hippocampal slices. The 
molecular layers are densely populated with reactive astrocytes by day 7 in vitro. 
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Figure A3.4 Graph illustrating tubulin levels in each reaction
XI
5[ig/ml 
Pellet fraction (89 kDa)
3 4 4  3 3 4 4  3 3 3  4 3 4  3 4 4
Supernatant fraction (34kDa)
3 4 4  3 3 4 4 3 3 3 4 3 4 3 4 4
20|ig/ml 
Pellet fraction (89 kDa)
3 4 4  3 3 4 4  3 3  3 4 3 4  3 4 4
Supernatant fraction (34kDa)
3 4 4  3 3 4 4  3 3  3 4 3 4  3 4 4
Figure A3.5 Microtubule binding of apoE E3 and E4 at apoE 
concentrations of 5pg/ml and 20 pg/ml
Illustrative examples o f apoE immunoblotting. At both concentrations apoE E4 
was found to be greater in the pellet fraction. In the pellet fraction the apoE is 
microtubule bound and is present in a band at approximately 89kDa (apoE 
34kDa + tubulin 55kDa). In the pellet fraction apoE E3 was found to greater 
compared to apoE E4.
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